

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number  
**WO 01/44276 A2**

(51) International Patent Classification<sup>7</sup>: C07K 14/00

(21) International Application Number: PCT/EP00/12698

(22) International Filing Date:  
14 December 2000 (14.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/171,121 16 December 1999 (16.12.1999) US

(71) Applicant (for all designated States except US): BASF  
PLANT SCIENCE GMBH [DE/DE]; 67056 Ludwigshafen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LERCHL, Jens [DE/DE]; Im Steg 36, 68256 Ladenburg (DE). RENZ, Andreas [DE/DE]; Heinrich-von-Kleist-Strasse 6, 67117 Limburgerhof (DE). EHRHARDT, Thomas [DE/DE]; Maulbronner Hof 49, 67346 Speyer (DE). REINDL, Andreas [DE/DE]; Albertine-Scherer-Strasse 21, 67134 Birkenheide (DE). CIRPUS, Petra [DE/DE]; Landteilstrasse 12, 68163 Mannheim (DE). BISCHOFF, Friedrich [DE/DE]; Eichelsheimer Strasse 6, 68163 Mannheim (DE). FRANK, Markus [DE/DE]; Georg-Herwegh-Strasse 14, 67061 Ludwigshafen (DE). FREUND, Annette [DE/DE]; Römerweg 17c, 67117 Limburgerhof (DE). DUWENIG,

Elke [DE/DE]; Sternwaldstrasse 7, 79102 Freiburg (DE). SCHMIDT, Ralf-Michael [DE/DE]; Am Schlossgarten 9 d, 67489 Kirrweiler (DE). RESKI, Ralf [DE/DE]; Am Osterbach 26, 79254 Oberried (DE). BADUR, Ralf [DE/DE]; Von Eckenbrecher-Strasse 2, 38642 Goslar (DE).

(74) Agent: FITZNER, Uwe; Lintorfer Strasse 10, 40878 Ratingen (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/44276 A2

(54) Title: MOSS GENES FROM PHYSCOMITRELLA PATENS ENCODING PROTEINS INVOLVED IN THE SYNTHESIS OF TOCOPHEROLS AND CAROTENOIDS

(57) Abstract: Isolated nucleic acid molecules, designated TCMRP nucleic acid molecules, which encode novel TCMRPs from e.g. *Physcomitrella patens* are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TCMRP nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated TCMRPs, mutated TCMRPs, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from transformed cells, organisms or plants based on genetic engineering of TCMRP genes in these organisms.

MOSS GENES FROM PHYSCOMITRELLA PATENS ENCODING PROTEINS INVOLVED IN THE SYNTHESIS  
OF TOCOPHEROLS AND CAROTENOIDS**Background of the Invention**

5 Certain products and by-products of naturally-occurring metabolic processes in cells have utility in a wide array of industries, including the food, feed, cosmetics, and pharmaceutical industries. These molecules, collectively termed 'fine chemicals', include organic acids, both proteinogenic and non-proteinogenic amino acids, nucleotides and nucleosides, lipids and fatty acids, carotenoids, diols, carbohydrates,  
10 aromatic compounds, vitamins and cofactors and enzymes.

Their production is most conveniently performed through the large-scale culture of bacteria developed to produce and secrete large quantities of one or more desired molecules. One particularly useful organism for this purpose is *Corynebacterium*  
15 *glutamicum*, a gram positive, nonpathogenic bacterium.

Through strain selection, a number of mutant strains of the respective microorganisms have been developed which produce an array of desirable compounds. However, selection of strains improved for the production of a particular molecule is a time-  
20 consuming and difficult process.


Alternatively the production of fine chemicals can be most conveniently performed via the large scale production of plants developed to produce one of aforementioned fine chemicals. Of particular interest for this purpose are all crop plants for food and feed  
25 uses. Increased or modulated compositions of fine chemicals like amino acids, vitamins and nucleotides, in these plants would lead to optimized nutritional qualities.

Through conventional breeding, a number of mutant plants have been developed which produce increased amounts of for example, carotenoids, and amino acids. However,  
30 selection of new plant cultivars improved for the production of a particular molecule is a time-consuming and difficult process.

**Summary of the Invention**

This invention provides novel nucleic acid molecules which may be used to modify tocopherols and carotenoids in plants, algae and microorganisms.

- 5 The naturally occurring eight compounds with vitamin E activity are derivatives of 6-chromanol (Ullmann's Encyclopedia of Industrial Chemistry, Vol. A 27 (1996), VCH Verlagsgesellschaft, Chapter 4., 478-488, Vitamin E). The group of the tocopherols (1a-  
 10  $\delta$ ) has a saturated side chain, while the group of the tocotrienols (2a- $\delta$ ) has an unsaturated side chain:




1a,  $\alpha$ -tocopherol:  $R^1 = R^2 = R^3 = \text{CH}_3$

1b,  $\beta$ -tocopherol:  $R^1 = R^3 = \text{CH}_3$ ,  $R^2 = \text{H}$

1c,  $\gamma$ -tocopherol:  $R^1 = \text{H}$ ,  $R^2 = R^3 = \text{CH}_3$

20 1d,  $\delta$ -tocopherol:  $R^1 = R^2 = \text{H}$ ,  $R^3 = \text{CH}_3$



2a,  $\alpha$ -tocotrienol:  $R^1 = R^2 = R^3 = \text{CH}_3$

2b,  $\beta$ -tocotrienol:  $R^1 = R^3 = \text{CH}_3$ ,  $R^2 = \text{H}$

30 2c,  $\gamma$ -tocotrienol:  $R^1 = \text{H}$ ,  $R^2 = R^3 = \text{CH}_3$

2d,  $\delta$ -tocotrienol:  $R^1 = R^2 = \text{H}$ ,  $R^3 = \text{CH}_3$

In the present invention, tocopherols are to be understood as meaning all the abovementioned tocopherols and tocotrienols and derivatives thereof with vitamin E activity.

- 5 These compounds with vitamin E activity (vitamin E compounds) are important natural lipid-soluble substances, which among other activities have especially the function of antioxidants. A lack of vitamin E in humans and animals leads to pathophysiological situations. Vitamin E compounds therefore have an important economical value as additives in the food and feed sectors, in pharmaceutical formulations and in cosmetic  
10 applications.

An economical method for the production of vitamin E compounds, and foodstuffs and animal feeds with an elevated vitamin E content are therefore of great importance.

- 15 WO 00/10380 describes the gene sequence encoding the 2-methyl-6-phytylplastoquinol-methyltransferase from the prokaryotic organism *Synechocystis* spec. PCC6803.  
WO 97/27285 describes the mapping of the gene locus of p-hydroxyphenylpyruvate dioxygenase encoding gene of *Arabidopsis thaliana*. Speculations are done about the effects of overexpression or downregulation of the plant enzyme on the vitamin E  
20 content or herbicide resistance in transgenic plants. WO 99/04622 and D. DellaPenna et al., Science 1998, 282, 2098–2100 describe gene sequences encoding a  $\gamma$ -tocopherol methyltransferase from *Synechocystis* PCC6803 and *Arabidopsis thaliana* and their incorporation into plants. However, the transgenic plants show only a shift in the spectrum of tocopherols, i.e. a shift from gamma-tocopherol to alpha-tocopherol because  
25 of the higher expression of  $\gamma$ -tocopherol methyltransferase. No data are shown concerning a higher yield of tocopherols, i. e. a quantitative improvement in tocopherol content.

- To date no economical methods are available for an effective production of tocopherols  
30 and/or carotinoids in transgenic organisms, i. e. for effectively increasing the metabolite flow in the direction of increased tocopherol and/or carotinoid content in transgenic organisms, for example in transgenic plants, by overexpressing one or several

biosynthesis genes, alone or in any combination, related to the tocopherol and/or carotinoid metabolism.

Methods which are particularly economical are biotechnological methods which exploit  
5 proteins and biosynthesis genes from tocopherol or carotinoid biosynthesis from organisms producing these compounds.

Microorganisms like *Corynebacterium* and fungi and algae like *Phaeodactylum* are commonly used in industry for the large-scale production of a variety of fine chemicals.

10

Given the availability of cloning vectors for use in *Corynebacterium glutamicum*, such as those disclosed in Sinskey et al., U.S. Patent No. 4,649,119, and techniques for genetic manipulation of *C. glutamicum* and the related *Brevibacterium* species (e.g., *lactofermentum*) (Yoshihama et al, *J. Bacteriol.* 162: 591-597 (1985); Katsumata et al.,  
15 *J. Bacteriol.* 159: 306-311 (1984); and Santamaria et al., *J. Gen. Microbiol.* 130: 2237-2246 (1984)), the nucleic acid molecules of the invention may be utilized in the genetic engineering of this organism to make it a better or more efficient producer of one or more fine chemicals. This improved production or efficiency of production of a fine chemical may be due to a direct effect of manipulation of a gene of the invention, or it  
20 may be due to an indirect effect of such manipulation.

Given the availability of cloning vectors and techniques for genetic manipulation of ciliates such as disclosed in WO9801572 or algae and related organisms such as *Phaeodactylum tricornutum* (described in Falcatore et al., 1999, *Marine Biotechnology*  
25 1 (3):239-251 as well as Dunahay et al. 1995, Genetic transformation of diatoms, *J. Phycol.* 31:10004-1012 and references therein) the nucleic acid molecules of the invention may be utilized in the genetic engineering of these organisms to make them better or more efficient producers of one or more fine chemicals. This improved production or efficiency of production of a fine chemical may be due to a direct effect of  
30 manipulation of a gene of the invention, or it may be due to an indirect effect of such manipulation.

The moss *Physcomitrella patens* represents one member of the mosses. It is related to other mosses such as *Ceratodon purpureus* which is capable to grow in the absense of light. Further *Physcomitrella patens* represents the only plant organism which can be utilized for targeted disruption of genes by homologous recombination. Mutants  
5 generated by this technique are useful to characterize the function for genes described in the invention. Mosses like *Ceratodon* and *Physcomitrella* share a high degree of homology on the DNA sequence and polypeptide level allowing the use of heterologous screening of DNA molecules with probes evolving from other mosses or organisms, thus enabling the derivation of a consensus sequence suitable for heterologous screening or  
10 functional annotation and prediction of gene functions in third species. The ability to identify such functions can therefor have significant relevance, e.g., prediction of substrate specificity of enzymes. Further, these nucleic acid molecules may serve as reference points for the mapping of moss genomes, or of genomes of related organisms.

15 This invention provides novel nucleic acid molecules which encode proteins, referred to herein as Tocopherol, and Carotenoid Metabolism Related Proteins (TCMRP). These TCMRPs are capable of, for example, performing an enzymatic step involved in the metabolism of certain fine chemicals, including tocopherols and/or carotenoids.

20 Given the availability of cloning vectors for use in plants and plant transformation, such as those published in and cited therein: Plant Molecular Biology and Biotechnology (CRC Press, Boca Raton, Florida), chapter 6/7, S.71-119 (1993); F.F. White, Vectors for Gene Transfer in Higher Plants; in: Transgenic Plants, Vol. 1, Engineering and Utilization, eds.: Kung und R. Wu, Academic Press, 1993, 15-38; B. Jenes et al.,  
25 Techniques for Gene Transfer, in: Transgenic Plants, Vol. 1, Engineering and Utilization, eds.: Kung und R. Wu, Academic Press (1993), 128-143; Potrykus, Annu. Rev. Plant Physiol. Plant Molec. Biol. 42 (1991), 205-225)) the nucleic acid molecules of the invention may be utilized in the genetic engineering of a wide variety of plants to make it a better or more efficient producer of one or more fine chemicals. This improved  
30 production or efficiency of production of a fine chemical may be due to a direct effect of manipulation of a gene of the invention, or it may be due to an indirect effect of such manipulation.

There are a number of mechanisms by which the alteration of an TCMRP of the invention may directly affect the yield, production, and/or efficiency of production of a fine chemical in plant due to such an altered protein.

The nucleic acid and protein molecules of the invention may directly improve the  
5 production or efficiency of production of one or more desired fine chemicals from microorganisms and plants. Using recombinant genetic techniques well known in the art, one or more of the biosynthetic or degradative enzymes of the invention for tocopherols and/or carotinoids may be manipulated such that its function is modulated. For example, a biosynthetic enzyme may be improved in efficiency, or its allosteric control region  
10 destroyed such that feedback inhibition of production of the compound is prevented.

Similarly, a degradative enzyme may be deleted or modified by substitution, deletion, or addition such that its degradative activity is lessened for the desired compound without impairing the viability of the cell.

Further, one gene or one enzyme of the invention for tocopherols and/or carotinoids or  
15 preferably a combination of several genes or enzymes of the invention can be transformed into host cells (e. g. starting organism or already genetically modified host system), whereby the gene(s) or enzyme(s) can be modified either in their activity or number in the corresponding host cell (e.g. plant). Besides, the host cell itself might be already genetically manipulated (e.g. in key position of the pathway) in the way that the  
20 flux of metabolites can be directed to higher yields of tocopherols and/or carotinoids, when the cell is used to be transformed with one or more genes (encoding the corresponding enzymes) of the invention for tocopherols and/or carotinoids. In each case, the overall yield or rate of production of the desired fine chemical may be increased.

In one preferred embodiment of the instant invention the genes encoding the TCMR  
25 proteins  $\gamma$ -tocopherol-methyltransferase (gamma-TMT type I), 2-methyl-6-phytylplastoquinol methyltransferase (gamma-TMT type II) and/or 4-hydroxyphenylpyruvate dioxygenase alone or in any combination have a substantial effect on the production of the desired fine chemical, preferred vitamin E compounds or in the production of relevant precursors, e.g. tocopherol precursors such as homogentisic  
30 acid and/or phytylpyrophosphate and/or geranylgeranyl-pyrophosphate. In the instant invention, the genes encoding these enzymes mentioned above, i.e.  $\gamma$ -tocopherol-methyltransferase (gamma-TMT type I), 2-methyl-6-phytylplastoquinol methyltransferase (gamma-TMT type II) and/or 4-hydroxyphenylpyruvate dioxygenase,

can be isolated from the moss *Physcomitrella patens* and transferred into suitable host cells, but the invention is not limited to this organism as a source for the nucleic acid isolation. Thus, the mentioned genes and/or enzymes can also be isolated from any other organisms, e.g. prokaryotes or eukaryotes, which comprises an endogenous sequence  
5 mentioned above. Preferred examples for such organisms, especially in view to the enzyme 4-hydroxyphenylpyruvate dioxygenase, are *Streptomyces avermitilis* (database accession number of the corresponding gene is AL 096852), *Rattus norvegicus* (database accession number AF 082834), *Synechocystis spec.* PCC6803 or *Arabidopsis thaliana* (DellaPenna, D. et al., 1998, Science, 282, 2098-2100).

10

It is also possible that alterations in the protein and nucleotide molecules of the invention may improve the production of other fine chemicals besides the tocopherols and/or carotinoids through indirect mechanisms. Metabolism of any one compound is necessarily intertwined with other biosynthetic and degradative pathways within the cell,  
15 and necessary cofactors, intermediates, or substrates in one pathway are likely supplied or limited by another such pathway. Therefore, by modulating the activity of one or more of the proteins of the invention, the production or efficiency of activity of another fine chemical biosynthetic or degradative pathway may be impacted. For example, amino acids serve as the structural units of all proteins, yet may be present  
20 intracellularly in levels which are limiting for protein synthesis; therefore, by increasing the efficiency of production or the yields of one or more amino acids within the cell, proteins, such as biosynthetic or degradative proteins, may be more readily synthesized. Likewise, an alteration in a metabolic pathway enzyme such that a particular side reaction becomes more or less favored may result in the over- or under-production of  
25 one or more compounds which are utilized as intermediates or substrates for the production of a desired fine chemical.

Those TCMRPs involved in the transport of fine chemical molecules from the cell may be increased in number or activity such that greater quantities of these compounds are  
30 allocated to different plant cell compartments or the cell exterior space from which they are more readily recovered and partitioned into the biosynthetic flux or deposited. Similarly, those TCMRPs involved in the import of nutrients necessary for the biosynthesis of one or more fine chemicals (e.g. tocopherols and/or carotinoids) may be



increased in number or activity such that these precursors, cofactors, or intermediate compounds are increased in concentration within the cell or within the storing compartments. The invention pertains to an isolated nucleic acid molecule which encodes an TCMRP or an TCMRP polypeptide involved in assisting in transmembrane  
5 transport.

The mutagenesis of one or more TCMRPs of the invention may also result in TCMRPs having altered activities which indirectly impact the production of one or more desired fine chemicals from plants. For example, TCMRPs of the invention involved in the  
10 export of waste products may be increased in number or activity such that the normal metabolic wastes of the cell (possibly increased in quantity due to the overproduction of the desired fine chemical) are efficiently exported before they are able to damage nucleic acids and proteins within the cell (which would decrease the viability of the cell) or to interfere with fine chemical biosynthetic pathways (which would decrease the  
15 yield, production, or efficiency of production of the desired fine chemical). Further, the relatively large intracellular quantities of the desired fine chemical may in itself be toxic to the cell or may interfere with enzyme feedback mechanisms such as allosteric regulation, so by increasing the activity or number of transporters able to export this compound from the compartment, one may increase the viability of seed cells, in turn  
20 leading to a greater number of cells in the culture producing the desired fine chemical. The TCMRPs of the invention may also be manipulated such that the relative amounts of different tocopherols and/or carotinoids are produced. This can be appreciable for optimizing plant nutritional composition. In plants these changes can moreover also influence other characteristic like tolerance towards abiotic and biotic stress conditions.

25

This invention provides novel nucleic acid molecules which encode TCMRPs, which are capable of, for example, performing an enzymatic step involved in the metabolism of molecules important for the normal functioning of cells, such as tocopherols and/or carotinoids. Nucleic acid molecules encoding an TCMRP are referred to herein as  
30 TCMRP nucleic acid molecules. In a preferred embodiment, the TCMRP performs an enzymatic step related to the metabolism of one or more tocopherols and/or carotinoids. Examples of such proteins include those encoded by the genes set forth in the Appendix A and B and Table 1.

As biotic and abiotic stress tolerance is a general trait wished to be inherited into a wide variety of plants like maize, wheat, rye, oat, triticale, rice, barley, sorghum, potato, tomato, soyabean, bean, pea, peanut, cotton, rapeseed, canola, alfalfa, grape, fruit plants  
5 (apple, pear, pineapple), bushy plants (coffee, cacao, tea), trees (oil palm, coconut), legumes, perennial grasses, and forage crops. These crops plants are also preferred target plants for a genetic engineering as one further embodiment of the present invention. More preferably are crop plants and oil seed plants and most preferably are rape and soyabean.

10

The nucleic acid constructs according to the invention can be used for the generation of genetically modified organisms, hereinbelow also termed transgenic organisms.

Starting or host organisms are to be understood as meaning prokaryotic or eukaryotic  
15 organisms such as, for example, microorganisms, mosses or plants. Preferred micororganisms are bacteria, yeasts, algae or fungi. In one preferred embodiment of the instant invention host organisms are plants.

Examples of preferred plants are Tagetes, sunflowers, Arabidopsis, tobacco, red pepper,  
20 soyabeans, tomatoes, aubergines, capsicums, carrots, potatoes, maize, saladings and cabbages, cereals, alfalfa, oats, barley, rye, wheat, Triticale, panic grasses, rice, lucerne, flax, cotton, hemp, Brassicaceae such as, for example, oilseed rape or canola, sugar beet, sugar cane, nut and grapevine species or woody species such as, for example, aspen or yew. More preferably are crop plants or oil seed plants, most preferably are Arabidopsis  
25 thaliana, Tagetes erecta, *Brassica napus*, *Nicotiana tabacum*, canola or potatoes. Especially preferred are rape or soyabeans.

Genetically modified or transgenic organisms are to be understood as meaning the corresponding transformed starting organisms.

30

The invention relates to a genetically modified organism where the genetic modification of the gene expression of a nucleic acid according to the invention relative to a wild type is increased in the event that the starting organism comprises a nucleic acid according to

the invention or caused in the event that the starting organism does not contain a nucleic acid according to the invention.

Transgenic organisms comprising at least one exogenous or at least one additional  
5 endogenous gene according to the invention which already in the form of the starting organisms possess the biosynthesis genes for the production of tocopherols such as, for example, plants or other photosynthetically active organisms such as, for example, cyanobacteria, mosses or algae exhibit an increased tocopherol content compared with the respective wild type or starting organism.

10

Accordingly, the invention furthermore relates to genetically modified organisms, wherein the genetically modified organism exhibits an increased tocopherol content relative to the wild type in the case where the starting organism is capable of producing tocopherols, or is capable of producing tocopherols in the case where the starting  
15 organism comprises the genes required for tocopherol biosynthesis.

The invention preferably relates to an above-described genetically modified organism which exhibits an increased tocopherols content over the wild type.

20 Used in a preferred embodiment as organisms and for the generation of organisms with an increased tocopherols content compared with the wild type are plants, not only as starting organisms but also, accordingly, as genetically modified organisms.

The present invention therefore also relates to processes for the production of  
25 tocopherols by growing a genetically modified organism according to the invention, preferably a genetically modified plant according to the invention, which exhibits an increased tocopherol content over the wild type, harvesting the organism and subsequently isolating the tocopherol compounds from the organism.

30 Genetically modified plants according to the invention with an increased tocopherol content which can be consumed by humans and animals can also be used as foodstuffs or feeds for example directly or after processing which is known per se.

The invention furthermore relates to a method for the generation of genetically modified organisms by introducing a nucleic acid according to the invention or a nucleic acid construct according to the invention into the genome of the starting organism.

5 Accordingly, one aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs) comprising a nucleotide sequence encoding an TCMRP or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection or amplification of TCMRP-encoding nucleic acid (e.g., DNA or mRNA). In another embodiment, the isolated nucleic acid molecule is at  
10 least 15 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising a nucleotide sequence of Appendix A. Preferably, the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes a naturally-occurring *Physcomitrella patens* TCMRP, or a biologically active portion thereof. In particularly preferred embodiments,  
15 the isolated nucleic acid molecule comprises one of the nucleotide sequences set forth in Appendix A or the coding region or a complement thereof of one of these nucleotide sequences. In other particularly preferred embodiments, the isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80%  
20 or 90%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence set forth in Appendix A, or a portion thereof. In other preferred embodiments, the isolated nucleic acid molecule encodes one of the amino acid sequences set forth in Appendix B. The preferred TCMRP of the present invention also preferably possess at least one of the TCMRP activities described herein.

25

In another embodiment, the instant nucleic acid molecule is full length or nearly full length nucleic acid molecule with an homology of at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80% or 90%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence  
30 set forth in Appendix A.

In another embodiment, the isolated nucleic acid molecule encodes a protein or portion thereof wherein the protein or portion thereof includes an amino acid sequence which is

sufficiently homologous to an amino acid sequence of Appendix B, e.g., sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains an TCMRP activity. Preferably, the protein or portion thereof encoded by the nucleic acid molecule maintains the ability to perform an enzymatic reaction in a tocopherol and/or carotinoid metabolic pathway. In one embodiment, the protein encoded by the nucleic acid molecule is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90% and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an amino acid sequence of Appendix B (e.g., an entire amino acid sequence selected from those sequences set forth in Appendix B). In another preferred embodiment, the protein is a full length or nearly full length *Physcomitrella patens* protein is substantially homologous to an entire amino acid sequence of Appendix B (encoded by an open reading frame shown in Appendix A). As used herein, a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence is least about 50% homologous to the selected amino acid sequence, e.g., the entire selected amino acid sequence. A protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence can also be least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, or 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to the selected amino acid sequence.

In another preferred embodiment, the isolated nucleic acid molecule is derived from *Physcomitrella patens* and encodes a protein (e.g., an TCMRP fusion protein) which includes a biologically active domain which is at least about 50% or more homologous to one of the amino acid sequences of Appendix B and is able to perform an enzymatic reaction in a tocopherol and/or carotinoid metabolic pathway or has one or more of the activities set forth in Table 1, and which also includes heterologous nucleic acid sequences encoding a heterologous polypeptide or regulatory regions.

Preferably, so-called conservative exchanges are carried out in which the amino acid which is replaced has a similar property as the original amino acid, for example the exchange of Glu by Asp, Gln by Asn, Val by Ile, Leu by Ile, and Ser by Thr. Deletion is

the replacement of an amino acid by a direct bond. Preferred positions for deletions are the termini of the polypeptide and the linkages between the individual protein domains.

Insertions are introductions of amino acids into the polypeptide chain, a direct bond  
5 formally being replaced by one or more amino acids.

One embodiment of the invention pertains to TCMRP polypeptides, where by of one or more amino acids are substituted or exchanged by one or more amino acids.

10 Another aspect of the invention pertains to an TCMRP polypeptide whose amino acid sequence can be modulated with the help of art-known computer simulation programmes resulting in an polypeptide with e.g. improved activity or altered regulation (molecular modelling). On the basis of this artificially generated polypeptide sequences, a  
15 corresponding nucleic acid molecule coding for such a modulated polypeptide can be synthesized in-vitro using the specific codon-usage of the desired host cell, e.g. of microorganisms, mosses, algae, ciliates, fungi or plants (back-translated nucleic acid sequences). In a preferred embodiment, even these artificial nucleic acid molecules coding for improved TCMRP proteins are within the scope of this invention.

20 Another aspect of the invention pertains to vectors, e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention, and host cells into which such vectors have been introduced, especially microorganisms, plant cells, plant tissue, organs or whole plants. In one embodiment, such a host cell is a cell capable of storing fine chemical compounds in order to isolate the desired compound from harvested material.  
25 The compound or the TCMRP can then be isolated from the medium or the host cell, which in plants are cells containing and storing fine chemical compounds, most preferably cells of storage tissues like epidermal and seed cells.

Yet another aspect of the invention pertains to a genetically altered *Physcomitrella*  
30 *patens* plant in which an TCMRP gene has been introduced or altered. In one embodiment, the genome of the *Physcomitrella patens* plant has been altered by introduction of a nucleic acid molecule of the invention encoding wild-type or mutated TCMRP sequence as a transgene. In another embodiment, an endogenous TCMRP gene

within the genome of the *Physcomitrella patens* plant has been altered, e.g., functionally disrupted, by homologous recombination with an altered TCMRP gene. In a preferred embodiment, the plant organism belongs to the genus *Physcomitrella* or *Ceratodon*, with *Physcomitrella* being particularly preferred. In a preferred embodiment, the

5 *Physcomitrella patens* plant is also utilized for the production of a desired compound, such as tocopherols and/or carotinoids. Hence in another preferred embodiment, the moss *Physcomitrella patens* can be used to show the function of new, yet unidentified genes of mosses or plants using homologous recombination based on the nucleic acids described in this invention.

10

Still another aspect of the invention pertains to an isolated TCMRP or a portion, e.g., a biologically active portion, thereof. In a preferred embodiment, the isolated TCMRP or portion thereof can catalyze an enzymatic reaction involved in one or more pathways for the metabolism of tocopherols and/or carotinoids. In another preferred embodiment, the

15 isolated TCMRP or portion thereof is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to catalyze an enzymatic reaction involved in one or more pathways for the metabolism of tocopherols and/or carotinoids.

20 The invention also provides an isolated preparation of an TCMRP. In preferred embodiments, the TCMRP comprises an amino acid sequence of Appendix B. In another preferred embodiment, the invention pertains to an isolated full length protein which is substantially homologous to an entire amino acid sequence of Appendix B (encoded by an open reading frame set forth in Appendix A). In yet another

25 embodiment, the protein is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90%, and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an entire amino acid sequence of Appendix B. In other embodiments, the isolated TCMRP comprises an amino acid sequence which is at least about 50% or more homologous to one of the amino acid

30 sequences of Appendix B and is able to perform an enzymatic reaction in a tocopherol and/or carotinoid metabolic pathway in a microorganism or a plant cell or has one or more of the activities set forth in Table 1.

Alternatively, the isolated TCMRP can comprise an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80%, or 90%, and even more preferably at least about 95%, 96%, 97%,  
5 98,%, or 99% or more homologous, to a nucleotide sequence of Appendix B. It is also preferred that the preferred forms of TCMRP also have one or more of the TCMRP activities described herein.

The TCMRP polypeptide, or a biologically active portion thereof, can be operatively  
10 linked to a non-TCMRP polypeptide to form a fusion protein. In preferred embodiments, this fusion protein has an activity which differs from that of the TCMRP alone. In other preferred embodiment, this fusion protein performs an enzymatic reaction in a tocopherol and/or carotinoid metabolic pathway. In particularly preferred embodiments, integration of this fusion protein into a host cell modulates production of  
15 a desired compound from the cell. Further, the instant invention pertains to an antibody specifically binding to an MP polypeptide mentioned before or to a portion thereof.

Another aspect of the invention pertains to a test kit comprising a nucleic acid molecule encoding an TCMRP, a portion and/or a complement of this nucleid acid molecule used  
20 as probe or primer for identifying and/or cloning further nucleic acid molecules involved in the synthesis of amino acids, vitamins, cofactors, nucloetides and/or nucleosides or assisting in transmembrane transport in other cell types or organisms.

In another embodiment the test kit comprises an TCMRP-antibody for identifying and/or purifying further TCMRP molecules or fragments thereof in other cell types or  
25 organisms.

Another aspect of the invention pertains to a method for producing a fine chemical. This method involves either the culturing of a suitable microorganism, algae or culturing plant cells tissues, organs or whole plants containing a vector directing the expression of  
30 an TCMRP nucleic acid molecule of the invention, such that a fine chemical is produced. In a preferred embodiment, this method further includes the step of obtaining a cell containing such a vector, in which a cell is transformed with a vector directing the expression of an TCMRP nucleic acid. In another preferred embodiment, this method



further includes the step of recovering the fine chemical from the culture. In a particularly preferred embodiment, the cell is from the genus *Phaeodactylum*, mosses, algae or plants.

- 5 Another aspect of the invention pertains to a method for producing a fine chemical which involves the culturing of a suitable host cell whose genomic DNA has been altered by the inclusion of an TCMRP nucleic acid molecule of the invention. Further, the invention pertains to a method for producing a fine chemical which involves the culturing of a suitable host cell whose membrane has been altered by the inclusion of an  
10 TCMRP of the invention.

Another aspect of the invention pertains to methods for modulating production of a molecule from a host cell. Such methods include contacting the cell with an agent which modulates TCMRP activity or TCMRP nucleic acid expression such that a cell  
15 associated activity is altered relative to this same activity in the absence of the agent. In a preferred embodiment, the cell is modulated for one or more metabolic pathways for tocopherols and/or carotinoids such that the yields or rate of production of a desired fine chemical by this microorganism is improved. The agent which modulates TCMRP activity can be an agent which stimulates TCMRP activity or TCMRP nucleic acid  
20 expression. Examples of agents which stimulate TCMRP activity or TCMRP nucleic acid expression include small molecules, active TCMRPs, and nucleic acids encoding TCMRPs that have been introduced into the cell. Examples of agents which inhibit TCMRP activity or expression include small molecules and antisense TCMRP nucleic acid molecules.

25

Another aspect of the invention pertains to methods for modulating yields of a desired compound from a cell, involving the introduction of a wild-type or mutant TCMRP gene into a cell, either maintained on a separate plasmid or integrated into the genome of the host cell. If integrated into the genome, such integration can be random, or it can take  
30 place by recombination such that the native gene is replaced by the introduced copy, causing the production of the desired compound from the cell to be modulated or by using a gene in trans such as the gene is functionally linked to a functional expression

unit containing at least a sequence facilitating the expression of a gene and a sequence facilitating the polyadenylation of a functionally transcribed gene.

In a preferred embodiment, said yields are modified. In another preferred embodiment, said desired chemical is increased while unwanted disturbing compounds can be decreased. In a particularly preferred embodiment, said desired fine chemical is a tocopherols and/or carotinoids.

Another aspect of the invention pertains to the fine chemicals produced by a method described before and the use of the fine chemical or a polypeptide of the invention for the production of another fine chemical.

#### **Detailed Description of the Invention**

The present invention provides TCMRP nucleic acid and protein molecules which are involved in the metabolism of tocopherols and/or carotinoids in the moss *Physcomitrella patens*. The molecules of the invention may be utilized in the production or modulation of fine chemicals in microorganisms, algae and plants either directly (e.g., where overexpression or optimization of a vitamin biosynthesis protein has a direct impact on the yield, production, and/or efficiency of production of the vitamin from modified organisms), or may have an indirect impact which nonetheless results in an increase of yield, production, and/or efficiency of production of the desired compound or decrease of undesired compounds (e.g., where modulation of the metabolism of tocopherols and/or carotinoids results in alterations in the yield, production, and/or efficiency of production or the composition of desired compounds within the cells, which in turn may impact the production of one or more other fine chemicals).

Preferred microorganisms for the production or modulation of fine chemicals are for example *Corynebacterium*, *Synechocystis spec.*, *Synechococcus spec.*, *Ashbya gossypii*, *Neurospora crassa*, *Aspergillus spec.*, *Saccharomyces cerevisiae*. Preferred algae for the production or modulation of fine chemicals are *Chlorella spec.*, *Cryptocodineum spec.*, *Phylodactenum spec.*. Preferred plants for the production or modulation of fine chemicals are for example mayor crop plants for example maize, wheat, rye, oat,

triticale, rice, barley, sorghum, potato, tomato, soybean, bean, pea, peanut, cotton, rapeseed, canola, alfalfa, grape, fruit plants (apple, pear, pineapple), bushy plants (coffee, cacao, tea), trees (oil palm, coconut), legumes, perennial grasses, and forage crops.

- 5 Particularly suited for the production or modulation of lipophilic fine chemicals such as tocopherols and/or carotinoids are oil seed plants containing high amounts of lipid compounds like rapeseed, canola, linseed, soybean and sunflower.

Aspects of the invention are further explicated below.

10

#### Fine Chemicals

The term 'fine chemical' is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries. Such compounds include

15 lipids, fatty acids, vitamins, cofactors and enzymes, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described e.g. in Kuninaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm et al., eds. VCH: Weinheim, and references contained therein), lipids, both saturated and polyunsaturated fatty acids (e.g.,

20 arachidonic acid), diols (e.g., propane diol, and butane diol), carbohydrates (e.g., hyaluronic acid and trehalose), aromatic compounds (e.g., aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, Vitamins, p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A.S., Niki, E. & Packer, L. (1995) Nutrition, Lipids, Health, and

25 Disease"Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research, Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press, (1995)), enzymes, and all other chemicals described in Gutcho (1983) Chemicals by Fermentation, Noyes Data Corporation, ISBN: 0818805086 and references therein. The metabolism and uses of certain of these

30 fine chemicals are further explicated below.

#### Tocopherol and carotenoid metabolism and uses

Vitamins, cofactors, and nutraceuticals comprise another group of fine chemical molecules which higher animals have lost the ability to synthesize and so must ingest. These molecules are readily synthesized by other organisms, such as bacteria, fungi, algae and plants. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of metabolic pathways. Besides their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications of these compounds, see, for example, Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996.) The term "vitamin" is art-recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself. One preferred embodiment of the instant invention pertains to vitamin E compounds (tocopherols) and their production in plants. The group of vitamins may encompass cofactors and nutraceutical compounds. The language "cofactor" includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the invention are preferably organic. The term "nutraceutical" includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids).

The biosynthesis of these molecules in organisms capable of producing them, such as bacteria and plants, has been largely characterized (Friedrich, W. "Handbuch der Vitamine", Urban und Schwarzenberg, 1987 ; Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996; Michal, G. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley & Sons; Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research – Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press: Champaign, IL X, 374 S).

The metabolism and uses of certain of these vitamins are further explicated below.

### Tocopherols (vitamin E):

The fat-soluble vitamin E has received great attention for its essential role as an antioxidant in nutritional and clinical applications (Liebler DC 1993. Critical Reviews in Toxicology 23(2):147-169) thus representing a good area for food design, feed applications and pharmaceutical applications. In addition, beneficial effects are encountered in retarding diabetes-related high-age damages, anticancerogenic effects as well as a protective role against erythrems and skin aging. Alpha-tocopherol as the most important antioxidant helps to prevent the oxidation of unsaturated fatty acids by oxygen in humans by its redox potential (Erin AN, Skrypin VV, Kragan VE 1985, Biochim. Biophys. Acta 815: 209).

The demand for this vitamin has increased year after year. The supply of tocopherols has been limited to the chemically synthesized racemate of alpha-tocopherol or a mixture of alpha-, beta(gamma)- and delta-tocopherols from vegetable oils. Altogether, the group of compounds with vitamin E activity now comprises alpha-, beta-, gamma-, and delta-tocopherol as well as alpha-, beta-, gamma-, and delta-tocotrienol.

Biologically, tocopherols are indispensable components of the lipid bilayer of cell membranes. A reduction of availability of tocopherols leads to structural and functional damaging of membranes. This stabilizing effect of the tocopherols on membranes is accepted to be related to three functions: 1) tocopherols react with lipid peroxide radicals, 2) quenching of reactive molecular oxygen, and 3) reducing the molecular mobility of the membrane bilayer by the formation of tocopherol-fatty acids complexes.

In addition to the occurrence of tocopherols in plants, their presence has been determined in various microorganisms, especially in many chlorophyll-containing organisms (Taketomi H, Soda K, Katsui G 1983, Vitamins (Japan) 57: 133-138). Algae, for example *Eugenia gracilis*, also contain tocopherols and *Eugenia gracilis* is described as a suitable host for the production of tocopherols since the most valuable form alpha-tocopherol is the major component of tocopherols (Shigeoka S, Onishi T, Nakano Y, Kitaoka S 1986, Agric. Biol. Chem. 50: 1063-1065). Also, yeasts and bacteria were found to synthesize tocopherols (Forbes M, Zilliken F, Roberts G, György P 1958, J. Am. Chem. Soc. 80: 385-389; Hughes and Tove 1982, J Bacteriol., 151:

1397-1402; Ruggeri BA, Gray RJH, Watkins TR, Tomlins RI 1985, Appl. Env. Microbiol. 50: 1404-1408).

Tocopherol is synthesized from geranylgeranylpyrophosphate which is generated from isopentenylpyrophosphate (IPP). IPP can be produced via two independent pathways. One pathway is located in the cytoplasm, whereas the other is located in the chloroplasts (for descriptions and reviews see Trelfall DR, Whistance GR in Aspects of Terpenoid Chemistry and Biochemistry, Goodwin TW Ed., Academic Press, London, 1971: 357-404; Michal G Ed. 1999, Biochemical Pathways, Spektrum Akademischer Verlag GmbH Heidelberg, and references cited therein; McCaskill D, Croteau R 1998, Tibtech 16: 349-355 and references cited therein; Rhomer M 1998, Progress in Drug Research 50: 135-154; Lichtenthaler HK 1999, Annu. Rev. Plant Physiol. Plant Mol. Biol. 50: 47-65; Lichtenthaler HK, Schwender J, Disch A, Rhomer M 1997, FEBS Letters 400: 271-274; Schultz G, Soll J 1980 Deutsche Tierärztliche Wochenschrift 87: 401-424; Arigoni D, Sagner S, Latzel C, Eisenreich W, Bacher A, Zenk, MH 1997 Proc. Natl. Acad. Sci. USA 94(2): 10600-10605). For a general review of isoprene biosynthesis and products derived from that pathway (Chappell 1995, Annu. Rev. Plant Physiol. Plant Mol. Biol. 46:521-547; Sharkey TD, 1996, Endeavor 20: 74-78).

The cyclic structures which are required for tocopherol biosynthesis are quinones. Quinones are synthesized from products of the shikimate pathway (for review see Dewick PM 1995, Natural Products Reports 12(6): 579-607; Weaver LM, Herrmann KM 1997, Trends in Plant Science 2(9): 346-351; Schmid J, Amrhein N 1995, Phytochemistry 39(4): 737-749).

Plant genes originating from *Physcomitrella patens* can be used to modify tocopherol metabolism in plants as well as algae and microorganisms enabling these host cells to increase their capacity to produce tocopherols as well as improving survival and fitness of the host cell. Thereby, one or several genes, alone or in combination, preferably of the genes encoding the  $\gamma$ -tocopherol-methyltransferase ( $\gamma$ -TMT type I), 2-methyl-6-phytylplastoquinol methyltransferase ( $\gamma$ -TMT type II) or 4-hydroxyphenylpyruvate dioxygenase, can be used to modify the tocopherol metabolism.

30

Carotenoids:

Carotenoids are naturally occurring pigments synthesized as hydrocarbons (carotenes) and their oxygenated derivatives (xanthophylls) are produced by plants and microorganisms. The application potential was broadly investigated during the last 20 years. Besides the use of carotenoids as coloring agents, it is assumed that carotenoids  
5 play an important role in the prevention of cancer (Rice-Evans et al. 1997, Free Radic. Res. 26:381-398; Gerster 1993, Int. J. Vitam. Nutr. Res. 63:93-121; Bendich 1993, Ann. New York Acad. Sci. 691:61-67) thus representing a good area for food design, feed applications and pharmaceutical applications.

The major function of carotenoids in plants and microorganisms is in  
10 protection against oxidative damage by quenching photosensitizers interacting with singlet oxygen and scavenging peroxiradicals, thus preventing the accumulation of harmful oxygen species and subsequent maintenance of membrane integrity (Havaux 1998, Trends in Plant Science Vol 3 (4):147-151; Krinsky 1994, Pur Appl. Chem. 66:1003-1010). Thus an application is also given for the optimization of fermentation  
15 processes with respect to lesser susceptibility to oxidative damage. For a review of biotechnological potential see Sandmann et al. (1999, Tibtech 17; 233-237).

Plant genes originating from *Physcomitrella patens* can be used to modify carotenoid metabolism in plants as well as algae and microorganisms enabling these host cells to increase their capacity to produce carotenoids and to produce newly  
20 designed carotenoids as well as improving survival and fitness of the host cell due to the expression of plant carotenoid biosynthetic genes.

Due to results obtained in labelling experiments it is clear that carotenes arise from the isoprenoid biosynthesis pathway via geranylgeranylpyrophosphate synthesis. For review of products of the isoprenoid biosynthetic pathway including  
25 carotenoids see Chappell 1995, Annu. Rev. Plant Physiol. Plant Mol. Biol. 46:521-547. The biosynthesis of carotenoids in microorganisms and plants is described in following articles and references therein: Armstrong 1997, Annu. Rev. Microbiol., 51:629-659; Sandmann 1994, Eur. J. Biochem. 223:7-24; Misawa et al. 1995, J. Bacteriol. 177 (22):6575-6584; Hirschberg et al. 1997, Pure & Appl. Chem 69 (10):2151-2158; Lotan  
30 & Hirschberg 1995, FEBS Letters 364:125-128; US5916791).

The large-scale production of the fine chemical compounds described above has largely relied on cell-free chemical syntheses. Production through large scale

fermentation of microorganism has not yet proven to be useful, due to insufficient efficiency and high costs. Although not yet applicable for large scale production it has been shown that production of fine chemicals can be enhanced in genetically modified plants as exemplified for phytoene in rice (Burkhardt et al. Plant Journal 11(5):1071-8, 5 1997) and vitamin E in Arabidopsis thaliana and other plants (Shintani nad DellaPenna. Science 282(5396):2098-100, 1998; WO99/23231). Increased amounts of such compounds in plants are especially appreciable because the plants can be directly applied for food and feed purposes.

#### 10 Elements and Methods of the Invention

The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as TCMRP nucleic acid and protein molecules, which play a role in or function in one or more cellular metabolic pathways in *Physcomitrella patens*. In one embodiment, the TCMRP molecules catalyze an enzymatic reaction involving one or 15 more tocopherol and/or carotenoid metabolic pathways. In a preferred embodiment, the activity of the TCMRP molecules of the present invention in one or more *Physcomitrella patens* metabolic pathways for tocopherols and carotenoids has an impact on the production of a desired fine chemical by this organism. In a particularly preferred embodiment, the TCMRPs encoded by TCMRP nucleotides of the invention 20 are modulated in activity, such that the *microorganisms' or plants'* metabolic pathways which the TCMRPs of the invention regulate are modulated in yield, production, and/or efficiency of production and/or transport of a desired fine chemical by microorganisms and plants.

25 The language, TCMRP or TCMRP polypeptide includes proteins which play a role in, e.g., catalyze an enzymatic reaction, in one or more tocopherol and carotenoid metabolic pathways in microorganisms and plants. Examples of TCMRPs include those encoded by the TCMRP genes set forth in Table 1 and Appendix A. The terms TCMRP gene or TCMRP nucleic acid sequence include nucleic acid sequences encoding an 30 TCMRP, which consist of a coding region or a part thereof and/or also corresponding untranslated 5' and 3' sequence regions. Examples of TCMRP genes include those set forth in Table 1. The terms production or productivity are art-recognized and include the concentration of the fermentation product (for example, the desired fine chemical)



formed within a given time and a given fermentation volume (e.g., kg product per hour per liter). The term efficiency of production includes the time required for a particular level of production to be achieved (for example, how long it takes for the cell to attain a particular rate of output of a fine chemical). The term yield or product/carbon yield is art-recognized and includes the efficiency of the conversion of the carbon source into the product (i.e., fine chemical). This is generally written as, for example, kg product per kg carbon source. By increasing the yield or production of the compound, the quantity of recovered molecules, or of useful recovered molecules of that compound in a given amount of culture over a given amount of time is increased. The terms biosynthesis or a biosynthetic pathway are art-recognized and include the synthesis of a compound, preferably an organic compound, by a cell from intermediate compounds in what may be a multistep and highly regulated process. The terms degradation or a degradation pathway are art-recognized and include the breakdown of a compound, preferably an organic compound, by a cell to degradation products (generally speaking, smaller or less complex molecules) in what may be a multistep and highly regulated process. The language metabolism is art-recognized and includes the totality of the biochemical reactions that take place in an organism. The metabolism of a particular compound, then, (e.g., the metabolism of a fatty acid) comprises the overall biosynthetic, modification, and degradation pathways in the cell related to this compound.

In another embodiment, the TCMRP molecules of the invention are capable of modulating the production of a desired molecule, such as a fine chemical, in microorganisms and plants. There are a number of mechanisms by which the alteration of an TCMRP of the invention may directly affect the yield, production, and/or efficiency of production of a fine chemical from a microorganisms or plant strain incorporating such an altered protein. Those TCMRPs involved in the transport of fine chemical molecules within or from the cell may be increased in number or activity such that greater quantities of these compounds are transported across membranes. Similarly, those TCMRPs involved in the import of nutrients necessary for the biosynthesis of one or more fine chemicals may be increased in number or activity such that these precursor, cofactor, or intermediate compounds are increased in concentration within a desired cell. Further TCMRPs may be increased in number or activity which lead to a regeneration of a pool of fine chemicals in a desired state. The mutagenesis of one or more TCMRP

genes of the invention may also result in TCMRPs having altered activities which indirectly impact the production of one or more desired fine chemicals from microorganisms, algae and plants. For example, a biosynthetic enzyme may be improved in efficiency, or its allosteric control region destroyed such that feedback inhibition of production of the compound is prevented. Similarly, a degradative enzyme may be deleted or modified by substitution, deletion, or addition such that its degradative activity is lessened for the desired compound without impairing the viability of the cell. In each case, the overall yield or rate of production of one of these desired fine chemicals may be increased.

10 It is also possible that such alterations in the protein and nucleotide molecules of the invention may improve the production of other fine chemicals besides the tocopherols and carotenoids. Metabolism of any one compound is necessarily intertwined with other biosynthetic and degradative pathways within the cell, and necessary cofactors, intermediates, or substrates in one pathway are likely supplied or limited by another such pathway. Therefore, by modulating the activity of one or more of the proteins of the invention, the production or efficiency of activity of another fine chemical biosynthetic or degradative pathway may be impacted. For example, amino acids serve as the structural units of all proteins, yet may be present intracellularly in levels which are limiting for protein synthesis; therefore, by increasing the efficiency of production or the yields of one or more amino acids within the cell, proteins, such as biosynthetic or degradative proteins, may be more readily synthesized. Likewise, an alteration in a metabolic pathway enzyme such that a particular side reaction becomes more or less favored may result in the over- or under-production of one or more compounds which are utilized as intermediates or substrates for the production of a desired fine chemical.

25 TCMRPs of the invention involved in the export of waste products may be increased in number or activity such that the normal metabolic wastes of the cell (possibly increased in quantity due to the overproduction of the desired fine chemical) are efficiently exported before they are able to damage nucleotides and proteins within the cell (which would decrease the viability of the cell) or to interfere with fine chemical biosynthetic pathways (which would decrease the yield, production, or efficiency of production of the desired fine chemical). Further, the relatively large intracellular quantities of the desired fine chemical may in itself be toxic to the cell, so by increasing

the activity or number of transporters able to export this compound from the cell, one may increase the viability of the cell in culture, in turn leading to a greater number of cells in the culture producing the desired fine chemical.

The TCMRPs of the invention may also be manipulated such that the relative  
5 amounts of different tocopherols and carotenoids are produced. The isolated nucleic acid sequences of the invention are contained within the genome of a *Physcomitrella patens* strain available through the moss collection of the University of Hamburg. The nucleotide sequence of the isolated *Physcomitrella patens* TCMRP cDNAs and the predicted amino acid sequences of the respective *Physcomitrella patens* TCMRPs are  
10 shown in Appendices A and B, respectively.

Computational analyses were performed which classified and/or identified these nucleotide sequences as sequences which encode proteins involved in the metabolism of amino acids, vitamins, cofactors, nutraceuticals, nucleotide or nucleosides.

The present invention also pertains to proteins which have an amino acid  
15 sequence which is substantially homologous to an amino acid sequence of Appendix B. As used herein, a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence is least about 50% homologous to the selected amino acid sequence, e.g., the entire selected amino acid sequence. A protein which has an amino acid sequence which is substantially homologous to a selected  
20 amino acid sequence can also be least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, or 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to the selected amino acid sequence.

The TCMRP or a biologically active portion or fragment thereof of the invention  
25 can catalyze an enzymatic reaction in one or more tocopherol and carotenoid metabolic pathways in plants and microorganisms, or have one or more of the activities set forth in Table 1. Various aspects of the invention are described in further detail in the following subsections:

#### 30 A. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode TCMRP polypeptides or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes or primers for the identification

or amplification of TCMRP-encoding nucleic acid (e.g., TCMRP DNA). As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. This term also encompasses untranslated  
5 sequence located at both the 3' and 5' ends of the coding region of the gene: at least about 100 nucleotides of sequence upstream from the 5' end of the coding region and at least about 20 nucleotides of sequence downstream from the 3' end of the coding region of the gene. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An "isolated" nucleic acid molecule is one which is  
10 separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated TCMRP nucleic acid  
15 molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (e.g., a *Physcomitrella patens* cell). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by  
20 recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having a nucleotide sequence of Appendix A, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein.  
25 For example, a *P. patens* TCMRP cDNA can be isolated from a *P. patens* library using all or portion of one of the sequences of Appendix A as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). Moreover, a nucleic acid  
30 molecule encompassing all or a portion of one of the sequences of Appendix A can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this sequence (e.g., a nucleic acid molecule encompassing all or a portion of one of the sequences of Appendix A can be isolated by the polymerase chain reaction using

oligonucleotide primers designed based upon this same sequence of Appendix A). For example, mRNA can be isolated from plant cells (e.g., by the guanidinium-thiocyanate extraction procedure of Chirgwin et al. (1979) *Biochemistry* 18: 5294-5299) and cDNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL). Synthetic oligonucleotide primers for polymerase chain reaction amplification can be designed based upon one of the nucleotide sequences shown in Appendix A. A nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to an TCMRP nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises one of the nucleotide sequences shown in Appendix A. The sequences of Appendix A correspond to the *Physcomitrella patens* TCMRP cDNAs of the invention. This cDNA comprises sequences encoding TCMRPs (i.e., the "coding region", indicated in each sequence in Appendix A), as well as 5' untranslated sequences and 3' untranslated sequences. Alternatively, the nucleic acid molecule can comprise only the coding region of any of the sequences in Appendix A or can contain whole genomic fragments isolated from genomic DNA. In another embodiment, the sequences of Appendix A can have corresponding longest nucleic acid molecules, e.g. full length or nearly full length nucleic acid molecules encoding a TCMRP. The corresponding clone name is given in Table 1.

For the purposes of this application, it will be understood that each of the sequences set forth in Appendix A has an identifying entry number. Each of these sequences comprises up to three parts: a 5' upstream region, a coding region, and a downstream region. Each of these three regions is identified by the same entry number designation to eliminate confusion. The recitation one of the sequences in Appendix A, then, refers to any of the sequences in Appendix A, which may be distinguished by their differing entry number designations. The coding region of each of these sequences is

translated into a corresponding amino acid sequence, which is set forth in Appendix B. The sequences of Appendix B are identified by the same entry numbers designations as Appendix A, such that they can be readily correlated. For example, the amino acid sequence in Appendix B designated 41\_bd10\_g03rev is a translation of the coding  
5 region of the nucleotide sequence of nucleic acid molecule 41\_bd10\_g03rev in Appendix A, and the amino acid sequence in Appendix B designated 68\_ck12\_d10fwd is a translation of the coding region of the nucleotide sequence of nucleic acid molecule 68\_ck12\_d10fwd in Appendix A.

In another preferred embodiment, an isolated nucleic acid molecule of the  
10 invention comprises a nucleic acid molecule which is a complement of one of the nucleotide sequences shown in Appendix A, or a portion thereof. A nucleic acid molecule which is complementary to one of the nucleotide sequences shown in Appendix A is one which is sufficiently complementary to one of the nucleotide sequences shown in Appendix A such that it can hybridize to one of the nucleotide  
15 sequences shown in Appendix A, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 50-60%, preferably at least about 60-70%, more preferably at least about 70-80%, 80-90%, or 90-95%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to  
20 a nucleotide sequence shown in Appendix A, or a portion thereof. In an additional preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to one of the nucleotide sequences shown in Appendix A, or a portion thereof.

Moreover, the nucleic acid molecule of the invention can comprise only a portion  
25 of the coding region of one of the sequences in Appendix A, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of an TCMRP. The nucleotide sequences determined from the cloning of the TCMRP genes from *P. patens* allows for the generation of probes and primers designed for use in identifying and/or cloning TCMRPhomologues in other cell types and  
30 organisms, as well as TCMRP homologues from other *mosses* or related species. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably

about 40, 50 or 75 consecutive nucleotides of a sense strand of one of the sequences set forth in Appendix A, an anti-sense sequence of one of the sequences set forth in Appendix A, or naturally occurring mutants thereof. Primers based on a nucleotide sequence of Appendix A can be used in PCR reactions to clone TCMRP homologues.

5 Probes based on the TCMRP nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-

10 cells which misexpress an TCMRP, such as by measuring a level of an TCMRP-encoding nucleic acid in a sample of cells, e.g., detecting TCMRP mRNA levels or determining whether a genomic TCMRP gene has been mutated or deleted.

In one embodiment, the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently

15 homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to catalyze an enzymatic reaction in a tocopherol or carotenoid metabolic pathway in microorganisms or plants. As used herein, the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or equivalent (e.g., an amino

20 acid residue which has a similar side chain as an amino acid residue in one of the sequences of Appendix B) amino acid residues to an amino acid sequence of Appendix B such that the protein or portion thereof is able to catalyze an enzymatic reaction in a tocopherol or carotenoid metabolic pathway in microorganisms or plants. Protein members of such metabolic pathways, as described herein, function to catalyze the

25 biosynthesis or degradation or stabilisation of one or more tocopherols or carotenoids. Examples of such activities are also described herein. Thus, the function of an TCMRP" contributes either directly or indirectly to the yield,-production, and/or efficiency of production of one or more fine chemicals. Examples of TCMRP activities are set forth in Table 1.

30 In another embodiment, the protein is at least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of Appendix B.

Portions of proteins encoded by the TCMRP nucleic acid molecules of the invention are preferably biologically active portions of one of the TCMRP. As used herein, the term "biologically active portion of an TCMRP" is intended to include a portion, e.g., a domain/motif, of an TCMRP that participates in the metabolism of fine chemicals like amino acids, vitamins, cofactors, nutraceuticals, nucleotides, or nucleosides in microorganisms or plants or has an activity as set forth in Table 1. To determine whether an TCMRP or a biologically active portion thereof can participate in the metabolism of fine chemicals like amino acids, vitamins, cofactors, nutraceuticals, nucleotides, or nucleosides in microorganisms or plants, an assay of enzymatic activity may be performed. Such assay methods are well known to those skilled in the art, as detailed in Example 17 of the Exemplification.

Additional nucleic acid fragments encoding biologically active portions of an TCMRP can be prepared by isolating a portion of one of the sequences in Appendix B, expressing the encoded portion of the TCMRP or peptide (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the TCMRP or peptide.

The invention further encompasses nucleic acid molecules that differ from one of the nucleotide sequences shown in Appendix A (and portions thereof) due to degeneracy of the genetic code and thus encode the same TCMRP as that encoded by the nucleotide sequences shown in Appendix A. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in Appendix B. In a still further embodiment, the nucleic acid molecule of the invention encodes a full length *Physcomitrella patens* protein which is substantially homologous to an amino acid sequence of Appendix B (encoded by an open reading frame shown in Appendix A).

In addition to the *Physcomitrella patens* TCMRP nucleotide sequences shown in Appendix A, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of TCMRPs may exist within a population (e.g., the *Physcomitrella patens* population). Such genetic polymorphism in the TCMRP gene may exist among individuals within a population due to natural variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding an TCMRP, preferably a *Physcomitrella patens* TCMRP. Such natural variations can typically result



in 1-5% variance in the nucleotide sequence of the TCMRP gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in TCMRPs that are the result of natural variation and that do not alter the functional activity of TCMRPs are intended to be within the scope of the invention.

5 Nucleic acid molecules corresponding to natural variants and non-*Physcomitrella patens* homologues of the *Physcomitrella patens* TCMRP cDNA of the invention can be isolated based on their homology to *Physcomitrella patens* TCMRP nucleic acid disclosed herein using the *Physcomitrella patens* cDNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under  
10 stringent hybridization conditions. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising a nucleotide sequence of Appendix A. In other embodiments, the nucleic acid is at least 30, 50, 100, 250 or more nucleotides in length. As used herein, the term "hybridizes under stringent  
15 conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such  
20 stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid  
25 molecule of the invention that hybridizes under stringent conditions to a sequence of Appendix A corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein). In one embodiment, the nucleic acid encodes a natural *Physcomitrella patens*  
30 TCMRP.

In addition to naturally-occurring variants of the TCMRP sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into a nucleotide sequence of Appendix A, thereby leading to

changes in the amino acid sequence of the encoded TCMRP, without altering the functional ability of the TCMRP. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in a sequence of Appendix A. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of one of the TCMRP proteins (Appendix B) without altering the activity of said TCMRP, whereas an "essential" amino acid residue is required for TCMRP activity. Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved in the domain having TCMRP activity) may not be essential for activity and thus are likely to be amenable to alteration without altering TCMRP activity.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding TCMRPs that contain changes in amino acid residues that are not essential for TCMRP activity. Such TCMRPs differ in amino acid sequence from a sequence contained in Appendix B yet retain at least one of the TCMRP activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 50% homologous to an amino acid sequence of Appendix B and is able to catalyze an enzymatic reaction in a tocopherol or carotenoid metabolic pathway in *P. patens*, or has one or more activities set forth in Table 1. Preferably, the protein encoded by the nucleic acid molecule is at least about 50-60% homologous to one of the sequences in Appendix B, more preferably at least about 60-70% homologous to one of the sequences in Appendix B, even more preferably at least about 70-80%, 80-90%, 90-95% homologous to one of the sequences in Appendix B, and most preferably at least about 96%, 97%, 98%, or 99% homologous to one of the sequences in Appendix B.

To determine the percent homology of two amino acid sequences (e.g., one of the sequences of Appendix B and a mutant form thereof) or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence (e.g., one of the sequences of Appendix B) is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (e.g., a mutant form of the sequence selected from Appendix B), then the molecules are homologous at that

position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = numbers of identical positions/total numbers of positions x 100).

5 An isolated nucleic acid molecule encoding an TCMRP homologous to a protein sequence of Appendix B can be created by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequence of Appendix A such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into one of the sequences of Appendix A  
10 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been  
15 defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g.,  
20 threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an TCMRP is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an TCMRP coding sequence, such as by saturation mutagenesis, and the  
25 resultant mutants can be screened for an TCMRP activity described herein to identify mutants that retain TCMRP activity. Following mutagenesis of one of the sequences of Appendix A, the encoded protein can be expressed recombinantly and the activity of the protein can be determined using, for example, assays described herein (see Example 17 of the Exemplification).

30 In addition to the nucleic acid molecules encoding TCMRPs described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the

coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire TCMRP cDNA coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an TCMRP. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding TCMRPs. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding TCMRPs disclosed herein (e.g., the sequences set forth in Appendix A), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of TCMRP mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of TCMRP mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of TCMRP mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-

5 methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a cell or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an TCMRP to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. The antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen. The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong prokaryotic, viral, or eukaryotic including plant promoters are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gaultier et al. (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue et al. (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes  
5 (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave TCMRP mRNA transcripts to thereby inhibit translation of TCMRP mRNA. A ribozyme having specificity for an TCMRP-encoding nucleic acid can be designed based upon the nucleotide sequence of an TCMRP cDNA disclosed herein. For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which  
10 the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an TCMRP -encoding mRNA. See, e.g., Cech et al. U.S. Patent No. 4,987,071 and Cech et al. U.S. Patent No. 5,116,742. Alternatively, TCMRP mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-  
15 1418.

Alternatively, TCMRP gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of an TCMRP nucleotide sequence (e.g., an TCMRP promoter and/or enhancers) to form triple helical structures that prevent transcription of an TCMRP gene in target cells. See generally, Helene, C.  
20 (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. et al. (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

#### *B. Recombinant Expression Vectors and Host Cells*

Another aspect of the invention pertains to vectors, preferably expression  
25 vectors, containing a nucleic acid encoding an TCMRP (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional  
30 DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host

cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are  
5 often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

10 The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed.

15 Suitable vectors for plants are described, inter alia, in "Methods in Plant Molecular Biology and Biotechnology" (CRC Press), chapter 6/7, pp. 71-119 (1993).

Within a recombinant expression vector, "operably linked" is intended to mean that the  
20 nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence are fused to each other so that both sequences fulfil the proposed function addicted to the sequence used. (e.g., in an *in vitro* transcription/ translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers  
25 and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990) or in Gruber and Crosby, in: Methods in Plant Molecular Biology and Biotechnology, CRC Press, Boca Raton, Florida, eds.:Glick and Thompson, Chapter 7, 89-108 including the references  
30 therein.

Other advantageous regulatory sequences are present in, for example, the Gram-positive promoters amy and SPO2, in the yeast or fungal promoters ADC1, MFa, AC, P-60,

CYC1, GAPDH, TEF, rp28, ADH or in the plant promoters CaMV/35S [Franck et al., Cell 21(1980) 285-294], PRP1 [Ward et al., Plant. Mol. Biol. 22 (1993)], SSU, OCS, leb4, usp, STLS1, B33, nos or in the ubiquitin or phaseolin promoters.

- 5 As regards plants as genetically modified organisms, any promoter capable of governing the expression of foreign genes in plants is suitable in principle as promoter of the expression cassette.

10 Preferably, it is in particular a plant promoter or a promoter derived from a plant virus which is used. Particularly preferred is the cauliflower mosaic virus CaMV 35S promoter (Franck et al., Cell 21 (1980), 285-294). As is known, this promoter comprises various recognition sequences for transcriptional effectors which, in totality, lead to permanent and constitutive expression of the gene which has been inserted (Benfey et al., EMBO J. 8 (1989), 2195-2202).

15

The expression cassette can also comprise a pathogen-inducible or chemically inducible promoter by means of which expression of the exogenous TCMRP genes in the plant can be governed at a particular point in time.

- 20 Examples of such promoters which can be used are, for example, the PRP1 promoter (Ward et al., Plant. Mol. Biol. 22 (1993), 361-366), a salicylic-acid-inducible promoter (WO95/19443), a benzenesulfonamide-inducible promoter (EP-A 388186), a tetracyclin-inducible promoter (Gatz et al., (1992) Plant J. 2, 397-404), an abscisic-acid-inducible promoter (EP-A 335528) or an ethanol- or cyclohexanone-inducible promoter  
25 (WO 93/21334).

Furthermore, preferred promoters are in particular those which ensure expression in tissues or plant organs in which, for example, the biosynthesis of tocopherol or its precursors takes place or in which the products are advantageously accumulated.

30

Promoters which must be mentioned in particular are those for the entire plant owing to constitutive expression, such as, for example, the CaMV promoter, the Agrobacterium OCS promoter (octopine synthase), the Agrobacterium NOS promoter (nopaline



synthase), the ubiquitin promoter, promoters of vacuolar ATPase subunits, or the promoter of a proline-rich protein from wheat (wheat WO 9113991).

Furthermore, promoters which must be mentioned in particular are those which ensure  
5 leaf-specific expression. Promoters which must be mentioned are the potato cytosolic FBPase promoter (WO9705900), the Rubisco (ribulose-1,5-bisphosphate carboxylase) SSU (small subunit) promoter or the potato ST-LSI promoter (Stockhaus et al., EMBO J. 8 (1989), 2445-245).

10 Examples of further suitable promoters are:

specific promoters for tubers, storage roots or roots such as, for example, the patatin promoter class I (B33), the potato cathepsin D inhibitor promoter, the starch synthase (GBSS1) promoter or the sporamin promoter, fruit-specific promoters such as, for  
15 example, the tomato fruit-specific promoter (EP 409625), fruit-maturation-specific promoters such as, for example, the tomato fruit-maturation-specific promoter (WO 9421794), flower-specific promoters such as, for example, the phytoene synthase promoter (WO 9216635) or the promoter of the P-rr gene (WO 9822593) or specific plastid or chromoplast promoters such as, for example, the RNA polymerase promoter  
20 (WO 9706250).

Other promoters which can advantageously be used are the Glycine max phosphoribosyl pyrophosphate amidotransferase promoter (see also Genbank Accession Number U87999) or another nodia-specific promoter as described in EP 249676.

25

In principle, all natural promoters together with their regulatory sequences like those mentioned above can be used for the process according to the invention. In addition, synthetic promoters can also be used advantageously.

30 Further, a seed-specific promoter (preferably the phaseolin promoter (US 5504200), the USP promoter (Baumlein, H. et al., Mol. Gen. Genet. (1991) 225 (3), 459-467), the Brassica Bce4 gene promoter (WO 9113980) or the LEB4 promoter (Fiedler and Conrad, 1995)), are advantageous.

Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells or under certain conditions. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., TCMRPs, mutant forms of TCMRPs, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of TCMRPs in prokaryotic or eukaryotic cells. For example, TCMRP genes can be expressed in bacterial cells such as *C. glutamicum*, insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, M.A. et al. (1992) Foreign gene expression in yeast: a review, *Yeast* 8: 423-488; van den Hondel, C.A.M.J.J. et al. (1991) Heterologous gene expression in filamentous fungi, in: *More Gene Manipulations in Fungi*, J.W. Bennet & L.L. Lasure, eds., p. 396-428: Academic Press: San Diego; and van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) Gene transfer systems and vector development for filamentous fungi, in: *Applied Molecular Genetics of Fungi*, Peberdy, J.F. et al., eds., p. 1-28, Cambridge University Press: Cambridge), algae (Falcioratore et al., 1999, *Marine Biotechnology* 1 (3):239-251), ciliates of the types: Holotrichia, Peritrichia, Spirotrichia, Suctoria, Tetrahymena, Paramecium, Colpidium, Glaucoma, Platyophrya, Potomacus, Pseudocohnilembus, Euplotes, Engelmaniella, and Stylonychia, especially of the genus Stylonychia lemnae with vectors following a transformation method as described in WO9801572 and multicellular plant cells (see Schmidt, R. and Willmitzer, L. (1988), High efficiency *Agrobacterium tumefaciens*-mediated transformation of *Arabidopsis thaliana* leaf and cotyledon explants, *Plant Cell Rep.*: 583-586); *Plant Molecular Biology and Biotechnology*, C Press, Boca Raton, Florida, chapter 6/7, S.71-119 (1993); F.F. White, B. Jenes et al., *Techniques for Gene Transfer*, in: *Transgenic Plants*, Vol. 1, Engineering and Utilization, eds.: Kung und R. Wu, Academic Press (1993), 128-43; Potrykus, *Annu. Rev. Plant Physiol. Plant Molec. Biol.* 42 (1991), 205-225; or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic

Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out with vectors  
5 containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein but also to the C-terminus or fused within suitable regions in the proteins. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to  
10 increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes,  
15 and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant  
20 protein. In one embodiment, the coding sequence of the TCMRP is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-X protein. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant TCMRP unfused to GST can be recovered by cleavage of the fusion  
25 protein with thrombin.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., (1988) *Gene* 69:301-315) and pET 11d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host  
30 RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident  $\lambda$

prophage harboring a T7 *gn1* gene under the transcriptional control of the *lacUV 5* promoter.

One strategy to maximize recombinant protein expression is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in the bacterium chosen for expression, such as *C. glutamicum* (Wada et al. (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the TCMRP expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, et al., (1987) *Embo J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al., (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Vectors and methods for the construction of vectors appropriate for use in other fungi, such as the filamentous fungi, include those detailed in: van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, J.F. Peberdy, et al., eds., p. 1-28, Cambridge University Press: Cambridge.

Alternatively, the TCMRPs of the invention can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC (Kaufman et al. (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F.,

and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

In another embodiment, the recombinant mammalian expression vector is  
5 capable of directing expression of the nucleic acid preferentially in a particular cell type  
(e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-  
specific regulatory elements are known in the art. Non-limiting examples of suitable  
tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al.  
(1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988)  
10 *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and  
Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji et al. (1983) *Cell*  
33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters  
(e.g., the neurofilament promoter; Byrne and Ruddle (1989) *PNAS* 86:5473-5477),  
pancreas-specific promoters (Edlund et al. (1985) *Science* 230:912-916), and mammary  
15 gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and  
European Application Publication No. 264,166). Developmentally-regulated promoters  
are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990)  
*Science* 249:374-379) and the fetoprotein promoter (Campes and Tilghman (1989)  
*Genes Dev.* 3:537-546).

20 In another embodiment, the TCMRPs of the invention may be expressed  
in unicellular plant cells (such as algae) see Falciatore et al., 1999, *Marine*  
*Biotechnology*.1 (3):239-251 and references therein and plant cells from higher plants  
(e.g., the spermatophytes, such as crop plants). Examples of plant expression vectors  
include those detailed in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992)  
25 "New plant binary vectors with selectable markers located proximal to the left border",  
*Plant Mol. Biol.* 20: 1195-1197; and Bevan, M.W. (1984) "Binary *Agrobacterium*  
vectors for plant transformation, *Nucl. Acid. Res.* 12: 8711-8721; Vectors for Gene  
Transfer in Higher Plants; in: *Transgenic Plants*, Vol. 1, Engineering and Utilization,  
eds.: Kung und R. Wu, Academic Press, 1993, S. 15-38.

30 Further, TCMRP genes can be incorporated into a derivative of the transformation  
vector pBin-19 with 35S promoter (Bevan, M., *Nucleic Acids Research* 12: 8711-8721  
(1984)).

A plant expression cassette preferably contains regulatory sequences capable to drive gene expression in plants cells and which are operably linked so that each sequence can fulfil its function such as termination of transcription such as polyadenylation signals. Preferred polyadenylation signals are those originating from Agrobacterium tumefaciens t-DNA such as the gene 3 known as octopine synthase of the Ti-plasmid pTiACH5 (Gielen et al., EMBO J. 3 (1984), 835 ff) or functional equivalents thereof but also all other terminators are suitable.

As plant gene expression is very often not limited on transcriptional levels a plant expression cassette preferably contains other operably linked sequences like translational enhancers such as the overdrive-sequence containing the 5'-untranslated leader sequence from tobacco mosaic virus enhancing the protein per RNA ratio (Gallie et al 1987, Nucl. Acids Research 15:8693-8711).

Plant gene expression has to be operably linked to an appropriate promoter conferring gene expression in a timely, cell or tissue specific manner. Preferred are promoters driving constitutive expression (Benfey et al., EMBO J. 8 (1989) 2195-2202) like those derived from plant viruses like the 35S CAMV (Franck et al., Cell 21(1980) 285-294), the 19S CaMV (see also US5352605 and WO8402913) or plant promoters like those from Rubisco small subunit described in US4962028.

Other preferred sequences for use operable linkage in plant gene expression cassettes are targeting-sequences necessary to direct the gene-product in its appropriate cell compartment (for review see Kermode, Crit. Rev. Plant Sci. 15, 4 (1996), 285-423 and references cited therein) such as the vacuole, the nucleus, all types of plastids like amyloplasts, chloroplasts, chromoplasts, the extracellular space, mitochondria, the endoplasmic reticulum, oil bodies, peroxisomes and other compartments of plant cells.

It is also possible to use expression cassettes whose DNA sequence encodes, for example, a fusion protein, part of the fusion protein being a transit peptide which governs the translocation of the polypeptide. Preferred are chloroplast-specific transit peptides, which are cleaved enzymatically from the moiety after the TCMRP gene product has been translocated into the chloroplasts. Particularly preferred is the transit peptide which is derived from the plastid Nicotiana tabacum transketolase or from

another transit peptide (for example the Rubisco small subunit transit peptide, or the ferredoxin NADP oxidoreductase and also the isopentenyl pyrophosphate isomerase-2) or its functional equivalent.

- 5 Especially preferred are DNA sequences of three cassettes of the plastid transit peptide of the tobacco plastid transketolase in three reading frames as KpnI/BamHI fragments with an ATG codon in the NcoI cleavage site:

pTP09

10

KpnI\_GGTACCATGGCGTCTTCTTCTTCTCACTCTCTCTCAAGCTATCCTCTC  
TCGTTCTGTCCCTCGCCATGGCTCTGCCTCTTCTTCTCAACTTTCCCCTTCTTC  
TCTCACTTTTTCCGGCCTTAAATCCAATCCCAATATCACCACCTCCCGCCGCC  
GTACTCCTTCCTCCGCCGCCGCCGCCGCCGTCGTAAGGTCACCGGCGATTCTG  
15 TGCCTCAGCTGCAACCGAAACCATAGAGAAAAGTCTGAGACTGCGGGATCC\_Ba  
mHI

pTP10

20 KpnI\_GGTACCATGGCGTCTTCTTCTTCTCACTCTCTCTCAAGCTATCCTCTC  
TCGTTCTGTCCCTCGCCATGGCTCTGCCTCTTCTTCTCAACTTTCCCCTTCTTC  
TCTCACTTTTTCCGGCCTTAAATCCAATCCCAATATCACCACCTCCCGCCGCC  
GTACTCCTTCCTCCGCCGCCGCCGCCGCCGTCGTAAGGTCACCGGCGATTCTG  
TGCCTCAGCTGCAACCGAAACCATAGAGAAAAGTCTGAGACTGCGCTGGATCC  
25 \_BamHI

pTP11

KpnI\_GGTACCATGGCGTCTTCTTCTTCTCACTCTCTCTCAAGCTATCCTCTC  
30 TCGTTCTGTCCCTCGCCATGGCTCTGCCTCTTCTTCTCAACTTTCCCCTTCTTC  
TCTCACTTTTTCCGGCCTTAAATCCAATCCCAATATCACCACCTCCCGCCGCC  
GTACTCCTTCCTCCGCCGCCGCCGCCGCCGTCGTAAGGTCACCGGCGATTCTG

TGCCTCAGCTGCAACCGAAACCATAGAGAAAAGTGGAGACTGCGGGGATCC\_  
BamHI.

5 The biosynthesis site of tocopherols is, inter alia, the leaf tissue, so that leaf-specific expression of the TCMRP genes constitutes a preferred embodiment. However, this does not constitute a limitation since tocopherol biosynthesis need not be restricted to leaf tissue but can also take place in a tissue-specific manner in all other parts of the plant, in particular in fatty seeds.

10 Accordingly, a further preferred embodiment relates to a seed-specific expression of the TCMRP genes.

In addition, constitutive expression of the exogenous TCMRP genes is advantageous. On the other hand, inducible expression may also appear desirable.

15 Expression efficacy of the recombinantly expressed genes can be determined for example *in vitro* by shoot meristem propagation. Also, changes in the nature and level of the expression of the genes, and their effect on tocopherol biosynthesis performance, can be tested on test plants in greenhouse experiments.

20 Plant gene expression can also be facilitated via a chemically inducible promoter (for review see Gatz 1997, Annu. Rev. Plant Physiol. Plant Mol. Biol., 48:89-108). Chemically inducible promoters are especially suitable if gene expression is wanted to occur in a time specific manner. Examples for such promoters are a salicylic acid inducible promoter (WO 95/19443), a tetracycline inducible promoter (Gatz et al.,  
25 (1992) Plant J. 2, 397-404) and an ethanol inducible promoter (WO 93/21334).

Also promoters responding to biotic or abiotic stress conditions are suitable promoters such as the pathogen inducible PRP1-gene promoter (Ward et al., Plant. Mol. Biol. 22 (1993), 361-366), the heat inducible hsp80-promoter from tomato  
30 (US5187267), cold inducible alpha-amylase promoter from potato (WO9612814) or the wound-inducible pinII-promoter (EP375091).

Especially those promoters are preferred which confer gene expression in storage tissues and organs such as cells of the endosperm and the developing embryo.



Suitable promoters are the napin-gene promoter from rapeseed (US5608152), the USP-promoter from *Vicia faba* (Baeumlein et al., Mol Gen Genet, 1991, 225 (3):459-67), the oleosin-promoter from *Arabidopsis* (WO9845461), the phaseolin-promoter from *Phaseolus vulgaris* (US5504200), the Bce4-promoter from *Brassica* (WO9113980) or  
5 the legumin B4 promoter (LeB4; Baeumlein et al., 1992, Plant Journal, 2 (2):233-9) as well as promoters conferring seed specific expression in monocot plants like maize, barley, wheat, rye, rice etc. Suitable promoters to note are the lpt2 or lpt1-gene promoter from barley (WO9515389 and WO9523230) or those described in WO9916890 (promoters from the barley hordein-gene, the rice glutelin gene, the rice oryzin gene, the  
10 rice prolamin gene, the wheat gliadin gene, wheat glutelin gene, the maize zein gene, the oat glutelin gene, the *Sorghum kasirin*-gene, the rye secalin gene).

Also especially suited are promoters that confer plastid-specific gene expression as plastids are the compartment where part of the biosynthesis of amino acids, vitamins, cofactors, nutraceuticals, nucleotide or nucleosides take place. Suitable  
15 promoters such as the viral RNA-polymerase promoter are described in WO9516783 and WO9706250 and the clpP-promoter from *Arabidopsis* described in WO9946394.

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense  
20 orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to TCMRP mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of  
25 cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be  
30 determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al., Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986 and Mol et al., 1990, FEBS Letters 268:427-430.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny  
5 of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, an TCMRP  
10 can be expressed in bacterial cells such as *E.coli*, *C. glutamicum*, insect cells, fungal cells or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells), algae, ciliates, plant cells or fungi. Other suitable host cells are known to those skilled in the art. Preferred are plant cells.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via  
15 conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection", conjugation and transduction are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, natural competence, chemical-  
20 mediated transfer, or electroporation. Suitable methods for transforming or transfecting host cells including plant cells can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) and other laboratory manuals such as *Methods in Molecular Biology*, 1995, Vol. 44, *Agrobacterium* protocols, ed: Gartland  
25 and Davey, Humana Press, Totowa, New Jersey.

Suitable methods are protoplast transformation by polyethylene-glycol-induced DNA uptake, the biolistic method using the gene gun - the so-called particle bombardment method, electroporation, incubation of dry embryos in DNA-containing solution,  
30 microinjection and agrobacterium-mediated gene transfer.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may

integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, 5 hygromycin and methotrexate or in plants that confer resistance towards a herbicide such as glyphosate or glufosinate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding an TCMRP or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by, for example, drug selection (e.g., cells that have incorporated 10 the selectable marker gene will survive, while the other cells die).

To create a homologous recombinant microorganism, a vector is prepared which contains at least a portion of an TCMRP gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the TCMRP gene. Preferably, this TCMRP gene is a *Physcomitrella patens* TCMRP gene, but it can 15 be a homologue from a related plant or even from a mammalian, yeast, or insect source. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous TCMRP gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a knock-out vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous 20 TCMRP gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous TCMRP). To create a point mutation via homologous recombination also DNA-RNA hybrids can be used known as chimeraplasty known from Cole-Strauss et al. 1999, Nucleic Acids Research 27(5):1323-1330 and Kmiec Gene therapy. 19999, 25 American Scientist. 87(3):240-247.

Whereas in the homologous recombination vector, the altered portion of the TCMRP gene is flanked at its 5' and 3' ends by additional nucleic acid of the TCMRP gene to allow for homologous recombination to occur between the exogenous TCMRP gene carried by the vector and an endogenous TCMRP gene in a microorganism or plant. 30 The additional flanking TCMRP nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several hundreds of basepairs up to kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see e.g., Thomas, K.R., and Capecchi, M.R. (1987) Cell 51: 503 for a

description of homologous recombination vectors or Strepp et al., 1998, PNAS, 95 (8):4368-4373 for cDNA based recombination in *Physcomitrella patens*). The vector is introduced into a microorganism or plant cell (e.g., via polyethyleneglycol mediated DNA) and cells in which the introduced TCMRP gene has homologously recombined  
5 with the endogenous TCMRP gene are selected, using art-known techniques.

In another embodiment, recombinant microorganisms can be produced which contain selected systems which allow for regulated expression of the introduced gene. For example, inclusion of an TCMRP gene on a vector placing it under control of the lac operon permits expression of the TCMRP gene only in the presence of IPTG. Such  
10 regulatory systems are well known in the art.

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) an TCMRP. An alternate method can be applied in addition in plants by the direct transfer of DNA into developing flowers via electroporation or *Agrobacterium* medium gene transfer. Accordingly, the invention  
15 further provides methods for producing TCMRPs using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding an TCMRP has been introduced, or into which genome has been introduced a gene encoding a wild-type or altered TCMRP) in a suitable medium until TCMRP is produced. In another embodiment, the method  
20 further comprises isolating TCMRPs from the medium or the host cell.

### *C. Isolated TCMRPs*

Another aspect of the invention pertains to isolated TCMRPs, and biologically active portions thereof. An "isolated" or "purified" protein or biologically active portion  
25 thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of TCMRP in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language "substantially  
30 free of cellular material" includes preparations of TCMRP having less than about 30% (by dry weight) of non-TCMRP (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-TCMRP, still more preferably less than about 10% of non-TCMRP, and most preferably less than about 5% non-TCMRP.

When the TCMRP or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The language "substantially free of chemical precursors or other chemicals" includes preparations of TCMRP in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of TCMRP having less than about 30% (by dry weight) of chemical precursors or non-TCMRP chemicals, more preferably less than about 20% chemical precursors or non-TCMRP chemicals, still more preferably less than about 10% chemical precursors or non-TCMRP chemicals, and most preferably less than about 5% chemical precursors or non-TCMRP chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same organism from which the TCMRP is derived. Typically, such proteins are produced by recombinant expression of, for example, a *Physcomitrella patens* TCMRP in other plants than *Physcomitrella patens* or microorganisms such as *C. glutamicum* or ciliates, algae or fungi.

An isolated TCMRP or a portion thereof of the invention can participate in the metabolism of amino acids, vitamins, cofactors, nutraceuticals, nucleotides or nucleosides in *Physcomitrella patens*, or has one or more of the activities set forth in Table 1. In preferred embodiments, the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to participate in the metabolism of fine chemicals like amino acids, vitamins, cofactors, nutraceuticals, nucleotides, or nucleosides in *Physcomitrella patens*. The portion of the protein is preferably a biologically active portion as described herein. In another preferred embodiment, an TCMRP of the invention has an amino acid sequence shown in Appendix B. In yet another preferred embodiment, the TCMRP has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to a nucleotide sequence of Appendix A. In still another preferred embodiment, the TCMRP has an amino acid sequence which is encoded by a nucleotide sequence that is at least about 50-60%, preferably at least about 60-70%, more preferably at least about 70-80%, 80-90%, 90-95%, and even more preferably at

least about 96%, 97%, 98%, 99% or more homologous to one of the amino acid sequences of Appendix B. The preferred TCMRPS of the present invention also preferably possess at least one of the TCMRP activities described herein. For example, a preferred TCMRP of the present invention includes an amino acid sequence encoded  
5 by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to a nucleotide sequence of Appendix A, and which can participate in the metabolism of tocopherols or carotenoids in *Physcomitrella patens*, or which has one or more of the activities set forth in Table 1.

In other embodiments, the TCMRP is substantially homologous to an amino acid  
10 sequence of Appendix B and retains the functional activity of the protein of one of the sequences of Appendix B yet differs in amino acid sequence due to natural variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the TCMRP is a protein which comprises an amino acid sequence which is at least about 50-60%, preferably at least about 60-70%, and more preferably at least  
15 about 70-80, 80-90, 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of Appendix B and which has at least one of the TCMRP activities described herein. In another embodiment, the invention pertains to a full *Physcomitrella patens* protein which is substantially homologous to an entire amino acid sequence of Appendix B.

20 Biologically active portions of an TCMRP include peptides comprising amino acid sequences derived from the amino acid sequence of an TCMRP, e.g., the an amino acid sequence shown in Appendix B or the amino acid sequence of a protein homologous to an TCMRP, which include fewer amino acids than a full length TCMRP or the full length protein which is homologous to an TCMRP, and exhibit at least one  
25 activity of an TCMRP. Typically, biologically active portions (peptides, e.g., peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif with at least one activity of an TCMRP. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the  
30 activities described herein. Preferably, the biologically active portions of an TCMRP include one or more selected domains/motifs or portions thereof having biological activity.

TCMRPs are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the TCMRP is expressed in the host cell. The TCMRP can then be  
5 isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, an TCMRP, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native TCMRP can be isolated from cells (e.g., endothelial cells), for example using an anti-TCMRP antibody, which can be produced by standard  
10 techniques utilizing an TCMRP or fragment thereof of this invention.

The invention also provides TCMRP chimeric or fusion proteins. As used herein, an TCMRP "chimeric protein" or "fusion protein" comprises an TCMRP polypeptide operatively linked to a non-TCMRP polypeptide. An "TCMRP polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an  
15 TCMRP, whereas a "non-TCMRP polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the TCMRP, e.g., a protein which is different from the TCMRP and which is derived from the same or a different organism. Within the fusion protein, the term "operatively linked" is intended to indicate that the TCMRP polypeptide and the non-TCMRP  
20 polypeptide are fused to each other so that both sequences fulfil the proposed function addicted to the sequence used. The non-TCMRP polypeptide can be fused to the N-terminus or C-terminus of the TCMRP polypeptide. For example, in one embodiment the fusion protein is a GST-TCMRP fusion protein in which the TCMRP sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the  
25 purification of recombinant TCMRPs. In another embodiment, the fusion protein is an TCMRP containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of an TCMRP can be increased through use of a heterologous signal sequence.

Preferably, an TCMRP chimeric or fusion protein of the invention is produced  
30 by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini,

filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor  
5 primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al. John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An TCMRP -  
10 encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the TCMRP.

Homologues of the TCMRP can be generated by mutagenesis, e.g., discrete point mutation or truncation of the TCMRP. As used herein, the term "homologue" refers to a variant form of the TCMRP which acts as an agonist or antagonist of the activity of the  
15 TCMRP. An agonist of the TCMRP can retain substantially the same, or a subset, of the biological activities of the TCMRP. An antagonist of the TCMRP can inhibit one or more of the activities of the naturally occurring form of the TCMRP, by, for example, competitively binding to a downstream or upstream member of the cell membrane component metabolic cascade which includes the TCMRP, or by binding to an TCMRP  
20 which mediates transport of compounds across such membranes, thereby preventing translocation from taking place.

In an alternative embodiment, homologues of the TCMRP can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the TCMRP for TCMRP agonist or antagonist activity. In one embodiment, a variegated library of  
25 TCMRP variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of TCMRP variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential TCMRP sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins  
30 (e.g., for phage display) containing the set of TCMRP sequences therein. There are a variety of methods which can be used to produce libraries of potential TCMRP homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the



synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential TCMRP sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) *Tetrahedron* 39:3; 5 Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477.

In addition, libraries of fragments of the TCMRP coding can be used to generate a variegated population of TCMRP fragments for screening and subsequent selection of homologues of an TCMRP. In one embodiment, a library of coding sequence fragments 10 can be generated by treating a double stranded PCR fragment of an TCMRP coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 15 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the TCMRP.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA 20 libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of TCMRP homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the 25 resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify TCMRP homologues (Arkin and 30 Yourvan (1992) *PNAS* 89:7811-7815; Delgrave et al. (1993) *Protein Engineering* 6(3):327-331).

In another embodiment, cell based assays can be exploited to analyze a variegated TCMRP library, using methods well known in the art.

#### D. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, fusion proteins, primers, vectors, and host cells described herein can be used in one or more of the following methods: identification of *Physcomitrella patens* and related organisms; mapping of genomes of organisms related to *Physcomitrella patens*; identification and localization of *Physcomitrella patens* sequences of interest; evolutionary studies; determination of TCMRP regions required for function; modulation of an TCMRP activity; modulation of the cellular production of one or more fine chemicals such as tocopherols or carotenoids. The TCMRP nucleic acid molecules of the invention have a variety of uses. First, they may be used to identify an organism as being *Physcomitrella patens* or a close relative thereof. Also, they may be used to identify the presence of *Physcomitrella patens* or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of *Physcomitrella patens* genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a *Physcomitrella patens* gene which is unique to this organism, one can ascertain whether this organism is present.

Further, the nucleic acid and protein molecules of the invention may serve as markers for specific regions of the genome. This has utility not only in the mapping of the genome, but also for functional studies of *Physcomitrella patens* proteins. For example, to identify the region of the genome to which a particular *Physcomitrella patens* DNA-binding protein binds, the *Physcomitrella patens* genome could be digested, and the fragments incubated with the DNA-binding protein. Those which bind the protein may be additionally probed with the nucleic acid molecules of the invention, preferably with readily detectable labels; binding of such a nucleic acid molecule to the genome fragment enables the localization of the fragment to the genome map of *Physcomitrella patens*, and, when performed multiple times with different enzymes, facilitates a rapid determination of the nucleic acid sequence to which the protein binds. Further, the nucleic acid molecules of the invention may be sufficiently homologous to the sequences of related species such that these nucleic acid molecules may serve as markers for the construction of a genomic map in related mosses, such as *Physcomitrella patens*.

The TCMRP nucleic acid molecules of the invention are also useful for evolutionary and protein structural studies. The metabolic and transport processes in which the molecules of the invention participate are utilized by a wide variety of prokaryotic and eukaryotic cells; by comparing the sequences of the nucleic acid molecules of the present invention to those encoding similar enzymes from other organisms, the evolutionary relatedness of the organisms can be assessed. Similarly, such a comparison permits an assessment of which regions of the sequence are conserved and which are not, which may aid in determining those regions of the protein which are essential for the functioning of the enzyme. This type of determination is of value for protein engineering studies and may give an indication of what the protein can tolerate in terms of mutagenesis without losing function.

Manipulation of the TCMRP nucleic acid molecules of the invention may result in the production of TCMRPs having functional differences from the wild-type TCMRPs. These proteins may be improved in efficiency or activity, may be present in greater numbers in the cell than is usual, or may be decreased in efficiency or activity.

There are a number of mechanisms by which the alteration of an TCMRP of the invention may directly affect the yield, production, and/or efficiency of production of a fine chemical like tocopherols and carotenoids incorporating such an altered protein into microorganisms, algae or plants. Recovery of fine chemical compounds from large-scale cultures of *C. glutamicum*, *ciliates*, *algae* or *fungi* is significantly improved if the cell secretes the desired compounds, since such compounds may be readily purified from the culture medium (as opposed to extracted from the mass of *cultured* cells). In the case of plants expressing TCMRPs increased transport can lead to improved partitioning within the plant tissue and organs. By either increasing the number or the activity of transporter molecules which export fine chemicals from the cell, it may be possible to increase the amount of the produced fine chemical which is present in the extracellular medium, thus permitting greater ease of harvesting and purification or in case of plants mor efficient partitioning. Conversely, in order to efficiently overproduce one or more fine chemicals, increased amounts of the cofactors, precursor molecules, and intermediate compounds for the appropriate biosynthetic pathways are required. Therefore, by increasing the number and/or activity of transporter proteins involved in the import of nutrients, such as carbon sources (i.e., sugars), nitrogen sources (i.e., amino acids, ammonium salts),

phosphate, and sulfur, it may be possible to improve the production of a fine chemical, due to the removal of any nutrient supply limitations on the biosynthetic process.

The engineering of one or more TCMRP genes of the invention may also result in TCMRPs having altered activities which indirectly impact the production of one or more desired fine chemicals from algae, plants, ciliates or fungi or other microorganisms like *C. glutamicum*. For example, the normal biochemical processes of metabolism result in the production of a variety of waste products (e.g., hydrogen peroxide and other reactive oxygen species) which may actively interfere with these same metabolic processes (for example, peroxynitrite is known to nitrate tyrosine side chains, thereby inactivating some enzymes having tyrosine in the active site (Groves, J.T. (1999) *Curr. Opin. Chem. Biol.* 3(2): 226-235). While these waste products are typically excreted, cells utilized for large-scale fermentative production are optimized for the overproduction of one or more fine chemicals, and thus may produce more waste products than is typical for a wild-type cell. By optimizing the activity of one or more TCMRPs of the invention which are involved in the export of waste molecules, it may be possible to improve the viability of the cell and to maintain efficient metabolic activity. Also, the presence of high intracellular levels of the desired fine chemical may actually be toxic to the cell, so by increasing the ability of the cell to secrete these compounds, one may improve the viability of the cell.

Further, the TCMRPs of the invention may be manipulated such that the relative amounts of various lipophilic fine chemicals like for example vitamin E or carotenoids are altered. This may have a profound effect on the lipid composition of the membrane of the cell. Since each type of lipid has different physical properties, an alteration in the lipid composition of a membrane may significantly alter membrane fluidity. Changes in membrane fluidity can impact the transport of molecules across the membrane, which, as previously explicated, may modify the export of waste products or the produced fine chemical or the import of necessary nutrients. Such membrane fluidity changes may also profoundly affect the integrity of the cell; cells with relatively weaker membranes are more vulnerable abiotic and biotic stress conditions which may damage or kill the cell. By manipulating TCMRPs involved in the production of fatty acids and lipids for membrane construction such that the resulting membrane has a membrane composition more amenable to the environmental conditions extant in the cultures utilized to produce fine chemicals, a greater proportion of the cells should survive and multiply. Greater

numbers of *producing* cells should translate into greater yields, production, or efficiency of production of the fine chemical from the culture.

The aforementioned mutagenesis strategies for TCMRPs to result in increased yields of a fine chemical are not meant to be limiting; variations on these strategies will be readily apparent to one skilled in the art. Using such strategies, and incorporating the mechanisms disclosed herein, the nucleic acid and protein molecules of the invention may be utilized to generate *algae, ciliates, plants, fungi or other microorganisms like C. glutamicum* expressing mutated TCMRP nucleic acid and protein molecules such that the yield, production, and/or efficiency of production of a desired compound is improved. This desired compound may be any natural product of algae, ciliates, plants, fungi or *C. glutamicum*, which includes the final products of biosynthesis pathways and intermediates of naturally-occurring metabolic pathways, as well as molecules which do not naturally occur in the metabolism of said cells, but which are produced by a said cells of the invention.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, and published patent applications cited throughout this application are hereby incorporated by reference.

## 20 Exemplification

### Example 1: General processes

#### a) General cloning processes:

Cloning processes such as, for example, restriction cleavages, agarose gel electrophoresis, purification of DNA fragments, transfer of nucleic acids to nitrocellulose and nylon membranes, linkage of DNA fragments, transformation of *Escherichia coli* and yeast cells, growth of bacteria and sequence analysis of recombinant DNA were carried out as described in Sambrook et al. (1989) (Cold Spring Harbor Laboratory Press: ISBN 0-87969-309-6) or Kaiser, Michaelis and Mitchell (1994) „Methods in Yeast Genetics“ (Cold Spring Harbor Laboratory Press: ISBN 0-87969-451-3). Transformation and cultivation of algae such as *Chlorella* or *Phaeodactylum* are transformed as described by El-Sheekh (1999), *Biologia Plantarum*

42: 209-216; Apt et al. (1996), Molecular and General Genetics 252 (5): 872-9.

b)Chemicals:

5 The chemicals used were obtained, if not mentioned otherwise in the text, in p.a. quality from the companies Fluka (Neu-Ulm), Merck (Darmstadt), Roth (Karlsruhe), Serva (Heidelberg) and Sigma (Deisenhofen). Solutions were prepared using purified, pyrogen-free water, designated as H<sub>2</sub>O in the following text, from a Milli-Q water system water purification plant (Millipore, Eschborn). Restriction endonucleases, DNA-  
10 modifying enzymes and molecular biology kits were obtained from the companies AGS (Heidelberg), Amersham (Braunschweig), Biometra (Göttingen), Boehringer (Mannheim), Genomed (Bad Oeynhausen), New England Biolabs (Schwalbach/Taunus), Novagen (Madison, Wisconsin, USA), Perkin-Elmer (Weiterstadt), Pharmacia (Freiburg), Qiagen (Hilden) and Stratagene (Amsterdam,  
15 Netherlands). They were used, if not mentioned otherwise, according to the manufacturer's instructions.

c)Plant material

20 For this study, plants of the species *Physcomitrella patens* (Hedw.) B.S.G. from the collection of the genetic studies section of the University of Hamburg were used. They originate from the strain 16/14 collected by H.L.K. Whitehouse in Gransden Wood, Huntingdonshire (England), which was subcultured from a spore by Engel (1968, Am J Bot 55, 438-446). Proliferation of the plants was carried out by means of spores and by  
25 means of regeneration of the gametophytes. The protonema developed from the haploid spore as a chloroplast-rich chloronema and chloroplast-low caulonema, on which buds formed after approximately 12 days. These grew to give gametophores bearing antheridia and archegonia. After fertilization, the diploid sporophyte with a short seta and the spore capsule resulted, in which the meiospores mature.

30

d) Plant growth

Culturing was carried out in a climatic chamber at an air temperature of 25°C and light

intensity of 55 micromols-1m-2 (white light; Philips TL 65W/25 fluorescent tube) and a light/dark change of 16/8 hours. The moss was either modified in liquid culture using Knop medium according to Reski and Abel (1985, Planta 165, 354-358) or cultured on Knop solid medium using 1% oxoid agar (Unipath, Basingstoke, England).

- 5 The protonemas used for RNA and DNA isolation were cultured in aerated liquid cultures. The protonemas were comminuted every 9 days and transferred to fresh culture medium.

10

**Example 2: Total DNA isolation from plants**

The details for the isolation of total DNA relate to the working up of one gram fresh weight of plant material.

15

CTAB buffer: 2% (w/v) N-cethyl-N,N,N-trimethylammonium bromide (CTAB); 100 mM Tris HCl pH 8.0; 1.4 M NaCl; 20 mM EDTA.

20

N-Laurylsarcosine buffer: 10% (w/v) N-laurylsarcosine; 100 mM Tris HCl pH 8.0; 20 mM EDTA.

- The plant material was triturated under liquid nitrogen in a mortar to give a fine powder and transferred to 2 ml Eppendorf vessels. The frozen plant material was then covered with a layer of 1 ml of decomposition buffer (1 ml CTAB buffer, 100 ml of N-laurylsarcosine buffer, 20 ml of b-mercaptoethanol and 10 ml of proteinase K solution, 10 mg/ml) and incubated at 60 C for one hour with continuous shaking. The homogenate obtained was distributed into two Eppendorf vessels (2 ml) and extracted twice by shaking with the same volume of chloroform/isoamyl alcohol (24:1). For phase separation, centrifugation was carried out at 8000 x g and RT for 15 min in each case.
- 25 The DNA was then precipitated at -70 C for 30 min using ice-cold isopropanol. The precipitated DNA was sedimented at 4 C and 10,000 g for 30 min and resuspended in 180 ml of TE buffer (Sambrook et al., 1989, Cold Spring Harbor Laboratory Press: ISBN 0-87969-309-6). For further purification, the DNA was treated with NaCl (1.2 M
- 30

final concentration) and precipitated again at  $-70^{\circ}\text{C}$  for 30 min using twice the volume of absolute ethanol. After a washing step with 70% ethanol, the DNA was dried and subsequently taken up in 50 ml of  $\text{H}_2\text{O}$  + RNase (50 mg/ml final concentration). The DNA was dissolved overnight at  $4^{\circ}\text{C}$  and the RNase digestion was subsequently carried out at  $37^{\circ}\text{C}$  for 1 h. Storage of the DNA took place at  $4^{\circ}\text{C}$ .

### Example 3: Isolation of total RNA and poly-(A)<sup>+</sup> RNA from plants

For the investigation of transcripts, both total RNA and poly-(A)<sup>+</sup> RNA were isolated. The total RNA was obtained from wild-type 9d old protonemata following the GTC-method (Reski et al. 1994, Mol. Gen. Genet., 244:352-359).

Isolation of PolyA<sup>+</sup> RNA was isolated using Dyna Beads<sup>R</sup> (Dyna, Oslo) Following the instructions of the manufacturers protocol.

After determination of the concentration of the RNA or of the poly-(A)<sup>+</sup> RNA, the RNA was precipitated by addition of 1/10 volumes of 3 M sodium acetate pH 4.6 and 2 volumes of ethanol and stored at  $-70^{\circ}\text{C}$ .

### Example 4: cDNA library construction

For cDNA library construction first strand synthesis was achieved using Murine Leukemia Virus reverse transcriptase (Roche, Mannheim, Germany) and oligo-d(T)-primers, second strand synthesis by incubation with DNA polymerase I, Klenow enzyme and RNaseH digestion at  $12^{\circ}\text{C}$  (2h),  $16^{\circ}\text{C}$  (1h) and  $22^{\circ}\text{C}$  (1h). The reaction was stopped by incubation at  $65^{\circ}\text{C}$  (10 min) and subsequently transferred to ice. Double stranded DNA molecules were blunted by T4-DNA-polymerase (Roche, Mannheim) at  $37^{\circ}\text{C}$  (30 min). Nucleotides were removed by phenol/chloroform extraction and Sephadex -G50 spin columns. EcoRI adapters (Pharmacia, Freiburg, Germany) were ligated to the cDNA ends by T4-DNA-ligase (Roche,  $12^{\circ}\text{C}$ , overnight) and phosphorylated by incubation with polynucleotide kinase (Roche,  $37^{\circ}\text{C}$ , 30 min). This mixture was subjected to separation on a low melting agarose gel. DNA molecules larger than 300 basepairs were eluted from the gel, phenol extracted, concentrated on



Elutip-D-columns (Schleicher and Schuell, Dassel, Germany) and were ligated to vector arms and packed into lambda ZAPII – phages or lambda ZAP-Express phages using the Gigapack Gold Kit (Stratagene, Amsterdam, Netherlands) using material and following the instructions of the manufacturer.

5

#### Example 5: Identification of genes of interest

Gene sequences can be used to identify homologous or heterologous genes from cDNA or genomic libraries.

- 10 Homologous genes (e. g. full length cDNA clones) can be isolated via nucleic acid hybridization using for example cDNA libraries: Depended on the abundance of the gene of interest 100 000 up to 1 000 000 recombinant bacteriophages are plated and transferred to a nylon membrane. After denaturation with alkali, DNA is immobilized on the membrane by e. g. UV cross linking. Hybridization is carried out at high stringency
- 15 conditions. In aqueous solution hybridization and washing is performed at an ionic strength of 1 M NaCl and a temperature of 68 °C. Hybridization probes are generated by e. g. radioactive (<sup>32</sup>P) nick transcription labeling (Amersham Ready Prime). Signals are detected by exposure to x-ray films.

- Partially homologous or heterologous genes that are related but not identical can be
- 20 identified analog to the above described procedure using low stringency hybridization and washing conditions. For aqueous hybridization the ionic strength is normally kept at 1 M NaCl while the temperature is progressively lowered from 68 to 42 °C.

- Isolation of gene sequences with homologies only in a distinct domain of (for example
- 25 20 aminoacids) can be carried out by using synthetic radio labeled oligonucleotide probes. Radio labeled oligonucleotides are prepared by phosphorylation of the 5'-prime end of two complementary oligonucleotides with T4 polynucleotide kinase. The complementary oligonucleotides are annealed and ligated to form concatemers. The double stranded concatemers are then radiolabeled by for example nick transcription. Hybridization is normally performed at low stringency conditions using high
- 30 oligonucleotide concentrations.

Oligonucleotide hybridization solution:

6 x SSC

0.01 M sodium phosphate

1 mM EDTA (pH 8)

0.5 % SDS

100 µg/ml denaturated salmon sperm DNA

0.1 % nonfat dried milk

5

During hybridization temperature is lowered stepwise to 5-10 °C below the estimated oligonucleotide  $T_m$ .

Further details are described by Sambrook, J. *et al.* (1989), "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory Press or Ausubel, F.M. *et al.* 10 (1994) "Current Protocols in Molecular Biology", John Wiley & Sons.

**Example 6:** Identification of genes of interest by screening expression libraries with antibodies

15 C-DNA sequences can be used to produce recombinant protein for example in *E. coli* (e.g. Qiagen QIAexpress pQE system). Recombinant proteins are then normally affinity purified via Ni-NTA affinity chromatography (Qiagen). Recombinant proteins are then used to produce specific antibodies for example by using standard techniques for rabbit immunization. Antibodies are affinity purified using a Ni-NTA column saturated with 20 the recombinant antigen as described by Gu *et al.*, (1994) *BioTechniques* 17: 257-262. The antibody can then be used to screen expression cDNA libraries to identify homologous or heterologous genes via an immunological screening (Sambrook, J. *et al.* (1989), "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory Press or Ausubel, F.M. *et al.* (1994) "Current Protocols in Molecular Biology", John 25 Wiley & Sons).

**Example 7:** Northern-hybridization

For RNA hybridization, 20 mg of total RNA or 1 mg of poly-(A)<sup>+</sup> RNA were separated 30 by gel electrophoresis in 1.25% strength agarose gels using formaldehyde as described in Amasino (1986, *Anal. Biochem.* 152, 304), transferred by capillary attraction using 10 x SSC to positively charged nylon membranes (Hybond N<sup>+</sup>, Amersham, Braunschweig), immobilized by UV light and prehybridized for 3 hours at 68°C using

hybridization buffer (10% dextran sulfate w/v, 1 M NaCl, 1% SDS, 100 mg of herring sperm DNA). The labeling of the DNA probe with the "Highprime DNA labeling kit" (Roche, Mannheim, Germany) was carried out during the prehybridization using alpha-<sup>32</sup>P dCTP (Amersham, Braunschweig, Germany). Hybridization was carried out after  
5 addition of the labeled DNA probe in the same buffer at 68°C overnight. The washing steps were carried out twice for 15 min using 2 x SSC and twice for 30 min using 1 x SSC, 1% SDS at 68°C. The exposure of the sealed-in filters was carried out at -70°C for a period of 1-14d.

#### 10 Example 8: DNA Sequencing

CDNA libraries as described in Example 4 were used for DNA sequencing according to standard methods, in particular by the chain termination method using the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer, Weiterstadt,  
15 Germany). Random Sequencing was carried out subsequent to preparative plasmid recovery from cDNA libraries via in vivo mass excision and retransformation of DH10B on agar plates (material and protocol details from Stratagene, Amsterdam, Netherlands. Plasmid DNA was prepared from overnight grown E. coli cultures grown in Luria-Broth medium containing ampicillin (see Sambrook et al. (1989) (Cold Spring Harbor  
20 Laboratory Press: ISBN 0-87969-309-6)) on a Qiagen DNA preparation robot (Qiagen, Hilden) according to the manufacturers protocols. Sequencing primers with the following nucleotide sequences were used:

5'-CAGGAAACAGCTATGACC-3'

5'-CTAAAGGGAACAAAAGCTG-3'

25 5'-TGTAACGACGGCCAGT-3'

#### Example 9: Plasmids for plant transformation

For plant transformation binary vectors such as pBinAR-TkTp-9 (Badur, 1998 PhD  
30 thesis, Georg August University of Göttingen, Germany, „Molecular and functional analysis of isoenzymes for example of fructose-1,6-bisphosphate aldolase, phosphoglucose-isomerase and 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase“ [„Molekularbiologische und funktionelle Analyse von pflanzlichen

Isoenzymen am Beispiel der Fructose-1,6-bisphosphat Aldolase, Phosphoglucose-Isomerase und der 3-Deoxy-D-Arabino-Heptulosonat-7-Phosphat Synthase“) can be used. This vector is a derivative of pBinAR (Höfgen and Willmitzer, Plant Science 66(1990), 221-230) and contains the CaMV (cauliflower mosaic virus) 35S promoter  
5 (Franck et al., 1980), the termination signal of the octopine synthase gene (Gielen et al., 1984) and the DNA sequence encoding the transit peptide of the *Nicotiana tabacum* plastid transketolase. Construction of the binary vectors can be performed by ligation of the cDNA in sense or antisense orientation into the T-DNA.

5'-prime to the cDNA a plant promotor activates transcription of the cDNA. A  
10 polyadenylation sequence is located 3'-prime to the cDNA.

Tissue specific expression can be archived by using a tissue specific promotor. For example seed specific expression can be archived by cloning the napin or USP promotor 5'-prime to the cDNA. Also any other seed specific promotor element can be used. For constitutive expression within the whole plant the CaMV 35S promotor can be used.

15 The expressed protein can be targeted to a cellular compartment using a signal peptide, for example for plasmids, mitochondria or endoplasmatic reticulum (Kermode, Crit. Rev. Plant Sci. 15, 4 (1996), 285-423). The signal peptide is cloned 5'-prime in frame to the cDNA to archive subcellular localization of the fusionprotein.

Nucleic acid molecules from *Physcomitrella* are used for a direct gene knock-out by  
20 homologous recombination. Therefore *Physcometrella* sequences are useful for functional genomic approaches. The technique is described by Strepp et al., Proc. Natl. Acad. Sci. USA, 1998, 95: 4369 – 4373; Girke et al. (1998), Plant Journal 15: 39-48; Hofmann et al. (1999) Molecular and General Genetics 261: 92-99.

25

#### Example 10: Transformation of *Agrobacterium*

*Agrobacterium* mediated plant transformation can be performed using for example the GV3101(pTCMRP90) (Koncz and Schell, Mol. Gen. Genet. 204 (1986), 383-396) or  
30 LBA4404 (Clontech) *Agrobacterium tumefaciens* strain. Transformation can be performed by standard transformation techniques (Deblaere et al., Nucl. Acids. Res. 13 (1984), 4777-4788).

**Example 11: plant transformation**

Agrobacterium mediated plant transformation has been performed using standard transformation and regeneration techniques (Gelvin, Stanton B.; Schilperoort, Robert A,  
5 "Plant Molecular Biology Manual", 2nd Ed. - Dordrecht : Kluwer Academic Publ., 1995.  
- in Sect., Ringbuc Zentrale Signatur: BT11-P ISBN 0-7923-2731-4; Glick, Bernard R.;  
Thompson, John E., "Methods in Plant Molecular Biology and Biotechnology", Boca  
Raton : CRC Press, 1993. - 360 S., ISBN 0-8493-5164-2).

For example rapeseed can be transformed via cotyledon or hypocotyl transformation  
10 (Moloney et al., Plant cell Report 8 (1989), 238-242; De Block et al., Plant Physiol. 91  
(1989, 694-701). Use of antibiotics for agrobacterium and plant selection depends on  
the binary vector and the agrobacterium strain used for transformation. Rapeseed  
selection is normally performed using kanamycin as selectable plant marker.

15 Agrobacterium mediated gene transfer to flax can be performed using for example a  
technique described by Mlynarova et al. (1994), Plant Cell Report 13: 282-285.

Transformation of soybean can be performed using for example a technique described in  
EP 0424 047, US 322 783 (Pioneer Hi-Bred International) or in EP 0397 687, US 5 376  
20 543, US 5 169 770 (University Toledo).

Plant transformation using particle bombardment, Polyethylene Glycol mediated DNA  
uptake or via the Silicon Carbide Fiber technique is for example described by Freeling  
and Walbot "The maize handbook" (1993) ISBN 3-540-97826-7, Springer Verlag New  
25 York).

**Example 12: *In vivo* Mutagenesis**

*In vivo* mutagenesis of microorganisms can be performed by passage of plasmid (or  
30 other vector) DNA through *E. coli* or other microorganisms (e.g. *Bacillus* spp. or yeasts  
such as *Saccharomyces cerevisiae*) which are impaired in their capabilities to maintain  
the integrity of their genetic information. Typical mutator strains have mutations in the  
genes for the DNA repair system (e.g., mutHLS, mutD, mutT, etc.; for reference, see

Rupp, W.D. (1996) DNA repair mechanisms, in: *Escherichia coli* and *Salmonella*, p. 2277-2294, ASM: Washington.) Such strains are well known to those skilled in the art. The use of such strains is illustrated, for example, in Greener, A. and Callahan, M. (1994) *Strategies* 7: 32-34. Transfer of mutated DNA molecules into plants is preferably  
5 done after selection and testing in microorganisms. Transgenic plants are generated according to various examples within the exemplification of this document.

**Example 13: DNA Transfer Between *Escherichia coli* and *Corynebacterium glutamicum***

10 Several *Corynebacterium* and *Brevibacterium* species contain endogenous plasmids (as e.g., pHM1519 or pBL1) which replicate autonomously (for review see, e.g., Martin, J.F. et al. (1987) *Biotechnology*, 5:137-146). Shuttle vectors for *Escherichia coli* and *Corynebacterium glutamicum* can be readily constructed by using standard vectors for *E. coli* (Sambrook, J. et al. (1989), "Molecular Cloning: A Laboratory Manual", Cold Spring  
15 Harbor Laboratory Press or Ausubel, F.M. et al. (1994) "Current Protocols in Molecular Biology", John Wiley & Sons) to which a origin or replication for and a suitable marker from *Corynebacterium glutamicum* is added. Such origins of replication are preferably taken from endogenous plasmids isolated from *Corynebacterium* and *Brevibacterium* species. Of particular use as transformation markers for these species are genes for  
20 kanamycin resistance (such as those derived from the Tn5 or Tn903 transposons) or chloramphenicol (Winnacker, E.L. (1987) "From Genes to Clones — Introduction to Gene Technology, VCH, Weinheim). There are numerous examples in the literature of the construction of a wide variety of shuttle vectors which replicate in both *E. coli* and *C. glutamicum*, and which can be used for several purposes, including gene over-expression  
25 (for reference, see e.g., Yoshihama, M. et al. (1985) *J. Bacteriol.* 162:591-597, Martin J.F. et al. (1987) *Biotechnology*, 5:137-146 and Eikmanns, B.J. et al. (1991) *Gene*, 102:93-98). Using standard methods, it is possible to clone a gene of interest into one of the shuttle vectors described above and to introduce such a hybrid vectors into strains of *Corynebacterium glutamicum*. Transformation of *C. glutamicum* can be achieved by  
30 protoplast transformation (Kastsumata, R. et al. (1984) *J. Bacteriol.* 159:306-311), electroporation (Liebl, E. et al. (1989) *FEMS Microbiol. Letters*, 53:399-303) and in cases where special vectors are used, also by conjugation (as described e.g. in Schäfer, A et al. (1990) *J. Bacteriol.* 172:1663-1666). It is also possible to transfer the shuttle vectors for

*C. glutamicum* to *E. coli* by preparing plasmid DNA from *C. glutamicum* (using standard methods well-known in the art) and transforming it into *E. coli*. This transformation step can be performed using standard methods, but it is advantageous to use an *Mcr*-deficient *E. coli* strain, such as NM522 (Gough & Murray (1983) *J. Mol. Biol.* 166:1-19).

5

**Example 14:** Assessment of the Expression of a recombinant gene product in a transformed organism

The activity of a recombinant gene product in the transformed host organism has been  
10 measured on the transcriptional or/and on the translational level.

A useful method to ascertain the level of transcription of the gene (an indicator of the amount of mRNA available for translation to the gene product) is to perform a Northern blot (for reference see, for example, Ausubel et al. (1988) *Current Protocols in Molecular Biology*, Wiley: New York), in which a primer designed to bind to the gene of interest is  
15 labeled with a detectable tag (usually radioactive or chemiluminescent), such that when the total RNA of a culture of the organism is extracted, run on gel, transferred to a stable matrix and incubated with this probe, the binding and quantity of binding of the probe indicates the presence and also the quantity of mRNA for this gene. This information is evidence of the degree of transcription of the transformed gene. Total cellular RNA can  
20 be prepared from *cells, tissues or organs* by several methods, all well-known in the art, such as that described in Bormann, E.R. et al. (1992) *Mol. Microbiol.* 6: 317-326.

To assess the presence or relative quantity of protein translated from this mRNA, standard techniques, such as a Western blot, may be employed (see, for example, Ausubel et al. (1988) *Current Protocols in Molecular Biology*, Wiley: New  
25 York). In this process, total cellular proteins are extracted, separated by gel electrophoresis, transferred to a matrix such as nitrocellulose, and incubated with a probe, such as an antibody, which specifically binds to the desired protein. This probe is generally tagged with a chemiluminescent or colorimetric label which may be readily detected. The presence and quantity of label observed indicates the presence and  
30 quantity of the desired mutant protein present in the cell.

**Example 15:** Growth of Genetically Modified *Corynebacterium glutamicum* — Media and Culture Conditions

Genetically modified *Corynebacteria* are cultured in synthetic or natural growth media. A number of different growth media for *Corynebacteria* are both well-known and readily available (Lieb *et al.* (1989) *Appl. Microbiol. Biotechnol.*, 32:205-210; von der  
5 Osten *et al.* (1998) *Biotechnology Letters*, 11:11-16; Patent DE 4,120,867; Liebl (1992) "The Genus *Corynebacterium*, in: The Prokaryotes, Volume II, Balows, A. *et al.*, eds. Springer-Verlag). These media consist of one or more carbon sources, nitrogen sources, inorganic salts, vitamins and trace elements. Preferred carbon sources are sugars, such as mono-, di-, or polysaccharides. For example, glucose, fructose, mannose, galactose,  
10 ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose serve as very good carbon sources. It is also possible to supply sugar to the media via complex compounds such as molasses or other by-products from sugar refinement. It can also be advantageous to supply mixtures of different carbon sources. Other possible carbon sources are alcohols and organic acids, such as methanol, ethanol, acetic acid or lactic  
15 acid. Nitrogen sources are usually organic or inorganic nitrogen compounds, or materials which contain these compounds. Exemplary nitrogen sources include ammonia gas or ammonia salts, such as  $\text{NH}_4\text{Cl}$  or  $(\text{NH}_4)_2\text{SO}_4$ ,  $\text{NH}_4\text{OH}$ , nitrates, urea, amino acids or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract and others.

20 Inorganic salt compounds which may be included in the media include the chloride-, phosphorous- or sulfate- salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron. Chelating compounds can be added to the medium to keep the metal ions in solution. Particularly useful chelating compounds include dihydroxyphenols, like catechol or protocatechuate, or organic acids,  
25 such as citric acid. It is typical for the media to also contain other growth factors, such as vitamins or growth promoters, examples of which include biotin, riboflavin, thiamin, folic acid, nicotinic acid, pantothenate and pyridoxin. Growth factors and salts frequently originate from complex media components such as yeast extract, molasses, corn steep liquor and others. The exact composition of the media compounds depends strongly on  
30 the immediate experiment and is individually decided for each specific case. Information about media optimization is available in the textbook "Applied Microbiol. Physiology, A Practical Approach (eds. P.M. Rhodes, P.F. Stanbury, IRL Press (1997) pp. 53-73, ISBN 0



19 963577 3). It is also possible to select growth media from commercial suppliers, like standard 1 (Merck) or BHI (brain heart infusion, DIFC) or others.

All medium components are sterilized, either by heat (20 minutes at 1.5 bar and 121°C) or by sterile filtration. The components can either be sterilized together or, if  
5 necessary, separately. All media components can be present at the beginning of growth, or they can optionally be added continuously or batchwise.

Culture conditions are defined separately for each experiment. The temperature should be in a range between 15°C and 45°C. The temperature can be kept constant or can be altered during the experiment. The pH of the medium should be in the range of 5 to  
10 8.5, preferably around 7.0, and can be maintained by the addition of buffers to the media. An exemplary buffer for this purpose is a potassium phosphate buffer. Synthetic buffers such as MOPS, HEPES, ACES and others can alternatively or simultaneously be used. It is also possible to maintain a constant culture pH through the addition of NaOH or NH<sub>4</sub>OH during growth. If complex medium components such as yeast extract are utilized,  
15 the necessity for additional buffers may be reduced, due to the fact that many complex compounds have high buffer capacities. If a fermentor is utilized for culturing the microorganisms, the pH can also be controlled using gaseous ammonia.

The incubation time is usually in a range from several hours to several days. This time is selected in order to permit the maximal amount of product to accumulate in the  
20 broth. The disclosed growth experiments can be carried out in a variety of vessels, such as microtiter plates, glass tubes, glass flasks or glass or metal fermentors of different sizes. For screening a large number of clones, the microorganisms should be cultured in microtiter plates, glass tubes or shake flasks, either with or without baffles. Preferably 100 ml shake flasks are used, filled with 10% (by volume) of the required growth  
25 medium. The flasks should be shaken on a rotary shaker (amplitude 25 mm) using a speed-range of 100 – 300 rpm. Evaporation losses can be diminished by the maintenance of a humid atmosphere; alternatively, a mathematical correction for evaporation losses should be performed.

If genetically modified clones are tested, an unmodified control clone or a control  
30 clone containing the basic plasmid without any insert should also be tested. The medium is inoculated to an OD<sub>600</sub> of 0.5 – 1.5 using cells grown on agar plates, such as CM plates (10 g/l glucose, 2.5 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract,

22 g/l agar, pH 6.8 with 2M NaOH) that had been incubated at 30°C. Inoculation of the media is accomplished by either introduction of a saline suspension of *C. glutamicum* cells from CM plates or addition of a liquid preculture of this bacterium.

5 **Example 16: *In vitro* Analysis of the Function of *Physcomitrella* genes in transgenic organisms**

The determination of activities and kinetic parameters of enzymes is well established in the art. Experiments to determine the activity of any given altered  
10 enzyme must be tailored to the specific activity of the wild-type enzyme, which is well within the ability of one skilled in the art. Overviews about enzymes in general, as well as specific details concerning structure, kinetics, principles, methods, applications and examples for the determination of many enzyme activities may be found, for example, in the following references: Dixon, M., and Webb, E.C., (1979) *Enzymes*. Longmans:  
15 London; Fersht, (1985) *Enzyme Structure and Mechanism*. Freeman: New York; Walsh, (1979) *Enzymatic Reaction Mechanisms*. Freeman: San Francisco; Price, N.C., Stevens, L. (1982) *Fundamentals of Enzymology*. Oxford Univ. Press: Oxford; Boyer, P.D., ed. (1983) *The Enzymes*, 3<sup>rd</sup> ed. Academic Press: New York; Bisswanger, H., (1994) *Enzymkinetik*, 2<sup>nd</sup> ed. VCH: Weinheim (ISBN 3527300325); Bergmeyer, H.U.,  
20 Bergmeyer, J., Graßl, M., eds. (1983-1986) *Methods of Enzymatic Analysis*, 3<sup>rd</sup> ed., vol. I-XII, Verlag Chemie: Weinheim; and Ullmann's *Encyclopedia of Industrial Chemistry* (1987) vol. A9, "Enzymes". VCH: Weinheim, p. 352-363.

The activity of proteins which bind to DNA can be measured by several well-established methods, such as DNA band-shift assays (also called gel retardation assays).  
25 The effect of such proteins on the expression of other molecules can be measured using reporter gene assays (such as that described in Kolmar, H. et al. (1995) *EMBO J.* 14: 3895-3904 and references cited therein). Reporter gene test systems are well known and established for applications in both pro- and eukaryotic cells, using enzymes such as beta-galactosidase, green fluorescent protein, and several others.

30 The determination of activity of membrane-transport proteins can be performed according to techniques such as those described in Gennis, R.B. (1989) "Pores, Channels and Transporters", in *Biomembranes, Molecular Structure and Function*, Springer: Heidelberg, p. 85-137; 199-234; and 270-322.

**Example 17: Analysis of Impact of Recombinant Proteins on the Production of the Desired Product**

5       The effect of the genetic modification in plants, algae, *C. glutamicum*, fungi, ciliates or on production of a desired compound (such as vitamins) can be assessed by growing the modified microorganism or plant under suitable conditions (such as those described above) and analyzing the medium and/or the cellular component for increased production of the desired product (i.e. fine chemicals). Such analysis techniques are  
10 well known to one skilled in the art, and include spectroscopy, thin layer chromatography, staining methods of various kinds, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example, Ullman, Encyclopedia of Industrial Chemistry, vol. A2, p. 89-90 and p. 443-613, VCH: Weinheim (1985); Fallon, A. et al., (1987)  
15 "Applications of HPLC in Biochemistry" in: Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17; Rehm et al. (1993) Biotechnology, vol. 3, Chapter III: "Product recovery and purification", page 469-714, VCH: Weinheim; Belter, P.A. et al. (1988) Bioseparations: downstream processing for biotechnology, John Wiley and Sons; Kennedy, J.F. and Cabral, J.M.S. (1992) Recovery processes for biological materials,  
20 John Wiley and Sons; Shaeiwitz, J.A. and Henry, J.D. (1988) Biochemical separations, in: Ulmann's Encyclopedia of Industrial Chemistry, vol. B3, Chapter 11, page 1-27, VCH: Weinheim; and Dechow, F.J. (1989) Separation and purification techniques in biotechnology, Noyes Publications.)

25       In addition to the measurement of the final product in plant cells, microorganisms and algae, it is also possible to analyze other components of the metabolic pathways utilized for the production of the desired compound, such as intermediates and side-products, to determine the overall efficiency of production of the compound. Analysis methods include measurements of nutrient levels in the medium (e.g., sugars, hydrocarbons,  
30 nitrogen sources, phosphate, and other ions), measurements of biomass composition and growth, analysis of the production of common metabolites of biosynthetic pathways, and measurement of gasses produced during fermentation. Standard methods for these measurements are outlined in Applied Microbial Physiology, A Practical Approach,

P.M. Rhodes and P.F. Stanbury, eds., IRL Press, p. 103-129; 131-163; and 165-192 (ISBN: 0199635773) and references cited therein.

Material to be analyzed can be disintegrated via sonification, glass milling, liquid  
5 nitrogen and grinding or via other applicable methods. The material has to be centrifuged after disintegration.

#### Vitamin E:

- 10 The determination of tocopherols in cells has been either conducted according to Kurilich et al 1999, J. Agric. Food. Chem. 47: 1576-1581 or alternatively as described in Tani Y and Tsumura H 1989 (Agric. Bio. Chem. 53: 305-312).

#### Carotenoids:

- 15 The large scale production and purification of carotenoids implies a solution for separation of lipophilic impurities from the host cell which have to be separated from the carotenoids. On a production scale the material has to be desintegrated for the production of oleoresins via centrifugation as known skilled in the art from various  
20 production processes or via desintegration followed by evaporation and extraction. Acetone or hexane extraction for 8-12 hours in the dark to avoid carotenoid break down. After removal of the solvent the residue is dissolved in a diethylether-hexane mixture or, in case of hydroxycarotenoids, in acetone-petrol and purified via silica-gel column. Suitable solvent mixtures are diethylether:hexane or petrol (1:4 v/v) for carotenes and  
25 acetone:hexane or petrol (1:4 v/v) for hydroxycarotenoids. To determine carotenoid purity in isolated fractions HPLC techniques are most appropriate (Linden et al., FEMS Microbiol. Let. 106:99-104; Piccaglia et al., 1998; Industrial Crops and Products 8:45-51 and references therein).

30

**Example 18: Purification of the desired Product from transformed organisms**

Recovery of the desired product from plants material or fungi, algae, ciliates or *C. glutamicum* cells or supernatant of the above-described cultures can be performed by various methods well known in the art. If the desired product is not secreted from the cells. The cells, can be harvested from the culture by low-speed centrifugation, the cells  
5 can be lysed by standard techniques, such as mechanical force or sonification. Organs of plants can be separated mechanically from other tissue or organs. Following homogenization cellular debris is removed by centrifugation, and the supernatant fraction containing the soluble proteins is retained for further purification of the desired compound. If the product is secreted from desired cells, then the cells are removed from  
10 the culture by low-speed centrifugation, and the supernate fraction is retained for further purification.

The supernatant fraction from either purification method is subjected to chromatography with a suitable resin, in which the desired molecule is either retained on a chromatography resin while many of the impurities in the sample are not, or where the  
15 impurities are retained by the resin while the sample is not. Such chromatography steps may be repeated as necessary, using the same or different chromatography resins. One skilled in the art would be well-versed in the selection of appropriate chromatography resins and in their most efficacious application for a particular molecule to be purified. The purified product may be concentrated by filtration or ultrafiltration, and stored at a  
20 temperature at which the stability of the product is maximized.

There are a wide array of purification methods known to the art and the preceding method of purification is not meant to be limiting. Such purification techniques are described, for example, in Bailey, J.E. & Ollis, D.F. *Biochemical Engineering Fundamentals*, McGraw-Hill: New York (1986).

25 The identity and purity of the isolated compounds may be assessed by techniques standard in the art. These include high-performance liquid chromatography (HPLC), spectroscopic methods, staining methods, thin layer chromatography, NIRS, enzymatic assay, or microbiologically. Such analysis methods are reviewed in: Patek et al. (1994) *Appl. Environ. Microbiol.* 60: 133-140; Malakhova et al. (1996) *Biotekhnologiya* 11: 27-  
30 32; and Schmidt et al. (1998) *Bioprocess Engineer.* 19: 67-70. *Ullmann's Encyclopedia of Industrial Chemistry*, (1996) vol. A27, VCH: Weinheim, p. 89-90, p. 521-540, p. 540-547, p. 559-566, 575-581 and p. 581-587; Michal, G. (1999) *Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology*, John Wiley and Sons; Fallon, A. et al.

(1987) Applications of HPLC in Biochemistry in: Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17.

Example 19:

5 Generation of transgenic *Brassica napus* plants

The generation of transgenic oilseed rape plants followed in principle a procedure of Bade, J.B. and Damm, B. (in Gene Transfer to Plants, Potrykus, I. and Spangenberg, G., eds, Springer Lab Manual, Springer Verlag, 1995, 30-38), which also indicates the  
10 composition of the media and buffers used. transformations were done with the *Agrobacterium tumefaciens* strains EHA105 and GV3101, respectively. Recombinate plasmids were used for transformation. Seeds of *Brassica napus* var. Westar were surface-sterilized with 70% ethanol (v/v), washed for 10 minutes at 55°C in water, incubated for 20 minutes in 1% strength hypochlorite solution (25% v/v Teepol, 0.1%  
15 v/v Tween 20) and washed six times with sterile water for in each case 20 minutes. The seeds were dried for three days on filter paper and 10-15 seeds were germinated in a glass flask containing 15 ml of germination medium. Roots and apices were removed from several seedlings (approx. size 10 cm), and the hypocotyls which remained were cut into sections of approx. length 6 mm. The approx. 600 explants thus obtained were  
20 washed for 30 minutes in 50 ml of basal medium and transferred into a 300 ml flask. After addition of 100 ml of callus induction medium, the cultures were incubated for 24 hours at 100 rpm.

An overnight culture of agrobacterial strain was set up in Luria broth medium  
25 supplemented with kanamycin (20 mg/l) at 29°C, and 2 ml of this were incubated in 50 ml of Luria broth medium without kanamycin for 4 hours at 29°C until an OD<sub>600</sub> of 0.4-0.5 was reached. After the culture had been pelleted for 25 minutes at 2000 rpm, the cell pellet was resuspended in 25 ml of basal medium. The bacterial concentration of the solution was brought to an OD<sub>600</sub> of 0.3 by adding more basal medium.

30

The callus induction medium was removed from the oilseed rape explants using sterile pipettes, 50 ml of agrobacterial solution were added, and the reaction was mixed carefully and incubated for 20 minutes. The agrobacterial suspension was removed, the

oilseed rape explants were washed for 1 minute with 50 ml of callus induction medium, and 100 ml of callus induction medium were subsequently added. Coculturing was carried out for 24 hours on an orbital shaker at 100 rpm. Coculturing was stopped by removing the callus induction medium and explants were washed twice for in each case  
5 1 minute with 25 ml and twice for 60 minutes with in each case 100 ml of wash medium at 100 rpm. The wash medium together with the explants was transferred into 15 cm Petri dishes, and the medium was removed using sterile pipettes.

For regeneration, in each case 20-30 explants were transferred into 90 mm Petri dishes  
10 containing 25 ml of shoot induction medium supplemented with kanamycin. The Petri dishes were sealed with 2 layers of Leukopor and incubated at 25°C and 2000 lux at photoperiods of 16 hours light/8 hours darkness. Every 12 days, the calli which developed were transferred to fresh Petri dishes containing shoot induction medium. All further steps for the regeneration of intact plants were carried out as described by Bade,  
15 J.B and Damm, B. (in Gene Transfer to Plants, Potrykus, I. and Spangenberg, G., eds, Springer Lab Manual, Springer Verlag, 1995, 30-38).

#### Example 20:

##### Generation of transgenic *Nicotiana tabacum* plants

20 10 ml of YEB medium supplemented with antibiotic (5 g/l beef extract, 1 g/l yeast extract, 5 g/l peptone, 5 g/l sucrose and 2 mM MgSO<sub>4</sub>) were inoculated with a colony of *Agrobacterium tumefaciens* and the culture was grown overnight at 28°C. The cells were pelleted for 20 minutes at 4°C, 3500 rpm, using a bench-top centrifuge and then  
25 resuspended under sterile conditions in fresh YEB medium without antibiotics. The cell suspension was used for the transformation.

The sterile-grown wild-type plants were obtained by vegetative propagation. To this end, only the tip of the plant was cut off and transferred to fresh 2MS medium in a  
30 sterile preserving jar. As regards the rest of the plant, the hairs on the upper side of the leaves and the central veins of the leaves were removed. Using a razor blade, the leaves were cut into sections of approximate size 1 cm<sup>2</sup>. The agrobacterial culture was transferred into a small Petri dish (diameter 2 cm). The leaf sections were briefly drawn

through this solution and placed with the underside of the leaves on 2MS medium in Petri dishes (diameter 9 cm) in such a way that they touched the medium. After two days in the dark at 25°C, the explants were transferred to plates with callus induction medium and warmed at 28°C in a controlled-environment cabinet. The medium had to  
5 be changed every 7-10 days. As soon as calli formed, the explants were transferred into sterile preserving jars onto shoot induction medium supplemented with claforan (0.6% BiTec-Agar (g/v), 2.0 mg/l zeatin ribose, 0.02 mg/l naphthylacetic acid, 0.02 mg/l of gibberellic acid, 0.25 g/ml claforan, 1.6% glucose (g/v) and 50 mg/l kanamycin). Organogenesis started after approximately one month and it was possible to cut off the  
10 shoots which had formed. The shoots were grown on 2MS medium supplemented with claforan and selection marker. As soon as substantial root ball had developed, it was possible to pot up the plants in seed compost.

#### Example 21:

##### 15 Generation of transgenic *A. thaliana* plants

Wild-type *A. thaliana* plants (Columbia) were transformed with the *Agrobacterium tumefaciens* strain (EHA105) on the basis of a modified method (Steve Clough and Andrew Bent. Floral dip: a simplified method for *Agrobacterium* mediated  
20 transformation of *A. thaliana*. Plant J 16(6):735-43, 1998) of the vacuum infiltration method as described by Bechtold and coworkers (Bechtold, N. Ellis, J. and Pelltier, G., in planta *Agrobacterium*-mediated gene transfer by infiltration of adult *A. thaliana* plants. CRAcad Sci Paris, 1993. 1144(2):204-212).

#### 25 Example 22:

##### Characterization of the transgenic plants

To confirm that expression of the TCMRP genes affected vitamin E biosynthesis in the transgenic plants, the tocopherol and tocotrienol contents in leaves and seeds of the  
30 plants (*Arabidopsis thaliana*, *Brassica napus* and *Nicotiana tabacum*) which had been transformed with the above-described constructs were analyzed. To this end, the transgenic plants were grown in the greenhouse, and plants which express the gene encoding the TCMRP polypeptides were identified at Northern level. The tocopherol



content and the tocotrienol content in leaves and seeds of these plants were determined. In all cases, the tocopherol or tocotrienol concentration is elevated in comparison with untransformed plants.

5 Example 23

Isolation of full length *Physcomitrella patens* 78\_ppprot1\_092\_E12-260 cDNA

Utilizing the partial sequence of the *Physcomitrella patens* clone 78\_ppprot1\_092\_E12 as probe, an *Physcomitrella patens* cDNA library was screened by nucleic acid  
10 hybridization for full length cDNAs.

A large number of hybridizing clones were isolated. The isolated cDNA 78\_ppprot1\_092\_E12-260 (1968 bp) was sequenced completely. 78\_ppprot1\_092\_E12-260 encodes a 492 amino acid protein.

15 Example 24:

Amplification of the coding sequence (ORF) of the full length clone 78\_ppprot1\_092\_E12-260

The coding sequence (ORF) of the 78\_ppprot1\_092\_E12-260 clone was amplified using  
20 polymerase chain reaction (PCR). The sequence of the resultant PCR fragment is designated 092-260cds. The forward and reverse primers (78\_ppprot1\_092\_E125' and 78\_ppprot1\_092\_E123', respectively) were designed to add a BamHI site to the 5' and 3' end of the resulting amplication product.

25 Forward primer 78\_ppprot1\_092\_E12-260\_5':

GGATCCATCATGGCGGTCAATACCGAGC

Reverse primer 78\_ppprot1\_092\_E12-260\_3':

GGATCCCAAGATCATAATGCCTTGTAGGC

30

The PCR reaction was conducted in a 50µl reaction mixture, containing dNTPs (0.2 mM each), 1,5 mM Mg(OAc)<sub>2</sub>, 40 pmol 78\_ppprot1\_092\_E125', 40 pmol

78\_ppprot1\_092\_E123', 15 µl 3,3× rTth DNA Polymerase XLPuffer (PE Applied Biosystems), 5U rTth DNA Polymerase XL (PE Applied Biosystems).

The following conditions were used:

step 1: 5 minutes 94°C (denaturation)

5 step 2: 3 seconds 94°C (denaturation)

step 3: 2 minutes 65°C (annealing)

step 4: 1 minutes 72°C (elongation)

40 cycles step 2-4

step: 5: 10 minutes 72°C

10

The resulting PCR fragment was cloned into the PCR cloning vector pGEM-T (Promega) as described in the instructions. The recombinant plasmid (pGEM-Teasy/092-260cds) was sequenced to confirm the correct amplification.

#### 15 Example 25

Demonstration of 2-methyl-6-phytylplastoquinol-methyltransferase activity (TMT type II) of 78\_ppprot1\_092\_E12 cDNA clone by expression and biochemical analysis in *E.coli*

20 In order to demonstrate that the clone 78\_ppprot1\_092\_E12-260 encodes a protein involved in tocopherol biosynthesis the cDNA 092-260cds (cds = coding sequence amplified as described above) was expressed in *E.coli* and tested for 2-methyl-6-phytylplastoquinol-methyltransferase activity.

Hence, the 092-260cds BamHI fragment was subcloned in the correct reading frame into  
25 the BamHI site of the *E.coli* pQE30 expression vector (QIAexpress Kit, Qiagen). The resulting plasmid (designated pQE30-092-260cds, see Figure 1) was used to transform the *E.coli* expression host strain M15[pREP4].

An *E.coli* colony transformed with the plasmid pQE30-092-260cds was used to  
30 inoculate an overnight culture of Luria broth containing 200µg/ml ampicillin. In the morning an aliquot of this culture was used to inoculate a 100 ml culture of Luria broth containing 200µg/ml ampicillin. This culture was incubated in a shaking incubator at 28°C until the OD<sub>600</sub> of the culture reached 0.4, at which time isopropyl-β-D-

thiogalactopyranosid (IPTG) was added to obtain a final concentration of 0.4 mM IPTG. The culture was incubated for additional three hours at 28°C. Afterwards the cells were harvested by centrifugation at 8000g.

The pellet was resuspended in 600µl lysis buffer (approximately 1-1.5 ml /g cell pellet ,  
5 10 mM HEPES KOH pH 7.8, 5 mM Dithiothreitol (DTT), 0.24 M Sorbitol ). Subsequently Phenylmethylsulfonat (PMSF) was added to a final concentration of 0.15 mM and the homogenate was incubated on ice for 10 minutes.

The cells were lysed by sonification with a microtip sonicator using several 10 second pulses.

10 After adding Triton X100 (f.c. 0.1%) the homogenate was incubated for 30 minutes on ice, and subjected to centrifugation at 25000g for 30 minutes. The supernatant was saved for methyltransferase assays.

The 2-methyl-6-phytylplastoquinol-methyltransferase assay was performed in a 500 µl  
15 volume containing 135µl (about 300-600µg total protein) *E.coli* extract expressing the 092-260 cDNA (prepared as described above), 200µl (125mM) Tricine-NaOH pH 8.0, 100µl (1.25 mM) Sorbitol, 10µl (50mM) MgCl<sub>2</sub> and 20µl (250mM) Ascorbate, 15µl (0.46 mM <sup>14</sup>C-methyl-S-adenosylmethionine (SAM)) as methyl group-donor and 2-methyl-6-phytylplastoquinol as substrate. The reaction was incubated for four hours at  
20 25°C in the dark.

The reaction was stopped by adding 750µl Chloroform/Methanol (1:2) + 150µl 0.9% NaCl. The tube were mixed thoroughly, the phases were separated by centrifugation and the upper part was discarded. The lower part was transferred to a new tube and vaporized under a stream of nitrogen.

25 The dried residue was resuspended in 20µl ether and spotted onto a silica thin layer-chromatography (TLC) plate. The TLC plate was exposed to a phosphoimager screen. The result showed that the 092-260cds protein expressed was able to methylate 2-methyl-6-phytylplastoquinol. No radioactive labelling of the substrate was observed in assays using extracts from control cells.

30

#### Example 26

Construction of vectors for expressing the *Physcomitrella* 2-methyl-6-phytylplastoquinol-methyltransferase in *A. thaliana* and other plants for altering the content of tocopherols.

5 In order to manipulate the Vitamin E levels in seeds, the cDNA clone 78\_ppprot1\_092\_E12-260 encoding the *Physcomitrella patens* 2-methyl-6-phytylplastoquinol-methyltransferase was expressed under the control of a seed specific promoter in transgenic *A.thaliana* plants. The seed-specific plant gene expression plasmid was constructed using a pBin19 (Bevan, Nucleic Acid Research 12: 8711-8720,  
10 1984) derivative. The plasmid contains the *Vicia faba* seed specific promoter from the Legumin B4 gene (Bäumlein et al., Nucleic Acids Research 14: 2707-2719, 1996), the sequence encoding the transit peptide of the *N. tabacum* Transketolase (TkTp) (Badur,R., 1998, PhD thesis, Georg August University of Göttingen, Germany, „Molecular and functional analysis of isoenzymes for example of fructose-1,6-  
15 bisphosphate aldolase, phosphoglucose-isomerase and 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase“ [„Molekularbiologische und funktionelle Analyse von pflanzlichen Isoenzymen am Beispiel der Fructose-1,6-bisphosphat Aldolase, Phosphoglucose-Isomerase und der 3-Deoxy-D-Arabino-Heptulosonat-7-Phosphat Synthase“]) and the transcriptional termination sequence from the octopin synthase gene  
20 (Gielen et al., EMBO J. 3: 835-846, 1984). The cDNA 092-260cds was cloned in sense orientation as a BamHI fragment into the BamHI site of the pBin-LePTkTp9 vector. The created plasmid was designated pBinLePTkTp9-092-260cds. Due to the cloning in the correct reading frame, the cDNA 092-260cds was fused to the TkTp transit peptide, which governs the translocation of the 092-260cds protein into plastids.

25 A recombinant plasmid was obtained and designated pBin-LePTkTp9-092-260cds (see Figure 2). This seed-specific 78\_ppprot1\_092\_E12-260 plant gene expression construct (pBin-LePTkTp9-092-260cds) was used to transform wild type *A.thaliana* plants

30

#### Example 27

Isolation of full length *Physcomitrella patens* 78\_ppprot1\_087\_E12-259 cDNA

Utilizing the partial sequence of the *Physcomitrella patens* clone 78\_ppprot1\_087\_E12 as probe, an *Physcomitrella patens* cDNA library was screened by nucleic acid hybridization for full length cDNAs.

A large number of hybridizing clones were isolated. The isolated cDNA  
5 78\_ppprot1\_087\_E12-259 (1867 bp) was sequenced completely. 78\_ppprot1\_087\_E12-259 encodes a 371 amino acid protein.

Example 28:

10 Amplification of the coding sequence (ORF) of the full length clone 78\_ppprot1\_087\_E12-259

The coding sequences (ORF) of the 78\_ppprot1\_087\_E12-259 clone with homology to the  $\gamma$ -Tocopherol-methyltransferases (designated 087-259Cterm) was amplified using  
15 polymerase chain reaction (PCR). The forward and reverse primers (78\_ppprot1\_087\_E12-259\_5' and 78\_ppprot1\_087\_E12-259\_3', respectively) were designed to add a BamHI site to the 5' and 3' end of the resulting amplification product.

Forward primer 78\_ppprot1\_087\_E12-259\_5'

20 GGATCCCGGACGGAGCCGGAGCTTTACG

Reverse primer 78\_ppprot1\_087\_E12-259\_3'

GGATCCCTACTAGCGGAGACCTCAATCC

25

The PCR reaction was conducted in a 50 $\mu$ l reaction mixture, containing dNTPs (0.2 mM each), 1,5 mM Mg(OAc)<sub>2</sub>, 40 pmol 78\_ppprot1\_087\_E125', 40 pmol 78\_ppprot1\_087\_E123', 15  $\mu$ l 3,3 $\times$  rTth DNA Polymerase XLPuffer (PE Applied Biosystems), 5U rTth DNA Polymerase XL (PE Applied Biosystems).

30 The following conditions were used:

step 1: 5 minutes 94°C (denaturation)

step 2: 3 seconds 94°C (denaturation)

step 3: 2 minutes 65°C (annealing)

step 4: 2 minutes 72°C (elongation)

40 cycles step 2-4

step: 5: 10 minutes 72°C

- 5 The resulting PCR fragment was cloned into the PCR cloning vector pGEM-T (Promega) as described in the instruction. The recombinant plasmid (pGEM-Teasy/087-259C-term) was sequenced to confirm the correct amplification.

#### Example 29

- 10 Demonstration of  $\gamma$ -tocopherol-methyltransferase activity of 087-259Cterm cDNA clone by expression and biochemical analysis in *E.coli*

In order to demonstrate that the clone 087-259Cterm (amplified as described above) encodes a protein involved in tocopherol biosynthesis the cDNA 087-259Cterm was  
15 expressed in *E.coli* and tested for  $\gamma$ -Tocopherol methyltransferase activity.

Hence, the 087-259Cterm BamHI fragment was subcloned in the correct reading frame into the BamHI site of the *E.coli* pQE30 expression vector (QIAexpress Kit, Qiagen). The resulting plasmid (designated pQE30-087-259Cterm, see Figure 3) was used to transform the *E.coli* expression host strain M15[pREP4].

20

An *E.coli* colony transformed with the plasmid pQE30-087-259Cterm was used to inoculate an overnight culture of Luria broth containing 200  $\mu$ g/ml ampicillin. In the morning an aliquot of this culture was used to inoculate a 100 ml culture of Luria broth containing 200  $\mu$ g/ml ampicillin. This culture was incubated in a shaking incubator at  
25 28°C until the OD<sub>600</sub> of the culture reached 0.4, at which time isopropyl- $\beta$ -D-thiogalaktopyranosid (IPTG) was added to obtain a final concentration of 0.4 mM IPTG. The culture was incubated for additional three hours at 28°C. Afterwards the cells were harvested by centrifugation at 8000g.

The pellet was resuspended in 600  $\mu$ l lysisbuffer (approximately 1-1.5 ml /g cell pellet ;  
30 10 mM HEPES KOH pH 7.8, 5 mM Dithiothreitol (DTT), 0.24 M Sorbitol ). Subsequently Phenylmethylsulfonyl (PMSF) was added to a final concentration of 0.15 mM and incubated on ice for 10 minutes.

The cells were lysed by sonification with a microtip sonicator using several 10 second pulses. After adding Triton X100 (f.c. 0.1%) the homogenate was incubated for 30 minutes on ice, and subjected to centrifugation at 25000g for 30 minutes

The supernatant of this extract was assayed for  $\gamma$ -tocopherol-methyltransferase activity as follows.

The  $\gamma$ -Tocopherol-methyltransferase assay was performed in a 500 $\mu$ l volume containing 135 $\mu$ l (about 300-600 $\mu$ g total protein) *E.coli* extract expressing the 087-259 cDNA (prepared as described above), 200 $\mu$ l (125mM) Tricine-NaOH pH 7.6, 100 $\mu$ l (1.25 mM) Sorbitol, 10 $\mu$ l (50mM)  $MgCl_2$  and 20 $\mu$ l (250mM) Ascorbate, 15 $\mu$ l (0.46 mM  $^{14}C$ -methyl-S-adenosylmethionine (SAM)) as methyl group donor and 4,8mM  $\gamma$ -Tocopherol as substrate. The reaction was incubated for four hours at 25°C in the dark.

The reaction was stopped by adding 750 $\mu$ l Chloroform/Methanol (1:2) + 150 $\mu$ l 0.9% NaCl. The tube were mixed thoroughly, the phases were separated by centrifugation and the upper part was discarded. The lower part was transferred to a new tube and vaporized under a stream of nitrogen.

The dried residue was resuspended in 20 $\mu$ l ether and spotted onto a silica thin layer-chromatography (TLC) plate. The TLC plate was exposed to a phosphorimager screen.

The result shows that the in *E.coli* expressed 087-259Cterm protein was able to methylate  $\gamma$ -Tocopherol. No radioactive labelling of the substrate was observed in assays using extracts from control cells.

### Example 30

Construction of vectors for expressing the *Physcomitrella patens*  $\gamma$ -tocopherol-methyltransferase in *A.thaliana* and other plants for altering the content of tocopherols.

In order to manipulate the Vitamin E levels in seeds, the cDNA clone 78\_ppprot1\_087\_E12-259 encoding the *Physcomitrella patens*  $\gamma$ -tocopherol-methyltransferase was expressed under the control of a seed specific promoter in transgenic *A.thaliana* plants. The seed-specific plant gene expression plasmid was constructed using a pBin19 (Bevan, Nucleic Acid Research 12: 8711-8720, 1984) derivative. The plasmid contains the *Vicia faba* seed specific promotor from the Legumin B4 gene (Bäumlein et al., Nucleic Acids Research 14: 2707-2719, 1996), the

sequence encoding the transit peptide of the *N.tabacum* Transketolase (TkTp) (Badur, R., Ph.D thesis, 1998, Georg August University of Göttingen, Germany, „Molecular and functional analysis of isoenzymes for example of fructose-1,6-bisphosphate aldolase, phosphoglucose-isomerase and 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase“ [„Molekularbiologische und funktionelle Analyse von pflanzlichen Isoenzymen am Beispiel der Fructose-1,6-bisphosphat Aldolase, Phosphoglucose-Isomerase und der 3-Deoxy-D-Arabino-Heptulosonat-7-Phosphat Synthase“]) and the transcriptional termination sequence from the octopin synthase gene (Gielen et al., EMBO J. 3: 835–846, 1984). The cDNA 087-259Cterm was cloned in sense orientation as a BamHI fragment into the BamHI site of the pBin-LePTkTp9 vector. The created plasmid was designated pBinLePTkTp9-87-259Cterm. Due to the cloning in the correct reading frame the cDNA 087-259Cterm was fused to the TkTp transit peptide which governs the translocation of the 087-259Cterm protein into plastids. A recombinant plasmid designated pBin-LePTkTp9-087-259Cterm was obtained (see Figure 4). This seed-specific 78\_ppprot1\_087\_E12-259 plant gene expression construct (pBin-LePTkTp9-087-259Cterm) was used to transform wild type *A.thaliana* plants.

### Equivalents

Those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.



## Legends to the Figures:

- Figure 1: Expression vector pQE30 harboring the coding sequence of full length clone 78\_ppprot1\_092\_E12-260 resluting in vector pQE30-092-260cds
- 5
- Figure 2: Plant transformation vector pBinLePTkTp9-092-260cds with abbreviations as follows:
- LeB4: *Vicia faba* legumin B4 gene promoter (2700bp)
- TKTP: Sequence encoding the *N.tabacum* transketolase transit peptide (245 bp)
- 10 092-260cds: Sequence of the cDNA clone 092-260cds (1490bp)
- OCS: Octopin synthase transcriptional termination signal (219bp)
- Figure 3: Expression vector pQE30 harboring the coding sequence of full length clone 78\_ppprot1\_087\_E12-259 resluting in vector pQE30-087-259Cterm
- 15
- Figure 4: Plant transformation vector pBinLePTkTp9-092-260cds with abbreviations as follows:
- LeB4: *Vicia faba* legumin B4 gene promoter (2700bp)
- TKTP: Sequence encoding the *N.tabacum* transketolase transit peptide (245 bp)
- 20 092-260cds: Sequence of the cDNA clone 092-260cds (1490bp)
- OCS: Octopin synthase transcriptional termination signal (219bp)
- 25
- Table 1: Enzymes involved in production of tocopherols and/or carotenoids, the accession/entry number of the corresponding partial nucleic acid molecules, the corresponding longest clones and the position of open reading frames.
- 30
- Appendix A: Nucleic acid sequences encoding for TCMRPs (Tocopherol and Caotenoid Metabolism Related protein)
- Appendix B: TCMRP polypeptide sequences

**Claims**

1. An isolated nucleic acid molecule from a moss encoding a Tocopherol and Carotenoid Metabolism Related Protein (TCMRP), or a portion thereof.  
5
2. An isolated nucleic acid molecule wherein the moss is selected from *Physcomitrella patens* or *Ceratodon purpureus*.
3. The isolated nucleic acid molecule of claim 1 or 2, wherein said nucleic acid  
10 molecule encodes an TCMRP capable of performing an enzymatic step involved in the production of a fine chemical.
4. The isolated nucleic acid molecule of any one of claims 1 to 3, wherein said nucleic acid molecule encodes an TCMRP capable of performing an enzymatic step  
15 involved in the metabolism of tocopherols and/or carotenoids.
5. The isolated nucleic acid molecule of any one of claims 1 to 4, wherein said nucleic acid molecule encodes an TCMRP assisting in the transmembrane transport.
- 20 6. An isolated nucleic acid molecule from mosses selected from the group consisting of those sequences set forth in Appendix A, or a portion thereof.
7. An isolated nucleic acid molecule which encodes a polypeptide sequence selected from the group consisting of those sequences set forth in Appendix B.  
25
8. An isolated nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide selected from the group of amino acid sequences consisting of those sequences set forth in Appendix B.
- 30 9. An isolated nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to a nucleotide sequence selected from the group consisting of those sequences set forth in Appendix A, or a portion thereof.

10. An isolated nucleic acid molecule comprising a fragment of at least 15 nucleotides of a nucleic acid comprising a nucleotide sequence selected from the group consisting of those sequences set forth in Appendix A.
- 5 11. An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of any one of claims 1-10 under stringent conditions.
12. An isolated nucleic acid molecule comprising the nucleic acid molecule of any one of claims 1-11 or a portion thereof and a nucleotide sequence encoding a  
10 heterologous polypeptide.
13. A vector comprising one or more nucleic acid molecule(s) of any one of claims 1-12.
14. The vector of claim 13, which is an expression vector.
- 15 15. A host cell transformed with one or more expression vector(s) of claim 14.
16. The host cell of claim 15, wherein said cell is a microorganism.
- 20 17. The host cell of claim 15, wherein said cell belongs to the genus *mosses or algae*.
18. The host cell of claim 15, wherein said cell is a plant cell.
19. The host cell of any one of claims 15 to 18, wherein the expression of said nucleic  
25 acid molecule(s) results in the modulation of the production of a fine chemical from said cell.
20. The host cell of any one of claims 15 to 19, wherein the expression of said nucleic  
30 acid molecule(s) results in the modulation of the production of tocopherols and/or carotenoids from said cell.
21. Descendants, seeds or reproducible cell material derived from a host cell of any one of claims 15 to 20.

22. A method of producing one or more polypeptide(s) comprising culturing the host cell of any one of claims 15 to 20 in an appropriate culture medium to, thereby, produce the polypeptide.
- 5 23. An isolated TCMRP from *mosses or algae* or a portion thereof.
24. An isolated TCMRP from *microorganisms or fungi* or a portion thereof.
- 10 25. An isolated TCMRP from *plants* or a portion thereof.
26. The polypeptide of any one of claims 23 to 25, wherein said polypeptide is involved in the production of a fine chemical.
- 15 27. The polypeptide of any one of claims 23 to 25, wherein said polypeptide is involved in assisting in transmembrane transport.
28. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of those sequences set forth in Appendix B.
- 20 29. An isolated polypeptide comprising a naturally occurring allelic variant of a polypeptide comprising an amino acid sequence selected from the group consisting of those sequences set forth in Appendix B, or a portion thereof.
- 25 30. The isolated polypeptide of any of claims 23 to 29, further comprising heterologous amino acid sequences.
31. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to a nucleic acid selected from the group consisting of those sequences set forth in Appendix A.
- 30

32. An isolated polypeptide comprising an amino acid sequence which is at least 50% homologous to an amino acid sequence selected from the group consisting of those sequences set forth in Appendix B.
- 5 33. An antibody specifically binding to a TCMRP of any one of claims 23 to 32 or a portion thereof.
34. Test kit comprising a nucleic acid molecule of any one of claims 1 to 12, a portion and/or a complement thereof used as probe or primer for identifying and/or cloning  
10 further nucleic acid molecules involved in the production of tocopherols and/or carotenoids or assisting in transmembrane transport in other cell types or organisms.
35. Test kit comprising an TCMRP-antibody of claim 33 for identifying and/or purifying further TCMRP molecules or fragments thereof in other cell types or organisms.
- 15 36. A method for producing a fine chemical, comprising culturing a cell containing one or more vector(s) of claim 13 or 14 such that the fine chemical is produced.
37. The method of claim 36, wherein said method further comprises the step of  
20 recovering the fine chemical from said culture.
38. The method of claim 36 or 37, wherein said method further comprises the step of transforming said cell with one or more vector(s) of claim 13 or 14 to result in a cell containing said vector(s).
- 25 39. The method of any one of claims 36 to 38, wherein said cell is a microorganism.
40. The method of any one of claims 36 to 38, wherein said cell belongs to the genus *Corynebacterium* or *Brevibacterium*.
- 30 41. The method of any one of claims 36 to 38, wherein said cell belongs to the genus *mosses* or *algae*.

42. The method of any one of claims 36 to 38, wherein said cell is a plant cell.
43. The method of any one of claims 36 to 42, wherein expression of one or more nucleic acid molecule(s) from said vector(s) results in modulation of the production of said fine chemical.
44. The method of claim 43, wherein said fine chemical is selected from the group consisting of tocopherols and carotenoids.
45. A method for producing a fine chemical, comprising culturing a cell whose genomic DNA has been altered by the inclusion of one or more nucleic acid molecule(s) of any one of claims 1-12.
46. A method of claim 45, comprising culturing a cell whose membrane has been altered by the inclusion of one or more polypeptide(s) of any one of claims 22 to 32.
47. A fine chemical produced by a method of any one of claims 36 to 46.
48. Use of a fine chemical of claim 47 or polypeptide(s) of any one of claims 22 to 32 for the production of another fine chemical.

Fig. 1




Fig. 2

**pBinLePTkTp9-092-260cds**








Fig. 3



4/4

Fig. 4

**pBinLePTkTp-087-259Cterm**



**APPENDIX****Table I**

Function / Amino acid metabolism	Acc.no./Entry no.	Start of open reading frame	Stop of open reading frame
<b>Shikimate pathway</b>			
Chorismate Mutase	84_ppprot1_50_f12rev	66-68	255-257
4-hydroxyphenylpyruvate dioxygenase	41_bd10_g03rev	2-4	437-439
<b>Isoprenoid, tocopherole metabolism</b>			
Deoxyxylulose-P-Synthase	58_mm15_b11rev	3-5	561-563
Deoxyxylulose-P-Synthase	10_ppprot1_092_b08rev	38-40	392-394
Deoxyxylulose-P-Synthase	68_ck12_d10fwd	3-5	531-533
Deoxyxylulose-P-Synthase	39_ck27_g02fwdrev	2-4	116-118
Deoxyxylulose-P-Synthase	68_mm17_D10rev	3-5	519-521
Mevalonate Diphosphate Decarboxylase	93_ck10_h05fwdrev	3-5	450-452
HMG-CoA Reductase	66_bd09_c12rev	1-3	406-408
Mevalonate Kinase	26_ppprot140_E07rev	3-5	459-461
Farnesyl Pyrophosphate Synthase	45_ck24_h02fwd	2-4	455-457
Geranylgeranyl PP Synthase	95_bd02_h06rev	3-5	537-539
Geranylgeranyl Oxidoreductase	14_ppprot1_53_c07	1-3	583-585
Geranylgeranyl Oxidoreductase	34_ppprot1_092_f08rev	92-94	347-349
Geranylgeranyl Oxidoreductase	83_ppprot1_056_f06	22-24	601-603
Geranylgeranyl Oxidoreductase	23_ppprot1_071_d03rev	19-21	346-348
Geranylgeranyl Oxidoreductase	70_mb1_D11rev	2-4	470-472
Geranylgeranyl Oxidoreductase	84_ppprot1_36_F12rev	2-4	392-394
Geranylgeranyl Oxidoreductase	27_mm6_55_E02rev	3-5	513-515
Geranylgeranyl Oxidoreductase	54_ppprot1_081_a12rev	2-4	326-328
Geranylgeranyl Oxidoreductase	47_ppprot1_100_h03	307-309	499-501
Geranylgeranyl Oxidoreductase	25_mm18_e01rev	86-88	500-502

Geranylgeranyl transferase type I beta subunit	80_bd09_f10rev	1-3	271-273
gamma-Tocopherol Methyltransferase type I	78_ppprot1_087_e12rev	2-4	245-247
gamma-Tocopherol Methyltransferase type II	78_ppprot1_092_e12rev	2-4	506-508
<b>Carotenoid metabolism</b>			
lycopene epsilon cyclase	05_ck_19_a03	3-5	561-563
phytoene synthase	02_ppprot1_046_a07rev	2-4	395-397
phytoene desaturase	96_ck5_h12fwdrev	3-5	219-221
zeta-carotene desaturase	42_ck10_g09fwd	245-247	473-475
zeaxanthin epoxidase	84_mm11_f12rev	1-3	484-486
zeaxanthin epoxidase	41_ppprot1_085_g03rev	3-5	309-311
isopentenylpyrophosphate transferase	06_ppprot1_062_a09rev	2-4	431-433
nine-cis-epoxycarotenoid dioxygenase	16_ppprot1_082_c08	3-5	531-533
fucoxanthin chlorophyll a/c binding protein	30_ppprot1_064_e09	2-4	692-694
squalene epoxidase	55_ppprot1_093_b04rev	3-5	546-548
squalene-hopene-cyclase	02_mm14_a07rev	1-3	418-420
2-heptaprenyl-1,4-naphthoquinone methyltransferase	51_ppprot1_081_a05rev	3-5	468-470
copalylpyrophosphat-Synthase	93_ck24_h05fwd	2-4	473-475
ent-kaurene synthetase A of gibberellin biosynthesis	51_ppprot1_0052_a05	49-51	311-313

### Longest clones (full length)

Clone entry no. of longest clone	Start of open reading frame	Stop of open reading frame	Function / Amino acid metabolism	Clone entry no. of corresponding partial clone
78_ppprot1_087_e12-259rev	145-147	1255-1257	gamma-Tocopherol Methyltransferase type I	78_ppprot1_087_e12rev
78_ppprot1_092_e12-260rev	367-369	1840-1842	2-methyl-6-phytylplasto-quinol-methyltransferase	78_ppprot1_092_e12rev

**Appendix A: included genes****Shikimate pathway****84\_ppprot1\_50\_f12rev**

GCTTATGGTCAGGAAAGTGAATGAGCATGGGAAGGTTGACAATGCAAGGTA  
CAAGATCGATCCTGACCTTGCGGGCGCTCTTTACGAGGACTGGGTTATGC  
CTTTGACCAAGCAGGTCCAGGTGGCCTATCTTCTCCGACGTCTGGACTGA  
CGTCATTTAACTCGTGGCAGATAGTCAAGTTGAAGAGGATCATCACTGAC  
ATAGCCCATTTGTGGCCTCTTCACTCGTGAGTTAGCCTGTGTACAGAAAAC  
ATTTTAGTCTCATTTTTTTTGCATAGAAGCACCATCGATTGCTTCTTGCTT  
CCAAGTCCAGTTTTAGCGCATTCATTTCCCTGGTGAGCATACTTTCAACA  
TAAAGATCTCCACCTCCGAGGTTGAGCCAGTACGCCTAGATTCTGTGAAT  
CAGCAACGGCCAAAGCTTTTCTTCTCTGGATAGGTCAGTCAATGCATACA  
CTTGGCATAACATACCATGCGGTGTTAGTGCTTTTTTTTCGCTATCAAC  
CGAGGTTTTACTGCTTATGTGCAATAAGAGCAGCCAATACCTGCAAGTTT  
TTTCTAAAAA

**41\_bd10\_g03rev**

TCAAAATCGGAAAATGGGAACGGAAGTTAAGCTCACTAATGGAAACACCG  
TCACTGCACCTGCCGGAGAACAGACTAGTTCCGCCTACAAGCTAGTTGGC  
TTCGAAAACCTCGTCCGGAACAACCCTATGTCCGACAAAATTTACAGTCAA  
AAGCTTCCACCATGTTGAGTCTGGTGCTCCGACGCCACCAACACCGCCC  
GCCGTTTCTCCTGGGGACTCGGTATGCCAATCGTTTACAAGTCCGATTTA  
TCTACCGGAAACAATATCCACGCTTCTTACCTCCTCCGCTCCGGTCACCT  
CAATTTCTCTTTACCGCTCCTTATTCTCCTTCCATATCCACCGCCACCG  
CTTCCATTCTACGTTTTCTCACACCGACTGCCGCAACTTCACCGCCTCT  
CACGGTTTTGGTGTCCGCTCGATTGCTATTGAAGTTGAAGATGCCGACCN  
AGCT

**Isoprenoid, tocopherole metabolism****58\_mm15\_b11rev**

GATTTGCAATGGACCGAGCTGGGCTCGTTGGAGCCGATGGGCC  
TACTCACTGTGGGGCTTTCGATGTACCTACATGGCCTGCCTACCTAACA  
TGGTTGTAATGGCTCCTGCTGATGAAGCTGAGCTTTTCCACATGGTAGCA  
ACTGCTGCCGCTATTGATGACCGTCCCAGCTGTTTCAGGTATCCCAGAGG  
TAACGGGATTGGTGTCCAATTGCCTGCAAAGAACAAGGAATTCCTATTG  
AGGTCGGTAGAGGGCGAATTCTACTGGAAGGTACTGAAGTGGCACTTCTA  
GGTTATGGTACAATGGTCCAAAATTGCCTGGCTGCTCACGTCTTACTTGC  
CGACCTGGGGGTCTCAGCGACTGTGCGCGATGCTCGGTTTTGCAAGCCCC  
TTGACCGTGATCTTATTCGCCAGCTTGCTAAGAACCATCAAGTGCTTATT  
ACAGTGGAAGAGGGTTCTATTGGAGGCTTTGGTTCTCATGTTGTGCAATT  
CATGGCATTGGATGGGCTCCTCGACGGAAAGCTGAAGTGGAGACCACTTG  
TGCTACCTGACCGCTACATCGA

## 10\_ppprot1\_092\_b08rev

GATTNGCAATGGATCGTGCTGNTCTTGTTGGAGCTGATGGCCAACTCACT  
GTGGAGCGTTCGATGTAACCTACATGGCTTGCTACCTAATATGGTAGTC  
ATGGCTCCTGCTGACGAAGCGGAACCTTTCCACATGGTGGCCACTGCTGC  
TCAAATTGATGATCGACCTAGTTGTTTCAGGTATCCAAGGGGTAACGGAA  
TCGGTGCCCGATTGCCTGAGAATAACAAGGGGATCCCCGTCGAGATTGGT  
AAAGGAAGAATTCTATTAGAAGGTACGGAAGTGGCACTTTTGGGTATGG  
CACCATGGTCCAGAATTGTCTGGCTGCTCGCGCATTACTTGCCGACTTGG  
GTGTTGCGGCGACTGTTGCTGATGCTAGGTTCTGCAAGCCCCTTTAAATG  
AAATCTGAAAGGTTAGGAATAGGTGCTGCTGCTCTGAAATCGGAGCAGTC  
GGATGTTCTGTGGGGAGTTAGAGGCCTGTTCCGTTAGGGAGGATAATTTT  
CCCTTCAGTACGGTGCATCGAAGTACATGGCAAATTTTGTACCCTAC  
ACACTCTTGTAATTTATTCGTGGTGATCACCTCATTAATAAGTGAAATGG  
GACCGAAGTTGACCCTTCACTTTTTCAAAA

## 68\_ck12\_d10fwd

AGCCTTTTTGTAGTATCTATTCCCTCCTTCCTTCAAAGAGGAT  
ATGACCAGGTTGTACACGATGTAGATCTGCAGAAATTGCCAGTCCGATTT  
GCAATGGATCGTGCTGGTCTTGTTGGAGCTGATGGGCCAACTCACTGTGG  
AGCGTTCGATGTAACCTACATGGCTTGCTACCTAATATGGTAGTCATGG  
CTCCTGCTGACGAAGCGGAACCTTTCCACATGGTGGCCACTGCTGCTCAA  
ATTGATGATCGACCTAGTTGTTTCAGGTATCCAAGGGGTAACGGAAATCGG  
TGCCAGTTGCCTGAGAATAACAAGGGGATCCCCGTCGAGATTGGTAAAG  
GAAGAATTCTATTAGAAGGTACGGAAGTGGCACTTTTGGGTATGGCACC  
ATGGTCCAGAATTGTCTGGCTGCTCGCGCATTACTTGCCGACTTGGGTGT  
TGCGGCGACTGTTGCTGATGCTAGGTTCTGCAAGCCCCTTGACCGAGATC  
TTATTGCTCAACTTGCGAAGAACCACCAAGTGATTATAACCC

## 39\_ck27\_g02fwdrev

CATCGAGCATGGGGCTCCCAAGGACCAGTATGCCGAAGCAGGTCTAACTG  
CGGGTCACATTGCAGCCACTGCACTGAACGTTCTCGGGAAGACGAGAGAA  
GCGCTGCAAGTCATGACCTAAGATCTTCGTGGTTAAGATATGGTGAATTC  
GTTGCGAAGTATGATCCAGTCGACGACGGGCTTCTCATCAATCAAAGCAT  
TACCCAGATTGCATGTCTGAACATGCCATGTAATGAACATATTCTGGTCT  
ACTGTTTCGTCTCCTTAAATTTACAAGGCAACTTCTATCATTTGCTGATTG  
CTTAGCAGACTTGAAGATAGGGTCTTACTCGAAAGCTGAAACGTTGAATA  
TAGATGCTGCTACTCTAAAATTAGAGCAGTTGGATGGTTTCTAGGCAGTT  
ATTTGGTATGCTACGCCATGGAGGGCAATCCGTAAGTCACTGCTGTAGGC  
TTTGAGCCTAAACAATGCCAAAGTTTGTACTTTACACACTCTGTACACT  
ATAGTTTGATCATTCCCATTTAATAACTGTAATGGGGTGCATGATGACTC  
TTTTTCTCAAAAAAAAAA

## 68\_mm17\_D10rev

GATTTGCAATGGACCGAGCTGGGCTCGTTGGAGCCGATGGGCC  
TACTCACTGTGGGGCTTTCGATGTCACCTACATGGCCTGCCTACCTAACA  
TGTTTGTAATGGCTCCTGCTGATGAAGETGAGCTTTTCCACATGGTAGCA  
ACTGCTGCCGCTATTGATGACCGTCCCAGCTGTTTCAGGTATCCCAGAGG  
TAACGGGATTGGTGTCCAATTGCCTGCAAAGAACAAGGAATTCCTATTG  
AGGTGCGGTAGAGGGCGAATCTACTGGAAGGTACTGAAGTGGCACTTCTA  
GGTTATGGTACAATGGTCCAAAATTGCCTGGCTGCTCACGTCTTACTTGC  
CGACCTGGGGGTCTCAGCGACTGTCGCCGATGCTCGGTTTTGCAAGCCCC  
TTGACCGTGATCTTATTCGCCAGCTTGCTAAGAACCATCAAGTGCTTATT

ACAGTGGAAAGAGGGTTCTATTGGAGGCTTTGGTTCTCATGTTGTGCAATT  
CATGGCATTGGATGGGCTCCTCGACGGAAA

93\_ck10\_h05fwdrev

TTTCATTGCAGTCCTATTTCATTAGAAAAGTATTTGCCTTTGTTGGCATGC  
AGACTCATAGGGTTAGTAGAGCGATGGAATCGTCACGCAGGAGAACCACA  
GGTTGCCTACACGTTTGATGCTGGTCCGAATGCGGTAATGTTTGCCAAGA  
ACAAAGAAGTTGCAGCGCAGCTGCTTCAGCGCCTTCTGTACCAGTTCCCT  
CCATCCGCGGATACTGATATTTCCAGATATGTTACGGCGATCAAAGTAT  
TTTGGAGTCTGCTGGCGTGAATTCCTTGAAGGACATCGACTCCCTTTCTG  
CGCCAGCTGAGGTGGCTGGCATTCCCAATTTGCAGAGGATACCTGGAGAG  
GTTGACTATCTCATATGCACTAATGTTGGGAAAGGTGCATATGTATTGGG  
CGAGCAGGGTGCAAACCTGATAGACCCTGTTTCTGGTCTTCTGAAAAAGT  
AATAGCATTTAGTATCAGGTGCTAATTTGTTCTGGATCAAGCTCGCTCCA  
TCATGCTAAT

66\_bd09\_c12rev

AATGTTCTTGATTACCTTCAAACCGATTTCCCCGATATGGATGTCATGGG  
CATTTCTGGAACTATTGCTCGGACAAGAAACCGGCTGCGGTGAACTGGA  
TAGAAGGGCGTGGTAAATCTGTGGTTTGTGAAGCTGTGATCAAGGAAGAG  
GTGGTGAGCAAGGTTTTGAAAACCAATGTAGCCAGTTTGGTCGAACTTAA  
CATGCTCAAGAACCTAACCGGGTCAGCCATGGCTGGTGCCTTGGTGGGT  
TCAATGCGCATGCTAGCAATATAGTCTCGGCTATATATATAGCCACCGGT  
CAAGACCCAGCCAGAAATGTGAGAGTTCTCACTGCATCACCATGATGGA  
AGCCATTAACAATGGAAAAGATCTCCATATCTCAGTCACCATGCCTTCTA  
TTGANGTTG

26\_ppprot140\_E07rev

CTGGAAACGGTATATATACACCCATGGATCCGAAATTGCTTCCTCAACTG  
TACCTGATCTACACGAAGAATCCCAGCGATTCTGGCAAGGTGCATAGTAC  
GGTGAGGAAAAGGTGGTTAGACGGTGATGAATTGGTTAGGAATTGTATGA  
AAGAAGTTGCGAGTCTTGCCGTAAAGGGACGAGATGCTTTGCTTCGGCAA  
GATTTTTCCACCATCGCGAAGCTAATGGACACCAACTTTGACTTACGTAG  
AACTATGTTTGGCGATGCTACTCTTGAAAGATGAACATTAAAATGGTTG  
AGACTGCTCGCGGTGTTGGAGCTGCATGCAAGTTTACAGGGAGTGGAGGT  
GCAGTTATTGCATTCTGTCTGACGGCGAAAAGCAAGTGAAGGCTTTGCA  
GGAGGCTTGTGCTAAAGCTGGTTACACTGTTGAGGGTGTATTCTCTGCTC  
CAGCCAATGTCTAACCTATAATATCCTAGATTTCTGAGAGCGGGTGGGAA  
TTTCCAAGGTAATAATCATGGCTGAGTGCTATTTATTGAGCACTAAAAG  
AGGATTTTTTAAATACGCTCAATGCACGTATTTTTCTAGTTTCCTCTGTTT  
GACCATGAAAAAGGGAAATGTACATGATGAACTGACAAGGACACTGCAT  
CCAGTATAGTCCTTAACATTTTTTCTCTCCTTTCTTGAAAAA

45\_ck24\_h02fwd

CATGGATGACATTATGGACAATTCAGTCACTCGTCGAGGACA  
ACCTTGCTGGTACCGGTTCCAAAGGTTGGCCTCATTGCTATCAACGATG  
GAATAATCTTGAGAACGCATATCTCTCGTGTTCTGAAGAGACATTTCCGG  
CAGTCCCCAATCTATGTGGAACCTGTGCGACTTATTCAATGATGTGAGTA  
TCAGACAGCCTCTGGACAGATGTTGGACCTGATCACCCTCCAGCAGGAG  
AAGTTGATTTGTGCGAAATATGTATTACCCACTTATCTGCGAATCGTAAAA  
TACAAAACCTGCATATTATTCAATTTATCTTCCTGTGGCATGTGCCTTGCT

TTTAGCTGGGGAGACGAGCGTGGCCAAGTTTGAGGCAGCTAAGGAAGTCC  
TTGTACAGATGGGCACATACTCCAAGTCCAGGACGACTATCTTGACTGT  
TACGGCGCGCCAGAAGTGATTGGAAAGATCGGAACTGACATTGAAGACAC  
TAAATGTTTCCTGGCTGATAGTTCAAGCCTTAAAGCGTGCCAATGAATCCC  
AGAAAC

## 95\_bd02\_h06rev

CTGGAATTCAACTTTCTCTGTACAGATCAAATCTCAGCCGTCCATCCGTC  
TCACCCGGCACCATCTGCTTACCGTAGATTTACCATCATCTCCGGTATGGC  
CCAAAACCAATCATATTGGGATTCAATACATTGAGATATCGACTCCCACC  
TGAAAAAAGCCATTCCAATTCGTGAGCCCGTTTCCGTTTTCGAGCCAATG  
CACCATTGACATTTGCACCACCCAAATCCACCGCGTCGGCGTTGTGTAT  
AGCCGCTGTGAGCTAGTAGGCGGCCACCGGGAAGATGCAGTTGTGGCGG  
CGTCAGCCATTACCTAATGCATGCTTCTATATACTCATGAGCATCTC  
TTGCTAAGGGAACGGGCCATGCCGAATCCAGAATCCACACAAGTTTGG  
CCCGAATATCGAGCTTCTAACTGGCGATGGGTTTCTGCCTTTCGGGTTTG  
AGTTGCTGGCTGGATCTGCGAACCAGCTAGTAACAACCTGATAAATACT  
AAGGGTGATCATAGAGATCACCCGAGCCGTANGTGCTGAANGGA

## 14\_ppprot1\_53\_c07

CCGAAGTGTGACCACGTTGCAGTCGGAACGGGGACGGTCATCA  
ACAAGCCAGCCATCAAAAAGTACCAGACGGCCACGAGGAACCGGGCGAAG  
GACAAGATTGCCGGAGGAAAGATCATCAGGGTTGAGGCACACCCCATTC  
GGAGCACCCAAGGCCCTCGCAGGGCGAGCGACAGAGTGGCGTTAGTTGGGG  
ACGCGGCTGGATACGTGACGAAGTGCTCCGGGGAGGGTATCTACTTTGCT  
GCTAAGTCTGGACGCATGTGTGCTGAGGCTATTGTGGAAGGCTCCGCCAA  
CGGAACTCGTATGATTGACGAGTCAGATTTGAGGACATATCTAGATAAAT  
GGGACAAGAAGTACTGGGCAACTTACAAGGTGCTGGACATATTGCAGAAG  
GTTTTCTACAGGTCCAACCTGCCAGAGAGGCATTCGTCGAGATGTGCGC  
CGACGACTACGTGCAAAAGATGACGTTTGATAGTTATTTGTACAAGGTGG  
TGGTGCCCTGGAAACCCATTGGACGACCTGAAGCTAGCAGTTAACACTATC  
GGGAGCCTGATCAGAGCCAATGCATTGCGCAAGGAGTCTGAGA

## 34\_ppprot1\_092\_f08rev

TCTGGACGCATGTGTGCTGAGGCTATTGTGAAGGCTCCGCCAACGGAAC  
CGTATGATTGACGAGTCAGATTTGAGGACATATCTAGATAAATGGGACAA  
GAAGTACTGGCAACTTACAAGGTGCTGGACATATTGCAGAAGGTTTCTA  
CAGGTCCAACCTGCCAGAGAGGCATTCGTCGAGATGTGCGCCGACGACT  
ACGTGCAAAAGATGACGTTTGATAGTTATTTGTACAAGGTGGTGGTGCCT  
GGAAACCCATTGGACGACCTGAAGCTAGCAGTTAACACTATCGGGAGCCT  
GATCAGAGCCAATGCATTGCGCAAGGAGTCTGAGAAGATGACCGTATAGG  
TGTGGCGCTGGAAATCTTCTCAGTTGATATTGGCCAGTCCTCCTGGAATT  
GTAAAATTGTAGTGGTATATTCCGAGGCTCCCGGGCACGGCTCTGGTTTT  
GGTAATCAATTTTGACTACCATTCACTTACTGTAGAACAGAGTAAGTAT  
CCTTTTAGTATCCCGGGATTAGGAATGCTAGATAATACTTTGCAGCTAAT  
TTAACCGGCTCTGAATTTACTAAGCGTCCTGCGCGGTTTGACACATCCTG  
AATTCTAATTCTCTCAGATGTTGTTCCCTTGATGGCGAAAAAAAAAAAAA  
AAAAA

## 83\_ppprot1\_056\_f06

GTCATCTTGTGCGGGCCTGAGACATTGCGAGACATTCTGCAG



TCATGGCTTCTCTCCAGGCCGTTATCACCGCTTCCCCTGCCTCCTTCGCT  
GCGTCCTCTAGAGCCGCTCTCTCCCACTCGGAGACTGCTGCCGTCTTGGT  
GCCTTGCGCCAGCATTCTCTCCGAGGCGTGAGCACTTCTTGCCTGGGCT  
TTGTTGCCTCCAGCGGGCGTAATGCTTCGTTGAAGTCCTTCGAGGGCTTG  
AGGGGTTTGAATGCCAGTGGACCCACCTCCGCCGTGGAGAGCCTGAAGGC  
CGAGAGAAGAAGCAATGTGGTTGAAGAAGCCGGATACCAGCCTCTTCGGG  
TGTATGCCGCGAGGGGAAGTAAAAAGATTGAGGGGCGAAAGTTGCGAGTG  
GCAGTTGTGCGAGGTGGCCCTGCCGGTGGATGCGCTGCGGAGACTCTTGC  
CAAGGGCGGAATTGAGACATTTCTCATTGAGCGAAAGTTGGATAATGCTA  
AGCCATGTGGGGGAGCTATTTCCCTTTGCATGGTGGGAGAATTTCGACCTG  
CCGCCCCGAAATTATCGACCGCAAAGTGACGAAGATGAAAATGATTTCGCC  
TTNCAATGTTT

## 23\_ppprot1\_071\_d03rev

TGGACGCATGTGTGCTGAGGCTATTGTGAAGGCTCCGCCAACGGAACCTCG  
TATGATTGACGAGTCAGATTTGAGGACATATCTAGATAAATGGGACAAGA  
AGTACTGGGCAACTTACAAGGTGCTGGACATATTGCAGAAGGTTTTCTAC  
AGGTCCAACCCTGCCAGAGAGGCATTCGTGAGATGTGCGCCGACGACTA  
CGTGCAAAAGATGACGTTTGATAGTTATTTGTACAAGGTGGTGGTGCCTG  
GAAACCCATTGGACGACCTGAAGCTAGCAGTTAACTATCGGGAGCCTG  
ATCAGAGCCAATGCATTGCGCAAGGAGTCTGAGAAGATGACCGTATAGGT  
GTGGCGCTGGAAATCTTCTCAGTTGATATTGGCCAGTCCCTCCTGGAATTG  
TAAAATTGTAGTGGTATATTCGAGGCTCCCGGGCACGGCTCTGGTTTTG  
GTAATCAATTTTGACTACCATTCACTTACTTGTAGAACAGAGTAAGTATC  
CTTTTAGTATCCCGGGATTAGGAATGCTAGATAATACTTTGCAGCTAATT  
TAACCGGCTCTGAATTTACTAAGCGTCCTGCGCGGTTTGACAAAAA  
AAAA

## 70\_mbl\_D11rev

GGCTCATCCAATTCCAGAGCACCTAGGCCTCGCAGGGCGAGT  
AACCGGGTGGCGTTGATCGGGGATGCGGCAGGGTATGTTACCAAGTGCTC  
TGGGGAGGGAATTTACTTCGCTGCCAAGTCCGGGCGCATGTGTGCTGAGG  
CGATCGTGGAGGGATCCGCCAATGGTACTCGCATGGTGGACGAATCAGAC  
TTGAGAACAATACCTGGAAAAGTGGGATAAGAAGTACTGGGCCACATATAA  
GGTGTGAGACATCTTCAGAAAGGTTTTCTACAGATCGAACCTGCCCGAG  
AGGCGTTCTGAGGATGTGCGCCGATGACTATGTGCAGAAGATGACGTTT  
GACAGCTATCTGTACAAGGTGGTGGTGCCTGGAAACCCATTGGACGACAT  
CAAGTTGGCAATCAACACAATCGGGAGTTTGATTAGAGCCAACGCCTTGC  
GCAAGGAGTCGGAGAAGATGACCGTGTAGGGTAGGGTTCTTATCCGTTG  
ATACTGCCTAGACTTTCTGGTTTTATACAATTCGTAGAAGCACGTTCCGA  
GGTTCCTGAGCTTGGGTATGTATTTGTCAATCCATTGTGATGACTCTCAT  
TCACTTGTAACAGGACATCTTATCT

## 84\_ppprot1\_36\_F12rev

CGTGACGAAGTGCTCCGGGGAGGGTATCTACTTTGCTGCTAAGTCTGGAC  
GCATGTGTGCTGAGGCTATTGTGGAAGGCTCCGCCAACGGAACCTCGTATG  
ATTGACGAGTCAGATTTGAGGACATATCTAGATAAATGGGACAAGAAGTA  
CTGGGCAACTTACAAGGTGCTGGACATATTGCAGAAGGTTTTCTACAGGT  
CCAACCCTGCCAGAGAGGCATTCGTGAGATGTGCGCCGACGACTACGTG  
CAAAAGATGACGTTTGATAGTTATTTGTACAAGGTGGTGGTGCCTGGAAA  
CCCATTGGACGACCTGAAGCTAGCAGTTAACTATCGGGAGCCTGATCA  
GAGCCAATGCATTGCGCAAGGAGTCTGAGAAGATGACCGTATAGGTGTGG

CGCTGGAAATCTTCTCAGTTGATATTGGCCAGTCCTCCTGGAATTGTAA  
ATTGTAGTGGTATATTCCGAGGCTCCCGGGCACGGCTCTGGTTTTGGTAA  
TCAATTTTACTACCATTCATTTACTTGTAGAACAGAGTAAGTATCCTTT  
TAGTATCCCGGGATTAGGAATGCTAGATAATACTTTGCAGCTAATTTAAC  
CGGCTCTGAATTTACTAAGCGTCCTGCGCGGTTTGAC

## 27\_mm6\_55\_E02rev

CTCCTGCGGTGTTGGGAAGTCGATGCTGTAATTGGAGCTGACGG  
TGCCAACAGCAGGGTGGCCAAGGACATTGACGCTGGTGAGTACGACTACG  
CCATCGCTTTTCCAAGAAAGGATTAAGATTCTTGAGGATAAGATGGAGTAC  
TATGAGAAGCTTGGCAGAGATGTATGTCGGTGACGATGTGTGCCAGACTT  
CTACGGGTGGGTGTTCCCGAAGTGTGACCACGTTGCAGTCGGAACGGGGA  
CGGTCAACAAGCCAGCCATCAAAAAGTACCAGACGGCCACGAGGAAC  
CGGGCGAAGGACAAGATTGCCGGAGGAAAGATCATCAGGGTTGAGGCACA  
CCCCATTCCGGAGCACCCAAGGCCTCGCAGGGCGAGCGACAGAGTGGCGT  
TAGTTGGGGACGCGGCTGGATACGTGACGAAGTGCTCCGGGGAGGGTATC  
TACTTTGCTGCTAAGTCTGGACGCATGTGTGCTGAGGCTATTGTGGAAGC  
TCCGCCAACGGAAGCTCGTATGATTGA

## 54\_ppprot1\_081\_a12rev

TATTGTGGAAGGCTCCGCCAACGGAAGCTCGTATGATTGACGAGTCAGATT  
TGAGGACATATCTAGATAAATGGGACAAGAAGTACTGGGCAACTTACAAG  
GTGCTGGACATATTGCAGAAGGTTTTCTACAGGTCCAACCCTGCCAGAGA  
GGCATTTCGTCGAGATGTGCGCCGACGACTACGTGCAAAAGATGACGTTTG  
ATAGTTATTTGTACAAGGTGGTGGTGCCTGGAAACCCATTGGACGACCTG  
AAGCTAGCAGTTAACTATCGGGAGCCTGATCAGAGCCAATGCATTGCG  
CAAGGAGTCTGAGAAGATGACCGTATAGGTGTGGCGCTGGAAATCTTCTC  
AGTTGATATTGGCCAGTCCTCCTGGAATTGTAAAATTGTAGTGGTATATT  
CCGAGGCTCCCGGGCACGGCTCTGGTTTTGGTAATCAATTTTACTACCA  
TTCATTTACTTGTAGAACAGAGTAAGTATCCTTTTAGTATCCCGGGATTA  
GGAATGCTAGATAATACTTTGCAGCTAATTTAACCGGCTCTGAATTTACT  
AAGCGTCCTGCGCGGTTTGACACATCCTGAATTCTAATTCTCTCAGATGT  
TG

## 47\_ppprot1\_100\_h03

CACCGCTTCCCTGCTCCTTCGCTGCGTCCTCTAGAGCCGTC  
TCCTCCCACTCGGAGACTGCTGCCGTCTTGGTGCCTTGCGCCAGCATTTT  
CTCCCGAGGCGTGAGCACTTCTTGCCTGGGCTTTGTTGCCTCCAGCGGGC  
GTAATGCTTCGTTGAAGTCCTTCGAGGGCTTGAGGGGTTTGAATGCCAGT  
GGACCCACCTCCGCCGTGGAGAGCCTGAAGGCCGAGAGAAGAAGCAATGT  
GGTTGAAGAAGCCGGATACCAGCCTCTTCGGGTGTATGCCGCGAGGGGAA  
GTAAAAGATTGAGGGGCGAAAGTTGCGAGTGGCAGTTGTGCGAGGTGGC  
CTGCCGGTGGATGCGCTGCGGAGACTCTTGCCAAGGGCGGAATTGAGACA  
TTTCTCATTGAGCGAAAGTTGGATAATGCTAAGCCATGTGGGGGAGCTAT  
TCCCCTTTGCATGGTTCGGAGAATTCGACCTGCCGCCGAAATTATCGACCG  
CAAAGTGACGAAGATGAAAATGATTTGCGCTTCCAATGTTGCTG

## 25\_mm18\_e01rev

TGATAATACATAAATTAGTTCCAAAAATCATAAGAGAGGAATA  
CAAGACAATATACGACTAAAACAAATACATCCATAACAATGACCACCGGC  
AATGGTCACCTCTGTACCTACTTCGGGCACAATATATATTGAGAACTTGG  
CAGAGATGTATGTCGGTGACGATGTGTGCGCCAGACTTCTACGGGTGGGTG

TTCCCGAAGTGTGACCACGTTGCAGTCGGAACGGGGACGGTCATCAACAA  
GCCAGCCATCAAAAAGTACCAGACGGCCACGAGGAACCGGGCGAAGGACA  
AGATTGCCGGAGGAAAGATCATCAGGGTTGAGGCACACCCCATTCGGAG  
CACCCAAGGCCTCGCAGGGCGAGCGACAGAGTGGCGTTAGTTGGGGACGC  
GGCTGGATACGTGACGAAGTGCTCCGGGGAGGGTATCTACTTTGCTGCTA  
AGTCTGGACGCATGTGTGCTGAGCTATTGTGGAAGGCTCCGCCAACGGAA  
CTCGTATGATTGACGAGTCAGATTTGAGGACATATCTAGATAAATGGGAC  
AAGAAG

**80\_bd09\_f10rev**

AGTTCTCAGTTTCATTCTCTGAACAATACGGATTTCAGTTCCCAATAACAG  
TCATTTGGCAANCACATATTGTGCATTGGCTATATTGAAGACAGTTGGTT  
ATGACTTNTCACTTATTGACTCTCGGTCAATATATAAGTCAATGAAACAT  
CTTCAACAACCTGATGGCAGTTTCATGCCTATTCATACAGGAGCAGAGAC  
CGATTTACNGTNGTNTATTGTGCTGCTGTCNTTTCTCCTCTATTGGATA  
ATTGGAGTGGAATGGATNAAGACA

**78\_ppprot1\_087\_e12rev**

GTCGGACTACGTCTCCATAGCCAAAGACTTAGGCCTGCAGGATATCAAGA  
GCGAGGACTGGTCCGAGTACGTGACGCCCTTCTGGCCAGCGGTGATGAAA  
ACCGCCTTGTCCATGGAAGGGCTGGTGGGACTGGTCAAGTCCGGCTGGAC  
TACTATGAAAGGAGCTTTCGCCATGACGCTCATGATCCAGGGCTACCAGC  
GAGGGCTCATTAATTCGCTGCCATCACTTGCAGGAAGCGGGATTGACCG  
ACTGATTTCAGTCCTTCTCATTTCTCATGACATCATGGACAATGTGCGAA  
CCGATTACATTCTTATGCCAGTGAGGAATGGTTGCGTGGTTTCTGGTAAT  
CGTCAAGCTTCGGAGTATAAGGGATTGAGGTCTCCGCTAGTAGACTTTAC  
TATGGCATATTCAACCATCTGTACCTTGAGGGAGTAATCACCAATTCGTG  
CATACATCATTCGGCAAAAGATCATTGGACGTCAAAAA

**78\_ppprot1\_092\_e12rev**

ATCGATCGCCAGAAAATGTGCAGTCGAGTTTGAAGTTGGGGATTGCACCA  
AGATTAATTACCCTCACGCATCTTTTGATGTCATCTACAGTCGTGATACC  
ATTCTACACATTCAAGATAAACCTGCGCTTTTCAACGGTTTTATAAATG  
GTTGAAGCCTGGAGGTCGGGTGCTTATCAGTGACTACTGTAGAGCTCCAC  
AAACTCCGTCGGCGGAGTTCGCTGCATACATTACGAGAGGGGTTATGAT  
CTCCATAGCGTTTCAAGTACGGAGAGATGCTGGAAGATGCCGGTTTTGT  
GGAAGTGGTCGCAGAGGACCGCACGGATCAGTTCATTGAAGTGTTACAGA  
GGGAGCTAGCCACCACTGAAGCAGGTGCTGACCAGTTCATCAACGATTTC  
TCCGAGGAGGATTATACTACATTGTGAGCGGATGGAAGAGTAAGCTGAA  
GCGCTGTTTCAATGACGAACAGAAGTGGGGACTCTTCATAGCCTACAAGG  
CATTATGATCTTGAAATTATTTCCGATATAGATAAAACAGCATTGTTGGA  
ATAGTTCACACTTGAGAGTCTGTTTTGTCTTCTTATAAATAAACATCGAT  
ACTATTCACCCACTTAAAA

**Carotenoid metabolism:****05\_ck\_19\_a03**

TGTGCGCCTCCACCACAGTCCCTACGAGGATTTATGATGGAGTGGCGGAG  
GACCAAGAGGATTACATCAAGGCTGGTGGAGAAGAGTTGGATCTCGTGCA

GCTGCAGGCCTCCAAGTCCTTTGATCAGTCCAAGATTGGGGAGAAGTTAC  
AACTTCTGGGAGACGAAACGTTAGATTTGGTAGTTGTAGGCTGCGGTCCT  
GCTGGAATGTGCTTGGCAGCTGAAGCAGCGAAACAGGGCCTTAATGTGGG  
CCTCGTAGGCCCTGACCTACCGTTCGTCAACAATTATGGTGTGTTGGACTG  
ACGAATTTGCTGCATTGGGCCTCGAGGACTGCATAGAGCAAACCTGGAAA  
GACTCAGCTATGTATATTGAAGAGGACTCGCCTATAATGATAGGGCGTGC  
ATATGGTTCGTGTGAGTCGGACTCTTCTGAGAGAAGAGCTTCTGAGGAGGT  
GCGCTGAGGGAGGGGTTAGATACGTTGATTCTAAAGTTGACAGGATACTT  
GAAGTCGATGAGGATTTGAGTACCGTTCTATGCACCAATGGAAAAAATAT  
CAAGAGCAGACTT

02\_ppprot1\_046\_a07rev

TACCATCCTGAGGGATGTTGAAGAAGATGCACGCCGTGGCAGAGTATACCT  
CCCACAGGATGAACGGCACGTTTCGGTCTGTCGGATGCAGACATTTTTGT  
CGGAAAAGTTACTGATAAATGGAGGGCATTGATGAAAGACCAAATTTAAAG  
AGCTAGAGTGTCTTTGTGGAGGCTGAGAAAGGTGTACGTGAGCTGGACAA  
AGACAGTCGCTGGCCTGTGTGGTCCGCCCTCATTCTTTACCAGCAAATTCT  
GGACGCCATTGAAGCCAACGATTACGATAACTTCACAAAAAGAGCTTACGT  
AGGAAAGTGGAAAAAGCTGGCTTCTCTACCTATCGCTTATGGCAGAGCGTT  
GGTTCACCTCCAGATGCACTTCCAGGTTAGCACGTTAAGTTCTAACTTC  
TGATGTACCATGGGTATCGCTGGTCAACGAATTCACCAGAATCTGTTTCG  
CTGTCACAGGGAATCCTGAAAGAGCTGCATTTGCATCCCTGTCTTTTGACG  
AACTCCTAGAGCCGGAAGAGGCAAAATTGTAGATGTAGTGGAGTTGACA  
AGTCTTTTGTACCGTCCGTACTTCTGTACTTGGAACCATTATGTGAGCCG  
GTTGTTTATATAGCTGTGTATAGCTGAGCAGTCTTTGCTATCTACTAAATA  
AAATTCTTCCTTCTCTTCTTG

96\_ck5\_h12fwdrev

TTTACAAGACGGTGCCAGATTGTGAGCCTTGTAGGCCACTTCAAAGATCA  
CCTATTCCAAAGTTCTACATGGCGGGTGACTTCACTAAGCAGAAGTACCT  
CGCTTCTATGGAAGGGGCTGTGCTCTCTGGCAAATTTTGTGCCCAATCCA  
TTGTACAGGATTTCAAGGCAGGAAACTGAAAGCGGGCGGTGAGAAGGAA  
GCTGTGCTGGTCTCTCAATGACCAAAGCTTGAGACTCATTTACCCTTGTA  
CTTGTAATTCATTATACTTGTCGTTTGCACTGGTTGACGCGCGCTTCTC  
AGCTAACACATTTTACCAATAATAGGTGGGGCTGTGTTCAATGCGCAGA  
AATTTGGATTGGTACAGGATTCATGATCCACTGATTACGATGCAGCTGA  
TGGGTCTCGTTGTTAGGTAGGCTTCATTCATATGCCGCAAGCTGATTGCG  
CGGAAATCCAGCAATTCATGGTTTTTGAACGAAATGCTGGTTGAAGA  
TTTACTGTAAGCGGTTACCGCATGCTATTCACTGCACTTCATGTTCAAA  
TCTGAATCAATTTCTGTCAAAAAAA

42\_ck10\_g09fwd

GTGCAACAGCACTGAATTGGAATTGTGTTCAAGAGGTTTGGG  
ATTGTGGGTTAGTGTGTGCGTGCGAGTTTGAGAGAAGGGGGTTTTG  
AAGCTCAGGTTGCAAATATTTTGGTAGCTATGGCGGGGTTGGTGGTGCAG  
GCGGGGAGGTGTGCAGGGGTGGCTTCACTGTCGTTGGCTTCCTCGTCGTC  
GAGTCATGTGAAGGGATCGATTCCAGCGCCATGTTTTGCAGTTGTGGACT  
GAAAGGATGCCAGCAGCAGACGGACAGGGAGTGTGCGCGTCACAGCCAGC  
TTGCAAAGCATGGTGTGCGACATGAGCAGGAAAGCACCAGGAGTCTGTT  
CCCTCCCGAGCCCGAGGCTTACAAGGGGGCCCAAGCTCAAGGTCGCCATTA  
TTGGCGCTGGTCTTGCGGGCATGTCCACCGCTGTTGAGCTTCTCGAGCAA  
GGCCACGAGGTGGATATCTATGAGTCGCGAAAGT

## 84\_mm11\_f12rev

ATTACCGGAGAGTGGTACTGCAAGTTCGATACTTTCTCACCCG  
CAGCAGAGCGAGGCTTGCCAGTCACTCGAGTGATCAGTCGGATGAACTC  
CAGGAAATTCTTTCCGGTGCATTGGGATCAGAGTACATACAGAATGGCTC  
TAATGTGGTAGATTTTGTGGACGACGGGAACAAAGTGGAAGTCGTGCTGG  
AGGATGGACGGACATTTGAAGGGGACATCCTCGTCGGCGCTGATGGCATT  
CGCTCCAAGGTGCGAACGAAATTGCTAGGTGAGTCGTGACCGTGTATTTC  
TGATTACACCTGCTACACGGGGATTGCTGATTTTGTGCCCGCTGATATCG  
ACACCGTTGGGTACCGCGTCTTCCTCGGCCACAAACAGTACTTTGTTTCT  
TCGGACGTTGGGCAAGGGAAGATGCAGTGGTATGCGTTCTACAATGAACC  
TGCGGGCGGGGTAGACGCCCCAGCGGAAGGAAAGCAAGGTTGATGTCGTT  
GTTCCGGGGGATGGTGTGACAAGGTGGTGGATCTNCTACTGGC

## 41\_ppprot1\_085\_g03rev

CATGCGAAATAGAGCTTGGCGAGTTCCGGGCTGTGACGGAACCCGAAGTT  
GCACCACAGCATGCCAACTTGTGTTCAAAGACGGCGCCCTGTTTGTTAC  
GGACCTAGACAGCAAGACTGGCACGTGGATTACGAGTATCAGTGGTGGTC  
GCTGCAAATTGACCCCGAAAATGCCACTCGAGTTCACCCGGAGGATATC  
ATTGAGTTCGGCCCTGCCAAGGAGGCTCAGTACAAGGTGAAGCTCCGAAG  
GTCCAGCCAGCTAGATCAAACCTCTTACAAGACAGACTTGAATGCGCTGA  
AAGTGGCATAAGGGGACTCGATAAACTCCAGTATTCGACGACTATTCTGC  
AGTGATGGGACTCTAGCAGCATTGAATCTCCACCCCCCCCCCTTTTTTTT  
TTAATTTTAAAAACATCGATACAGCACTTGACTGGACCCACGGATTGAAT  
TGAATTGCAGCAATGTTGAAGGATTGCTGCAGCTCGACTCACAGGATAGG  
ATGTAACCCATGCCAGCTCTAGTGTATGAAATAGTAGGCTCTAGATAGAT  
TAACCCACTGTATATTGTTAGTGTGTAATCTGATCCAAAGGGATTCTTAA  
GATTTCTTGGTTCAAAAAA

## 06\_ppprot1\_062\_a09rev

AGTGGAAGGCGCGGCACAGAAGAGCGATTTTTCTTTTTCTAGAGGAATT  
CCAACGACACTCCAGGAATTATGTCAAAGGCAGTTAACATGGTTCCGAAA  
TAAAGGTCAAAGTGAGCAGATGTTCAACTGGATTGATGCCACACAGCCCT  
AGAAGTGATGGTGGACGCCTTAGCGAAAGAGTATGAAAGGCCCAATGAAGT  
GGTGAGCGATGTCTGAAAGCGGCAAGTGTTGTTACCAAGGAGTCTAGTTA  
CAAGGAGGAAAACCTTTTGAAGCGCTACCGAACTCAAAACAGGATATTTAC  
TAGTAACAGTGAGGCGCTCAAGCGTACTTTACAATGGATACGAGATACCCA  
GTGTCTATGGCGGAACAGTAGCACGGTGGATGATCTCCAAAAGAGAATGGA  
ATCATCCTTGACGACCTCTATGTAACGTTGCTTATTTTATGAGTGAAGATT  
TTGACT

## 16\_ppprot1\_082\_c08

CTCAGATTGTCATGATGCATGACTTTGCCATCACGGAAAATTA  
TGCAATCTTTATGGATCTTCCCCTCCTGATGGACGGCGAAAGTATGATGA  
AAGGAACTTCTTTATCAAGTTCGACGAAACCAAAGAAGCTCGGTTGGGA  
GTACTTCTTAGATACGCCACTAACGAGAGTCAGCTTCGCTGGTTCACCAT  
TCCCGTGTGTTTCATATTTACAACGCGAACGCTTGGGAGGAAGGCGATG  
AAATTGTCTTGCAATTCTTGTCGAATGGAAGAAATAAACCTAACGACGGCA  
GCAGACGGATTCAAAGAAAATGAACGCATTTCTCAACCTAAATTGTTTGA  
GTTTAGGATCAACCTTAAGACTGGTGAGGTGAGACAGAAACAGCTCTCAG  
TTCTGGTGGTGGATTTTCCAAGGGTCAACGAGGAGTATATGGGAAGGAAA

ACTCAATATATGTATGGAGCCATTATGGACAAAGAGTCTAAAATGGTAGG  
AGTCGGAAAGTTGACCTATTGAAAGAACCAGAGGTGAACC

## 30\_ppprot1\_064\_e09

CCACTGTGTTGTCTCTCATTCTCCACGGTTTTGGCAAATT  
TGTGTCCTTATTGTTTTTAGTAAAACAACAAATATGGCGGCCGCGATATC  
TTCAGTAAGTTGCATCTCTGCAGCTAAGCTCTTCTCCGTTGCAGCTGCAC  
CTCACGCAACGAGGCGCACTTCTGTGCTGCACATCAGCGCTGTAGCTGAC  
AAGGTCTCTCTGATCCAGCCGTCGTGCCCCCAAATGTGCTCGAGTATGC  
GAAGACAATGCCCGGAGTGACTGCTCCGTTGAGAACATCTTCGACCCTG  
CTGACCTCCTGGCCCGCGCTGCCTCCAGCCCCGACCCATTAAGGAGCTG  
AACAGGTGGAGGGAGTCGGAATCACTCACGGCCGTGTTGCCATGCTTGC  
CTCTTTAGGATTTATTGTCCAGGAGCAGCTCCAGGATTACTCTTTGTTCT  
ACAACTTTGACGGCCAAATCTCTGGTCCAGCTATCTACCACTTCCAGCAG  
GTTGAAGCTCGCGGTGCCGTCTTTGGGAGCCTCTTATCTTCGCCATCGC  
TCTTTGCGAGGCATACAGAGTAGGTCTTGGTTGGGCAACTCCCCGTTCCC  
AGGACTTCAACACATTGAGGGATGACTACGAACCCGGTAACTTGGGCTTT  
GACCCTTGGGCCTCTCCCAACTGATCCCGCTGAAAGGAAGGTTATGCAG  
A

## 55\_ppprot1\_093\_b04rev

TGGGGGATGCATTCAACATGAGACATCCTNTGACAGGCGGCGGCATGACC  
GTGGCTCTTTCCGATATTGTTCTGCTCCGGGACATGCTCAGGCCTTTAAG  
TAGTTTTCATGATGCTCAATCATTATGCGATTACTTGCAGGCTTTTACA  
CGCGACGCAAGCCTGTTGCAGCCACTATCAATACTCTTGCGGGAGCCCTT  
TACAAAGTGTTTTGTGACTCCCCTGATTTGGCGATGAAAGAAATGAGACA  
GGCTTGCTTTGACTATTTGAGCATTGGAGGTGTCTTCTCAAGTGACCAG  
TTGCCCTTTTGTCTGGACTTAACCCTCGTCCTTTGAGTCTAGTGGTCCAC  
TTCTTTGCGGTTGTCTGTATATGGAGTAGGGAGACTCCTTGTTCCCTTTTCC  
TTCAACGCTCAAGGGTATGGATTGGCGCACGTCTCTACGGGGAGCTGCGA  
ATATTATATTCCCGATCATTAAAGCAGAAGGAGTCAGGCAGATGTTCTTT  
CCAAATATGGTTTCTGCATATTACAAAGCACCACCGGCAGAGGAGTAAGT  
GAAATGTGATGGTGCGGTATTGAAATTAACCGGTCTCGTTTACTAATAAA  
CAGAGACTGGTCATTAATTCAACCAGTTCCTC

## 02\_mm14\_a07rev

CAGAACC CGGATGGCGGCTGGGGCGAGTCCTGCGCCTCGTACG  
TCGACCTGCAGCAGCGCGGTGTCGGCCCCAGCACCGCGTCCCAGACTGCG  
TGGGCACTCATGGCACTGGTGTGAGTGCGCCACTCCAGCGAGTACTACGA  
CGCAATCAGGAATGGTGTGGAGTATCTGGTGCGGACGCGCACAGCGGCAG  
GCTCATGGAGTGATGGCGGCCTATTACAGGCACTGGATTCCCTGGCAAC  
GTCGTAGGCACGCGGATCGATCTGGGCACCGATAGCTCCAAGCCGGGCCA  
TGGAACGAGCTCAGTCGCGGCTACATGTTGCGCTACCACATGTACCCGC  
ATTACTTTTCTCTCATGGCTCTTGGGCGGGCTCGCAAGTATTTCCAGCAT  
GTGAAGTCTCTCCCTCGTTCCCTCTGAATTTATCTGACTCTGAGGCTGCC  
CTCAAAATTTGTAGGCTGGAGAACAGAAATATTACCGACGTCTAAATATT  
AAATTAAATCCACCTCTGATCGGATCCAGTCCTTGTACACATAATAAGTC  
AAACAATGACAATGTGTGACTTTGAAGTACATATCAATGCATTTACAATG  
GGTATGTCA

## 51\_ppprot1\_081\_a05rev

GGTTTCCTGATGCTCATGTACAGGTCTAGATTTGTCGCCCTACTTTTTTA  
GCTGTGGCTCAATACATGGAGAAACAGAGGATCTCCAGCGGGCTTGAAG  
ACGCAGACCAATAAGTTGGGTACATGCAAATGGAGAGTGCACGGGCTTGC  
CAAGTTCATCTTTTGATGTGGTTTCGCTTGCCTTCGTGATTCATGAATGT  
CCTCAACATGCTATTAGAGGTTTACTGAAGGAGGCTCTCAGATTATTGAA  
ACCCGGAGGAACCGTGTGCTAAGTGAACAACGCCCCAAATCGAAGGTCC  
TTCAGAATTTGCCACCTGCAATATTTACTCTAATGAAGTCTACGGAGCCC  
TGGATGGATGAGTACTTCACTTTTGACTTGGAAGGTGAAATGGAGAAGAT  
TGGGTTTCATGAATGTCAATTCAATTATGACAAATCCACGACACCGTACTG  
TCACAGGCACGTGCTCCTTAGGAATGCCGGCAGATGGCTTAGAAGATTTTA  
GTATATGAATTGTTAAAGGGCATTTTGGAGAATCCATGGCCACTTTTTTA  
CTAGATCGAAGTTCCAAGCTCCAAGAGCAAGATGAATTAAGTTCTTTTTG  
AA

## 93\_ck24\_h05fwd

CGACTACTTGAACCAGCTCCTCATCAAGTTCGACCACGCTTG  
TCCAAACGTGTACCCCGTTGATCTCTTCGAGCGTTTGTGGATGGTAGACC  
GCCTACAAAGGCTGGGAATATCCCCTACTTCGAGCGAGAAATCAGAGAC  
TGTCTACAATATGTATACCGATACTGGAAGGATTGTGGTATTGGCTGGGC  
AAGCAATTCGTCCGTGCAGGACGTGGACGACACGGCCATGGCCTTCCGCC  
TTCTCCGCACACACGGATTTCGACGTCAAGGAGGACTGCTTCAGACAGTTT  
TTCAAAGATGGTGAGTTCTTCTGCTTCGCCGGCCAGTCCAGCCAAGCCGT  
CACGGGAATGTTCAACCTCAGCAGAGCATCGCAAACGCTCTTCCCAGGGG  
AATCACTCCTAAAAAAGGCCANAACCTTTTCCAGAACTTTTTGAGAACC  
AAGCATGAAAACAATGAATGCTTCGACAAGTGG

## 51\_ppprot1\_0052\_a05

ACTGGATTTTACCATAACGATGCCACTATCTTGCAACAAATCTCG  
GCTGAAAGAGAGAAGAAAATGAAAAAAGCAGGATTCCTATGGCGATGGTG  
TACAAGTACCCCACTACTTTTGCTGCATTCTCTGGAAGGCCTGCACCGGGA  
AGTGGACTGGAACAAGCTCCTCCAGCTACAGTCCGAGAATGGCTCCTTTC  
TGTATTACCCGCATCCACTGCATGCGCACTTGACACAAAAGATGTGAA  
GTGCTTCGACTACTTGAACCAGCTCCTCATCAAGTTCGACCACGCTTGTC  
CAAACGTGTACCCCGTTGATCTCT

## Longest clones

## 78\_ppprot1\_087\_e12-259rev

GGCAGGAGGATGAATGAGAGATAGATCGCAACGAAGCTGAAGAGGCCAG  
GCGTTGCGTGTGAAGGGCTGTCTTAGTAGCGCTCCCTTCCTCCTGGCGA  
TTCTGTTGGAGTTGTCGAGAGTTTCGACAACGTGCATAGCGATGGCTGTC  
GCACTGGGAGCAGCAGGTTCTTTTGCTGGTGCTGCTGCAGCACGGGCTGG  
ACTTGCAGTAGCAGCATCAGCAGTTGCAACGAGATCCGGACCCGGTTCGACG  
AGTGTACAGAGTGCGCAGGTTTGCGGTCTGATAAGGGCGGATGATGAGGTA  
GGACGACGCGCGTCAAGACGAGGAGTCTGCGGTCTGGGGGGGTGGTGAGG  
CGAGCTGTGCAGCGGACGGAGCCGGAGCTTTACGATGGCATCGCCCACTTC  
TACGATGAATCGTCGGGCGTATGGGAGGGCATTTGGGGGGAGCACATGCAC  
CATGGCTACTATGACGAGGAGATTGTGGAAGCCGTCGTTGACGGCGATCCT  
GACCACCGCGAGCGCAAATCAAGATGATTGAGAAATCTCTTGCGTATGCT

GGCGTTCTGATAGCAAAGATTTGAAACCGAAGACGATCGTCGATGTGGGT  
TGTGGGATAGGGGGAAGCTCACGTTACTTGGCCCGGAAATTCCAGGCCAAG  
GTGAATGCCATCACGCTCAGCCAGTGCAGGTTGAGAGAGCCGTAGACCTT  
ACTGCCAAGCAAGGCTTATCTGACCTCGTCAATTTCCAGGTAGCGAATGCC  
CTGAACCAGCCCTTTTCAAGGATGGTTTCGTTTGATCTCGTGTGGTCCATGGAG  
AGCGGCGAGCACATGCCAGACAAGAAAAAGTTTGTGGGCGAGCTTGCACGA  
GTAGCAGCTCCCGGCGGTTCGATTATCCTGGTGACGTGGTGCCACCGTGAT  
CTCAAGCCCGGTGAAACTTCTCTCAAGCCTGACGAGCAGGATCTTTTGGAC  
AAGATTTGTGACGCATTCTACTTGCCAGCCTGGTGCTCGCCGTCGGACTAC  
GTCTCCATAGCCAAAGACTTAGGCCTGCAGGATATCAAGAGCGAGGGCTGG  
TCCGAGTACGTGACGCCCTTCTGGCCAGCGGTGATGAAACCGCCTTGTCC  
ATGGAAGGGCTGGTGGGACTGGTCAAGTCCGGCTGGACTACTATGAAAGGA  
GCTTTCGCCATGACGCTCATGATCCAGGGCTACCAGCGAGGGCTCATTA  
TTCGCTGCCATCACTTGCAGGAAGCGGGATTGACCGACTGATTTCAGTCCTT  
CCTCATTTCTCATGACATCATGGACAATGTGCAACCGATTACATTCTTAT  
GCCAGTGAGGAATGGTTGCGTGGTTTCTGGTAATCGTCAAGCTTCGGAGTA  
TAAGGGATTGAGGTCTCCGCTAGTAGACTTTACTATGGCATATTCAACCAT  
CTGTACCTTGAGGGAGTAATCACCATTTCGTGCATACATCATTCGGCAAAA  
GATCATTGGACGTCTCTTCCAGAGAGAGATTTGACTGAACTCCATTAAGCT  
GCACTGCAAGACTTAAGTTACAATCAGCACCTGTTACAATGCATTTTTCAT  
GACTTTATTTTAAAGTGAGTTTCAAAGAGTTTATGATAGCTTGATTTTA  
AGCTTGAAATGGTGTGCAAGTCAAGTTTATGAAGAGTCTTCATCTTTAC  
AAGAATTTACAGAACTGTCAAATAGGTGATTATAATTTGGAACGGTCATC  
TTTGTTACATTGTGAAAATATGAATTATCCTACGTATCAGAGAACGTTATT  
CTGGGCTTGCATGTGTTCAATGAATTTTGAAAATAAAAAAGCATCATCTCA  
GTATGATAAAAAAAAAAAAAAAAAAAAA

78\_ppprot1\_092\_e12-260rev

GAATTCGGCACGAGGCGGAGCGATCTGTGTGTTGTGATCGGTGCCTCTCT  
CTTTCGTGTTCTCCTTATCGCGCGCTTCGTCTCGATCTGCCTGGAAGCCA  
ATGCACCAAAGGGGCAAGTCCATCAACCGACGCTCCCGGACTTTTTCTCG  
CACCCGCATCGCCATCGAAGGCCATTGATCCTGGCTCCGGGAGTGTTCCG  
AAAATTCTGATCTGCGGTGGTTGGGAGTTTGGGACGCTGGCTCTGGTTGC  
CTTGCCGTGACAAGGAGGCGCCCGCAAGAAGAAGAAGAAGAAGAAGA  
AGTCTTGAGTTGCGCGCTTTTCGTGACTGTTCCACCACTGAGATTGTTCT  
TGTCTCTGTGCAATCATGGCGGTCAATACCGAGCGTTCTCTTCAATCAA  
CTTACTGGAAGGAGCATTCTGTGGAGCCTAGCGTTGAGGCAATGATGCTT  
GATTTCGAGGCCTCCAACTCGATAAAGAAGAACGACCCGAGATTTTGTG  
GCTGTTGCCGCCATATGAAAACAAGGATGTCATGGAGCTCGGAGCAGGCA  
TCGGTTCGGTTTACTGGTGAGCTTGCAAAGCATGCAGGTCATGTGCTTGCC  
ATGGATTTTCATGGAGAATCTCATCAAGAAGAACGAGGATGTGAACGGTCA  
CTACAACAACATCGATTTCAAATGTGCGGATGTGACCTCTCCAGACCTGA  
ATATTGCAGCAGGTTCTGCGGATCTCGTGTTTTCAAATTGGCTTCTCATG  
TACTTGTCTGACGAAGAGGTTAAAGGCTTAGCATCACGCGTTATGGAGTG  
GCTCAGGCCTGGAGGATACATTTTCTTCAGAGAATCCTGCTTCCACCACT  
CAGGAGATCACAAGCGAAAGAACAATCCTACTCACTACCGTCAACCCAAC  
GAGTACACGAACATCTTCCAGCAGGCCTACATCGAAGAGGATGGGTCTTA  
TTTCAGGTTTGAAATGGTCCGATGCAAATGTGTGGCACATACGTGCGAA  
ATAAGAGAAATCAAACCAGGTGTGTTGGTTATGGAGGAAAGTTCAGTCG  
GATGGACCTGAGAGCGAGTGTTTCCAGAAGTTTTTGGACACCCAACAGTA  
CACGTCAACTGGAATCCTGCGTTACGAGCGTATTTTTGGAGAAGGATTG  
TTAGCACGGGTGGAATCGAAACCAGAAAGCTTTTGTAAGTATGCTGGAC  
TTGAAGCCAGGACAGCGTGTCTTGACGTTGGATGTGGGATCGGAGGTG



TGATTTCTACATGGCCGAAGAATATGATGCTGAAGTTGTTGGCATCGACC  
TGTCCTTAAATATGATTTTCGTTTGCTCTTGAACGATCGATCGGCAGAAAA  
TGTGCAGTCGAGTTTGAAGTTGGGGATTGCACCAAGATTAATTACCCTCA  
CGCATCTTTTGATGTCATCTACAGTCGTGATACCATTCTACACATTCAAG  
ATAAACCTGCGCTTTTTCAACGGTTTTATAAATGGTTGAAGCCTGGAGGT  
CGGGTGCTTATCAGTGACTACTGTAGAGCTCCACAACTCCGTGCGCGGA  
GTTTCGCTGCATACATTTCAGCAGAGGGGTTATGATCTCCATAGCGTTCAGA  
AGTACGGAGAGATGCTGGAAGATGCCGGTTTTGTGGAAGTGGTCGCAGAG  
GACCGCACGGATCAGTTCATTGAAGTGTTACAGAGGGAGCTAGCCACCAC  
TGAAGCAGGTCGTGACCAGTTCATCAACGATTTCTCCGAGGAGGATTATA  
ACTACATTGTGAGCGGATGGAAGAGTAAGCTGAAGCGCTGTTCGAATGAC  
GAACAGAAGTGGGGACTCTTCATAGCCTACAAGGCATTATGATCTTGAAA  
TTATTTTCGGATATAGATAAAACAGCATTGTTGGAATAGTTCACACTTGAG  
AGTCTGTTTTGTCTTCTTATAAATAAACATCGATACTATTACCCAAAAA  
AAAAAAAAAAAA

## Appendix B: included amino acid sequences

## 84\_ppprot1\_50\_f12rev

Pro Cys Gly Arg Ser Leu Arg Gly Leu Gly Tyr Ala Phe Asp Gln Ala  
Gly Pro Gly Gly Leu Ser Ser Pro Thr Ser Gly Leu Thr Ser Phe Asn  
Ser Trp Gln Ile Val Lys Leu Lys Arg Ile Ile Thr Asp Ile Ala His  
Cys Gly Leu Phe Thr Arg Glu Leu Ala Cys Val Gln Lys Thr Phe

## 41\_bd10\_g03rev

Gln Asn Arg Lys Met Gly Thr Glu Val Lys Leu Thr Asn Gly Asn Thr  
Val Thr Ala Pro Ala Gly Glu Gln Thr Ser Ser Ala Tyr Lys Leu Val  
Gly Phe Glu Asn Phe Val Arg Asn Asn Pro Met Ser Asp Lys Phe Thr  
Val Lys Ser Phe His His Val Glu Phe Trp Cys Ser Asp Ala Thr Asn  
Thr Ala Arg Arg Phe Ser Trp Gly Leu Gly Met Pro Ile Val Tyr Lys  
Ser Asp Leu Ser Thr Gly Asn Asn Ile His Ala Ser Tyr Leu Leu Arg  
Ser Gly His Leu Asn Phe Leu Phe Thr Ala Pro Tyr Ser Pro Ser Ile  
Ser Thr Ala Thr Ala Ser Ile Pro Thr Phe Ser His Thr Asp Cys Arg  
Asn Phe Thr Ala Ser His Gly Phe Gly Val Arg Ser Ile Ala Ile Glu  
Val Glu

## 58\_mm15\_b11rev

Phe Ala Met Asp Arg Ala Gly Leu Val Gly Ala Asp Gly Pro Thr His  
Cys Gly Ala Phe Asp Val Thr Tyr Met Ala Cys Leu Pro Asn Met Val  
Val Met Ala Pro Ala Asp Glu Ala Glu Leu Phe His Met Val Ala Thr  
Ala Ala Ala Ile Asp Asp Arg Pro Ser Cys Phe Arg Tyr Pro Arg Gly  
Asn Gly Ile Gly Val Gln Leu Pro Ala Lys Asn Lys Gly Ile Pro Ile  
Glu Val Gly Arg Gly Arg Ile Leu Leu Glu Gly Thr Glu Val Ala Leu  
Leu Gly Tyr Gly Thr Met Val Gln Asn Cys Leu Ala Ala His Val Leu  
Leu Ala Asp Leu Gly Val Ser Ala Thr Val Ala Asp Ala Arg Phe Cys  
Lys Pro Leu Asp Arg Asp Leu Ile Arg Gln Leu Ala Lys Asn His Gln  
Val Leu Ile Thr Val Glu Glu Gly Ser Ile Gly Gly Phe Gly Ser His  
Val Val Gln Phe Met Ala Leu Asp Gly Leu Leu Asp Gly Lys Leu Lys  
Trp Arg Pro Leu Val Leu Pro Asp Arg Tyr Ile

## 10\_ppprot1\_092\_b08rev

Trp Pro Thr His Cys Gly Ala Phe Asp Val Thr Tyr Met Ala Cys Leu  
Pro Asn Met Val Val Met Ala Pro Ala Asp Glu Ala Glu Leu Phe His  
Met Val Ala Thr Ala Ala Gln Ile Asp Asp Arg Pro Ser Cys Phe Arg  
Tyr Pro Arg Gly Asn Gly Ile Gly Ala Gln Leu Pro Glu Asn Asn Lys  
Gly Ile Pro Val Glu Ile Gly Lys Gly Arg Ile Leu Leu Glu Gly Thr  
Glu Val Ala Leu Leu Gly Tyr Gly Thr Met Val Gln Asn Cys Leu Ala  
Ala Arg Ala Leu Leu Ala Asp Leu Gly Val Ala Ala Thr Val Ala Asp  
Ala Arg Phe Cys Lys Pro Leu

## 68\_ck12\_d10fwd

Pro Phe Cys Ser Ile Tyr Ser Ser Phe Leu Gln Arg Gly Tyr Asp Gln  
Val Val His Asp Val Asp Leu Gln Lys Leu Pro Val Arg Phe Ala Met  
Asp Arg Ala Gly Leu Val Gly Ala Asp Gly Pro Thr His Cys Gly Ala  
Phe Asp Val Thr Tyr Met Ala Cys Leu Pro Asn Met Val Val Met Ala  
Pro Ala Asp Glu Ala Glu Leu Phe His Met Val Ala Thr Ala Ala Gln

Ile Asp Asp Arg Pro Ser Cys Phe Arg Tyr Pro Arg Gly Asn Gly Ile  
 Gly Ala Gln Leu Pro Glu Asn Asn Lys Gly Ile Pro Val Glu Ile Gly  
 Lys Gly Arg Ile Leu Leu Glu Gly Thr Glu Val Ala Leu Leu Gly Tyr  
 Gly Thr Met Val Gln Asn Cys Leu Ala Ala Arg Ala Leu Leu Ala Asp  
 Leu Gly Val Ala Ala Thr Val Ala Asp Ala Arg Phe Cys Lys Pro Leu  
 Asp Arg Asp Leu Ile Arg Gln Leu Ala Lys Asn His Gln Val Ile Ile  
 Thr

## 39\_ck27\_g02fwdrev

Ile Glu His Gly Ala Pro Lys Asp Gln Tyr Ala Glu Ala Gly Leu Thr  
 Ala Gly His Ile Ala Ala Thr Ala Leu Asn Val Leu Gly Lys Thr Arg  
 Glu Ala Leu Gln Val Met Thr

## 68\_mml7\_D10rev

Phe Ala Met Asp Arg Ala Gly Leu Val Gly Ala Asp Gly Pro Thr His  
 Cys Gly Ala Phe Asp Val Thr Tyr Met Ala Cys Leu Pro Asn Met Val  
 Val Met Ala Pro Ala Asp Glu Ala Glu Leu Phe His Met Val Ala Thr  
 Ala Ala Ala Ile Asp Asp Arg Pro Ser Cys Phe Arg Tyr Pro Arg Gly  
 Asn Gly Ile Gly Val Gln Leu Pro Ala Lys Asn Lys Gly Ile Pro Ile  
 Glu Val Gly Arg Gly Arg Ile Leu Leu Glu Gly Thr Glu Val Ala Leu  
 Leu Gly Tyr Gly Thr Met Val Gln Asn Cys Leu Ala Ala His Val Leu  
 Leu Ala Asp Leu Gly Val Ser Ala Thr Val Ala Asp Ala Arg Phe Cys  
 Lys Pro Leu Asp Arg Asp Leu Ile Arg Gln Leu Ala Lys Asn His Gln  
 Val Leu Ile Thr Val Glu Glu Gly Ser Ile Gly Gly Phe Gly Ser His  
 Val Val Gln Phe Met Ala Leu Asp Gly Leu Leu Asp Gly

## 93\_ck10\_h05fwdrev

Ser Leu Gln Ser Tyr Ser Leu Glu Lys Tyr Leu Pro Leu Leu Ala Cys  
 Arg Leu Ile Gly Leu Val Glu Arg Trp Asn Arg His Ala Gly Glu Pro  
 Gln Val Ala Tyr Thr Phe Asp Ala Gly Pro Asn Ala Val Met Phe Ala  
 Lys Asn Lys Glu Val Ala Ala Gln Leu Leu Gln Arg Leu Leu Tyr Gln  
 Phe Pro Pro Ser Ala Asp Thr Asp Ile Ser Arg Tyr Val His Gly Asp  
 Gln Ser Ile Leu Glu Ser Ala Gly Val Asn Ser Leu Lys Asp Ile Asp  
 Ser Leu Ser Ala Pro Ala Glu Val Ala Gly Ile Pro Asn Leu Gln Arg  
 Ile Pro Gly Glu Val Asp Tyr Leu Ile Cys Thr Asn Val Gly Lys Gly  
 Ala Tyr Val Leu Gly Glu Gln Gly Ala Asn Leu Ile Asp Pro Val Ser  
 Gly Leu Leu Lys Lys

## 66\_bd09\_c12rev

Asn Val Leu Asp Tyr Leu Gln Thr Asp Phe Pro Asp Met Asp Val Met  
 Gly Ile Ser Gly Asn Tyr Cys Ser Asp Lys Lys Pro Ala Ala Val Asn  
 Trp Ile Glu Gly Arg Gly Lys Ser Val Val Cys Glu Ala Val Ile Lys  
 Glu Glu Val Val Ser Lys Val Leu Lys Thr Asn Val Ala Ser Leu Val  
 Glu Leu Asn Met Leu Lys Asn Leu Thr Gly Ser Ala Met Ala Gly Ala  
 Leu Gly Gly Phe Asn Ala His Ala Ser Asn Ile Val Ser Ala Ile Tyr  
 Ile Ala Thr Gly Gln Asp Pro Ala Gln Asn Val Glu Ser Ser His Cys  
 Ile Thr Met Met Glu Ala Ile Asn Asn Gly Lys Asp Leu His Ile Ser  
 Val Thr Met Pro Ser Ile Xaa Val

## 26\_ppprot140\_E07rev

Gly Asn Gly Ile Tyr Thr Pro Met Asp Pro Lys Leu Leu Pro Gln Leu  
 Tyr Leu Ile Tyr Thr Lys Asn Pro Ser Asp Ser Gly Lys Val His Ser  
 Thr Val Arg Lys Arg Trp Leu Asp Gly Asp Glu Leu Val Arg Asn Cys  
 Met Lys Glu Val Ala Ser Leu Ala Val Lys Gly Arg Asp Ala Leu Leu

18/25

Arg Gln Asp Phe Ser Thr Ile Ala Lys Leu Met Asp Thr Asn Phe Asp  
 Leu Arg Arg Thr Met Phe Gly Asp Ala Thr Leu Gly Lys Met Asn Ile  
 Lys Met Val Glu Thr Ala Arg Gly Val Gly Ala Ala Cys Lys Phe Thr  
 Gly Ser Gly Gly Ala Val Ile Ala Phe Cys Pro Asp Gly Glu Lys Gln  
 Val Lys Ala Leu Gln Glu Ala Cys Ala Lys Ala Gly Tyr Thr Val Glu  
 Gly Val Ile Pro Ala Pro Ala Asn Val

## 45\_ck24\_h02fwd

Met Asp Asp Ile Met Asp Asn Ser Val Thr Arg Arg Gly Gln Pro Cys  
 Trp Tyr Arg Val Pro Lys Val Gly Leu Ile Ala Ile Asn Asp Gly Ile  
 Ile Leu Arg Thr His Ile Ser Arg Val Leu Lys Arg His Phe Arg Gln  
 Ser Pro Ile Tyr Val Glu Leu Val Asp Leu Phe Asn Asp Val Glu Tyr  
 Gln Thr Ala Ser Gly Gln Met Leu Asp Leu Ile Thr Thr Pro Ala Gly  
 Glu Val Asp Leu Ser Lys Tyr Val Leu Pro Thr Tyr Leu Arg Ile Val  
 Lys Tyr Lys Thr Ala Tyr Tyr Ser Phe Tyr Leu Pro Val Ala Cys Ala  
 Leu Leu Leu Ala Gly Glu Thr Ser Val Ala Lys Phe Glu Ala Ala Lys  
 Glu Val Leu Val Gln Met Gly Thr Tyr Phe Gln Val Gln Asp Asp Tyr  
 Leu Asp Cys Tyr Gly Ala Pro Glu

## 95\_bd02\_h06rev

Gly Ile Gln Leu Ser Leu Tyr Arg Ser Asn Leu Ser Arg Pro Ser Val  
 Ser Pro Ala Pro Ser Ala Tyr Arg Arg Phe Thr Ile Ile Ser Gly Met  
 Ala Gln Asn Gln Ser Tyr Trp Asp Ser Ile His Ser Asp Ile Asp Ser  
 His Leu Lys Lys Ala Ile Pro Ile Arg Glu Pro Val Ser Val Phe Glu  
 Pro Met His His Leu Thr Phe Ala Pro Pro Lys Ser Thr Ala Ser Ala  
 Leu Cys Ile Ala Ala Cys Glu Leu Val Gly Gly His Arg Glu Asp Ala  
 Val Val Ala Ala Ser Ala Ile His Leu Met His Ala Ser Ile Tyr Thr  
 His Glu His Leu Leu Leu Arg Glu Arg Ala Met Pro Glu Ser Arg Ile  
 Pro His Lys Phe Gly Pro Asn Ile Glu Leu Leu Thr Gly Asp Gly Phe  
 Leu Pro Phe Gly Phe Glu Leu Leu Ala Gly Ser Ala Asn Gln Leu Val  
 Thr Thr Leu Ile Asn Thr Lys Gly Asp His Arg Asp His Pro Ser Arg  
 Xaa Cys

## 14\_ppprot1\_53\_c07

Pro Lys Cys Asp His Val Ala Val Gly Thr Gly Thr Val Ile Asn Lys  
 Pro Ala Ile Lys Lys Tyr Gln Thr Ala Thr Arg Asn Arg Ala Lys Asp  
 Lys Ile Ala Gly Gly Lys Ile Ile Arg Val Glu Ala His Pro Ile Pro  
 Glu His Pro Arg Pro Arg Arg Ala Ser Asp Arg Val Ala Leu Val Gly  
 Asp Ala Ala Gly Tyr Val Thr Lys Cys Ser Gly Glu Gly Ile Tyr Phe  
 Ala Ala Lys Ser Gly Arg Met Cys Ala Glu Ala Ile Val Glu Gly Ser  
 Ala Asn Gly Thr Arg Met Ile Asp Glu Ser Asp Leu Arg Thr Tyr Leu  
 Asp Lys Trp Asp Lys Lys Tyr Trp Ala Thr Tyr Lys Val Leu Asp Ile  
 Leu Gln Lys Val Phe Tyr Arg Ser Asn Pro Ala Arg Glu Ala Phe Val  
 Glu Met Cys Ala Asp Asp Tyr Val Gln Lys Met Thr Phe Asp Ser Tyr  
 Leu Tyr Lys Val Val Val Pro Gly Asn Pro Leu Asp Asp Leu Lys Leu  
 Ala Val Asn Thr Ile Gly Ser Leu Ile Arg Ala Asn Ala Leu Arg Lys  
 Glu Ser Glu

## 34\_ppprot1\_092\_f08rev

Met Gly Gln Glu Val Leu Ala Thr Tyr Lys Val Leu Asp Ile Leu Gln  
 Lys Val Phe Tyr Arg Ser Asn Pro Ala Arg Glu Ala Phe Val Glu Met  
 Cys Ala Asp Asp Tyr Val Gln Lys Met Thr Phe Asp Ser Tyr Leu Tyr  
 Lys Val Val Val Pro Gly Asn Pro Leu Asp Asp Leu Lys Leu Ala Val  
 Asn Thr Ile Gly Ser Leu Ile Arg Ala Asn Ala Leu Arg Lys Glu Ser  
 Glu Lys Met Thr Val

19/25

## 83\_ppprot1\_056\_f06

Asp Ile Ala Arg His Ser Ala Val Met Ala Ser Leu Gln Ala Val Ile  
Thr Ala Ser Pro Ala Ser Phe Ala Ala Ser Ser Arg Ala Val Ser Ser  
His Ser Glu Thr Ala Ala Val Leu Val Pro Cys Ala Ser Ile Ser Ser  
Arg Gly Val Ser Thr Ser Cys Leu Gly Phe Val Ala Ser Ser Gly Arg  
Asn Ala Ser Leu Lys Ser Phe Glu Gly Leu Arg Gly Leu Asn Ala Ser  
Gly Pro Thr Ser Ala Val Glu Ser Leu Lys Ala Glu Arg Arg Ser Asn  
Val Val Glu Glu Ala Gly Tyr Gln Pro Leu Arg Val Tyr Ala Ala Arg  
Gly Ser Lys Lys Ile Glu Gly Arg Lys Leu Arg Val Ala Val Val Gly  
Gly Gly Pro Ala Gly Gly Cys Ala Ala Glu Thr Leu Ala Lys Gly Gly  
Ile Glu Thr Phe Leu Ile Glu Arg Lys Leu Asp Asn Ala Lys Pro Cys  
Gly Gly Ala Ile Pro Leu Cys Met Val Gly Glu Phe Asp Leu Pro Pro  
Glu Ile Ile Asp Arg Lys Val Thr Lys Met Lys Met Ile Ser Pro Xaa  
Asn Val

## 23\_ppprot1\_071\_d03rev

Gly Tyr Cys Glu Gly Ser Ala Asn Gly Thr Arg Met Ile Asp Glu Ser  
Asp Leu Arg Thr Tyr Leu Asp Lys Trp Asp Lys Tyr Trp Ala Thr  
Tyr Lys Val Leu Asp Ile Leu Gln Lys Val Phe Tyr Arg Ser Asn Pro  
Ala Arg Glu Ala Phe Val Glu Met Cys Ala Asp Asp Tyr Val Gln Lys  
Met Thr Phe Asp Ser Tyr Leu Tyr Lys Val Val Val Pro Gly Asn Pro  
Leu Asp Asp Leu Lys Leu Ala Val Asn Thr Ile Gly Ser Leu Ile Arg  
Ala Asn Ala Leu Arg Lys Glu Ser Glu Lys Met Thr Val

## 70\_mbl\_D11rev

Ala His Pro Ile Pro Glu His Pro Arg Pro Arg Arg Ala Ser Asn Arg  
Val Ala Leu Ile Gly Asp Ala Ala Gly Tyr Val Thr Lys Cys Ser Gly  
Glu Gly Ile Tyr Phe Ala Ala Lys Ser Gly Arg Met Cys Ala Glu Ala  
Ile Val Glu Gly Ser Ala Asn Gly Thr Arg Met Val Asp Glu Ser Asp  
Leu Arg Thr Tyr Ser Leu Glu Lys Trp Asp Lys Lys Tyr Trp Ala Thr Tyr  
Lys Val Leu Asp Ile Leu Gln Lys Val Phe Tyr Arg Ser Asn Pro Ala  
Arg Glu Ala Phe Val Glu Met Cys Ala Asp Asp Tyr Val Gln Lys Met  
Thr Phe Asp Ser Tyr Leu Tyr Lys Val Val Val Pro Gly Asn Pro Leu  
Asp Asp Ile Lys Leu Ala Ile Asn Thr Ile Gly Ser Leu Ile Arg Ala  
Asn Ala Leu Arg Lys Glu Ser Glu Lys Met Thr Val

## 84\_ppprot1\_36\_F12rev

Val Thr Lys Cys Ser Gly Glu Gly Ile Tyr Phe Ala Ala Lys Ser Gly  
Arg Met Cys Ala Glu Ala Ile Val Glu Gly Ser Ala Asn Gly Thr Arg  
Met Ile Asp Glu Ser Asp Leu Arg Thr Tyr Leu Asp Lys Trp Asp Lys  
Lys Tyr Trp Ala Thr Tyr Lys Val Leu Asp Ile Leu Gln Lys Val Phe  
Tyr Arg Ser Asn Pro Ala Arg Glu Ala Phe Val Glu Met Cys Ala Asp  
Asp Tyr Val Gln Lys Met Thr Phe Asp Ser Tyr Leu Tyr Lys Val Val  
Val Pro Gly Asn Pro Leu Asp Asp Leu Lys Leu Ala Val Asn Thr Ile  
Gly Ser Leu Ile Arg Ala Asn Ala Leu Arg Lys Glu Ser Glu Lys Met  
Thr Val

## 27\_mm6\_55\_E02rev

Pro Ala Val Leu Glu Val Asp Ala Val Ile Gly Ala Asp Gly Ala Asn  
Ser Arg Val Ala Lys Asp Ile Asp Ala Gly Glu Tyr Asp Tyr Ala Ile  
Ala Phe Gln Glu Arg Ile Lys Ile Pro Glu Asp Lys Met Glu Tyr Tyr  
Glu Asn Leu Ala Glu Met Tyr Val Gly Asp Asp Val Ser Pro Asp Phe  
Tyr Gly Trp Val Phe Pro Lys Cys Asp His Val Ala Val Gly Thr Gly

Thr Val Ile Asn Lys Pro Ala Ile Lys Lys Tyr Gln Thr Ala Thr Arg  
Asn Arg Ala Lys Asp Lys Ile Ala Gly Gly Lys Ile Ile Arg Val Glu  
Ala His Pro Ile Pro Glu His Pro Arg Pro Arg Arg Ala Ser Asp Arg  
Val Ala Leu Val Gly Asp Ala Ala Gly Tyr Val Thr Lys Cys Ser Gly  
Glu Gly Ile Tyr Phe Ala Ala Lys Ser Gly Arg Met Cys Ala Glu Ala  
Ile Val Glu Ala Pro Pro Thr Glu Leu Val

## 54\_ppprot1\_081\_a12rev

Ile Val Glu Gly Ser Ala Asn Gly Thr Arg Met Ile Asp Glu Ser Asp  
Leu Arg Thr Tyr Leu Asp Lys Trp Asp Lys Lys Tyr Trp Ala Thr Tyr  
Lys Val Leu Asp Ile Leu Gln Lys Val Phe Tyr Arg Ser Asn Pro Ala  
Arg Glu Ala Phe Val Glu Met Cys Ala Asp Asp Tyr Val Gln Lys Met  
Thr Phe Asp Ser Tyr Leu Tyr Lys Val Val Val Pro Gly Asn Pro Leu  
Asp Asp Leu Lys Leu Ala Val Asn Thr Ile Gly Ser Leu Ile Arg Ala  
Asn Ala Leu Arg Lys Glu Ser Glu Lys Met Thr Val

## 47\_ppprot1\_100\_h03

Gly Ala Lys Val Ala Ser Gly Ser Cys Arg Arg Trp Pro Ala Gly Gly  
Cys Ala Ala Glu Thr Leu Ala Lys Gly Gly Ile Glu Thr Phe Leu Ile  
Glu Arg Lys Leu Asp Asn Ala Lys Pro Cys Gly Gly Ala Ile Pro Leu  
Cys Met Val Gly Glu Phe Asp Leu Pro Pro Lys Leu Ser Thr Ala Lys

## 25\_mm18\_e01rev

Pro Pro Ala Met Val Thr Ser Val Pro Thr Ser Gly Thr Ile Tyr Ile  
Glu Asn Leu Ala Glu Met Tyr Val Gly Asp Asp Val Ser Pro Asp Phe  
Tyr Gly Trp Val Phe Pro Lys Cys Asp His Val Ala Val Gly Thr Gly  
Thr Val Ile Asn Lys Pro Ala Ile Lys Lys Tyr Gln Thr Ala Thr Arg  
Asn Arg Ala Lys Asp Lys Ile Ala Gly Gly Lys Ile Ile Arg Val Glu  
Ala His Pro Ile Pro Glu His Pro Arg Pro Arg Arg Ala Ser Asp Arg  
Val Ala Leu Val Gly Asp Ala Ala Gly Tyr Val Thr Lys Cys Ser Gly  
Glu Gly Ile Tyr Phe Ala Ala Lys Ser Gly Arg Met Cys Ala Glu Leu  
Leu Trp Lys Ala Pro Pro Thr Glu Leu Val

## 80\_bd09\_f10rev

Ser Ser Gln Phe His Ser Leu Asn Asn Thr Asp Ser Val Pro Asn Asn  
Ser His Leu Ala Xaa Thr Tyr Cys Ala Leu Ala Ile Leu Lys Thr Val  
Gly Tyr Asp Xaa Ser Leu Ile Asp Ser Arg Ser Ile Tyr Lys Ser Met  
Lys His Leu Gln Gln Pro Asp Gly Ser Phe Met Pro Ile His Thr Gly  
Ala Glu Thr Asp Leu Xaa Xaa Val Tyr Cys Ala Ala Val Xaa Ser Pro  
Leu Leu Asp Asn Trp Ser Gly Met Asp Xaa Asp

## 78\_ppprot1\_087\_e12rev

Ser Asp Tyr Val Ser Ile Ala Lys Asp Leu Gly Leu Gln Asp Ile Lys  
Ser Glu Asp Trp Ser Glu Tyr Val Thr Pro Phe Trp Pro Ala Val Met  
Lys Thr Ala Leu Ser Met Glu Gly Leu Val Gly Leu Val Lys Ser Gly  
Trp Thr Thr Met Lys Gly Ala Phe Ala Met Thr Leu Met Ile Gln Gly  
Tyr Gln Arg Gly Leu Ile Lys Phe Ala Ala Ile Thr Cys Arg Lys Arg  
Asp

## 78\_ppprot1\_092\_e12rev

Ser Ile Ala Arg Lys Cys Ala Val Glu Phe Glu Val Gly Asp Cys Thr

Lys Ile Asn Tyr Pro His Ala Ser Phe Asp Val Ile Tyr Ser Arg Asp  
Thr Ile Leu His Ile Gln Asp Lys Pro Ala Leu Phe Gln Arg Phe Tyr  
Lys Trp Leu Lys Pro Gly Gly Arg Val Leu Ile Ser Asp Tyr Cys Arg  
Ala Pro Gln Thr Pro Ser Ala Glu Phe Ala Ala Tyr Ile Gln Gln Arg  
Gly Tyr Asp Leu His Ser Val Gln Lys Tyr Gly Glu Met Leu Glu Asp  
Ala Gly Phe Val Glu Val Val Ala Glu Asp Arg Thr Asp Gln Phe Ile  
Glu Val Leu Gln Arg Glu Leu Ala Thr Thr Glu Ala Gly Arg Asp Gln  
Phe Ile Asn Asp Phe Ser Glu Glu Asp Tyr Asn Tyr Ile Val Ser Gly  
Trp Lys Ser Lys Leu Lys Arg Cys Ser Asn Asp Glu Gln Lys Trp Gly  
Leu Phe Ile Ala Tyr Lys Ala Leu

## 05\_ck\_19\_a03

Cys Ala Ser Thr Thr Val Pro Thr Arg Ile Tyr Asp Gly Val Ala Glu  
Asp Gln Glu Asp Tyr Ile Lys Ala Gly Gly Glu Glu Leu Asp Leu Val  
Gln Leu Gln Ala Ser Lys Ser Phe Asp Gln Ser Lys Ile Gly Glu Lys  
Leu Gln Leu Leu Gly Asp Glu Thr Leu Asp Leu Val Val Val Gly Cys  
Gly Pro Ala Gly Met Cys Leu Ala Ala Glu Ala Ala Lys Gln Gly Leu  
Asn Val Gly Leu Val Gly Pro Asp Leu Pro Phe Val Asn Asn Tyr Gly  
Val Trp Thr Asp Glu Phe Ala Ala Leu Gly Leu Glu Asp Cys Ile Glu  
Gln Thr Trp Lys Asp Ser Ala Met Tyr Ile Glu Glu Asp Ser Pro Ile  
Met Ile Gly Arg Ala Tyr Gly Arg Val Ser Arg Thr Leu Leu Arg Glu  
Glu Leu Leu Arg Arg Cys Ala Glu Gly Gly Val Arg Tyr Val Asp Ser  
Lys Val Asp Arg Ile Leu Glu Val Asp Glu Asp Leu Ser Thr Val Leu  
Cys Thr Asn Gly Lys Asn Ile Lys Ser Arg Leu

## 02\_ppprot1\_046\_a07rev

Thr Ile Leu Arg Asp Val Glu Glu Asp Ala Arg Arg Gly Arg Val Tyr  
Leu Pro Gln Asp Glu Leu Ala Arg Phe Gly Leu Ser Asp Ala Asp Ile  
Phe Val Gly Lys Val Thr Asp Lys Trp Arg Ala Phe Met Lys Asp Gln  
Ile Lys Arg Ala Arg Val Phe Phe Val Glu Ala Glu Lys Gly Val Arg  
Glu Leu Asp Lys Asp Ser Arg Trp Pro Val Trp Ser Ala Leu Ile Leu  
Tyr Gln Gln Ile Leu Asp Ala Ile Glu Ala Asn Asp Tyr Asp Asn Phe  
Thr Lys Arg Ala Tyr Val Gly Lys Trp Lys Lys Leu Ala Ser Leu Pro  
Ile Ala Tyr Gly Arg Ala Leu Val Pro Pro Pro Asp Ala Leu Pro Arg  
Leu Ala Arg

## 96\_ck5\_h12fwdrev

Tyr Lys Thr Val Pro Asp Cys Glu Pro Cys Arg Pro Leu Gln Arg Ser  
Pro Ile Pro Lys Phe Tyr Met Ala Gly Asp Phe Thr Lys Gln Lys Tyr  
Leu Ala Ser Met Glu Gly Ala Val Leu Ser Gly Lys Phe Cys Ala Gln  
Ser Ile Val Gln Asp Phe Lys Ala Gly Lys Leu Lys Ala Gly Gly Glu  
Lys Glu Ala Val Leu Val Ser Gln

## 42\_ck10\_g09fwd

Lys Asp Ala Ser Ser Arg Arg Thr Gly Ser Val Arg Val Thr Ala Ser  
Leu Gln Ser Met Val Ser Asp Met Ser Arg Lys Ala Pro Lys Gly Leu  
Phe Pro Pro Glu Pro Glu Ala Tyr Lys Gly Pro Lys Leu Lys Val Ala  
Ile Ile Gly Ala Gly Leu Ala Gly Met Ser Thr Ala Val Glu Leu Leu  
Glu Gln Gly His Glu Val Asp Ile Tyr Glu Ser Arg Lys

## 84\_mm11\_f12rev

Ile Thr Gly Glu Trp Tyr Cys Lys Phe Asp Thr Phe Ser Pro Ala Ala  
Glu Arg Gly Leu Pro Val Thr Arg Val Ile Ser Arg Met Lys Leu Gln  
Glu Ile Leu Ser Gly Ala Leu Gly Ser Glu Tyr Ile Gln Asn Gly Ser

22/25

Asn Val Val Asp Phe Val Asp Asp Gly Asn Lys Val Glu Val Val Leu  
 Glu Asp Gly Arg Thr Phe Glu Gly Asp Ile Leu Val Gly Ala Asp Gly  
 Ile Arg Ser Lys Val Arg Thr Lys Leu Leu Gly Glu Ser Ser Thr Val  
 Tyr Ser Asp Tyr Thr Cys Tyr Thr Gly Ile Ala Asp Phe Val Pro Ala  
 Asp Ile Asp Thr Val Gly Tyr Arg Val Phe Leu Gly His Lys Gln Tyr  
 Phe Val Ser Ser Asp Val Gly Gln Gly Lys Met Gln Trp Tyr Ala Phe  
 Tyr Asn Glu Pro Ala Gly Gly Val Asp Ala Pro Ala Glu Gly Lys Gln  
 Gly

## 41\_ppprot1\_085\_g03rev

Cys Glu Ile Glu Leu Gly Glu Phe Arg Ala Val Thr Glu Pro Glu Val  
 Ala Pro Gln His Ala Lys Leu Val Phe Lys Asp Gly Ala Leu Phe Val  
 Thr Asp Leu Asp Ser Lys Thr Gly Thr Trp Ile Thr Ser Ile Ser Gly  
 Gly Arg Cys Lys Leu Thr Pro Lys Met Pro Thr Arg Val His Pro Glu  
 Asp Ile Ile Glu Phe Gly Pro Ala Lys Glu Ala Gln Tyr Lys Val Lys  
 Leu Arg Arg Ser Gln Pro Ala Arg Ser Asn Ser Tyr Lys Thr Asp Leu  
 Asn Ala Leu Lys Val Ala

## 06\_ppprot1\_062\_a09rev

Val Glu Gly Ala Ala Thr Glu Glu Arg Phe Phe Leu Phe Leu Glu Glu  
 Phe Gln Arg His Ser Arg Asn Tyr Val Lys Arg Gln Leu Thr Trp Phe  
 Arg Asn Lys Gly Gln Ser Glu Gln Met Phe Asn Trp Ile Asp Ala Thr  
 Gln Pro Leu Glu Val Met Val Asp Ala Leu Ala Lys Glu Tyr Glu Arg  
 Pro Asn Glu Val Val Ser Asp Val Leu Lys Ala Ala Ser Val Val Thr  
 Lys Glu Ser Ser Tyr Lys Glu Glu Asn Leu Leu Lys Arg Tyr Arg Thr  
 Gln Asn Arg Ile Phe Thr Ser Asn Ser Glu Ala Leu Lys Arg Thr Leu  
 Gln Trp Ile Arg Asp Thr Gln Cys Leu Trp Arg Asn Ser Ser Thr Val  
 Asp Asp Leu Gln Lys Arg Met Glu Ser Ser Leu Thr Thr Ser Met

## 16\_ppprot1\_082\_c08

Gln Ile Val Met Met His Asp Phe Ala Ile Thr Glu Asn Tyr Ala Ile  
 Phe Met Asp Leu Pro Leu Leu Met Asp Gly Glu Ser Met Met Lys Gly  
 Asn Phe Phe Ile Lys Phe Asp Glu Thr Lys Glu Ala Arg Leu Gly Val  
 Leu Pro Arg Tyr Ala Thr Asn Glu Ser Gln Leu Arg Trp Phe Thr Ile  
 Pro Val Cys Phe Ile Phe His Asn Ala Asn Ala Trp Glu Glu Gly Asp  
 Glu Ile Val Leu His Ser Cys Arg Met Glu Glu Ile Asn Leu Thr Thr  
 Ala Ala Asp Gly Phe Lys Glu Asn Glu Arg Ile Ser Gln Pro Lys Leu  
 Phe Glu Phe Arg Ile Asn Leu Lys Thr Gly Glu Val Arg Gln Lys Gln  
 Leu Ser Val Leu Val Val Asp Phe Pro Arg Val Asn Glu Glu Tyr Met  
 Gly Arg Lys Thr Gln Tyr Met Tyr Gly Ala Ile Met Asp Lys Glu Ser  
 Lys Met Val Gly Val Gly Lys Phe Asp Leu Leu Lys Glu Pro Glu Val  
 Asn

## 30\_ppprot1\_064\_e09

His Cys Val Val Leu Ser Phe Ser Pro Arg Phe Trp Gln Ile Cys Val  
 Leu Ile Val Phe Ser Lys Thr Thr Asn Met Ala Ala Ala Ile Ser Ser  
 Val Ser Cys Ile Ser Ala Ala Lys Leu Phe Ser Val Ala Ala Ala Pro  
 His Ala Thr Arg Arg Thr Ser Val Leu His Ile Ser Ala Val Ala Asp  
 Lys Val Ser Pro Asp Pro Ala Val Val Pro Pro Asn Val Leu Glu Tyr  
 Ala Lys Thr Met Pro Gly Val Thr Ala Pro Phe Glu Asn Ile Phe Asp  
 Pro Ala Asp Leu Leu Ala Arg Ala Ser Ser Pro Arg Pro Ile Lys  
 Glu Leu Asn Arg Trp Arg Glu Ser Glu Ile Thr His Gly Arg Val Ala  
 Met Leu Ala Ser Leu Gly Phe Ile Val Gln Glu Gln Leu Gln Asp Tyr  
 Ser Leu Phe Tyr Asn Phe Asp Gly Gln Ile Ser Gly Pro Ala Ile Tyr  
 His Phe Gln Gln Val Glu Ala Arg Gly Ala Val Phe Trp Glu Pro Leu



Ile Phe Ala Ile Ala Leu Cys Glu Ala Tyr Arg Val Gly Leu Gly Trp  
 Ala Thr Pro Arg Ser Gln Asp Phe Asn Thr Leu Arg Asp Asp Tyr Glu  
 Pro Gly Asn Leu Gly Phe Asp Pro Trp Ala Ser Ser Gln Leu Ile Pro  
 Leu Lys Gly Arg Leu Cys Arg

## 55\_ppprot1\_093\_b04rev

Gly Asp Ala Phe Asn Met Arg His Pro Xaa Thr Gly Gly Gly Met Thr  
 Val Ala Leu Ser Asp Ile Val Leu Arg Asp Met Leu Arg Pro Leu  
 Ser Ser Phe His Asp Ala Gln Ser Leu Cys Asp Tyr Leu Gln Ala Phe  
 Tyr Thr Arg Arg Lys Pro Val Ala Ala Thr Ile Asn Thr Leu Ala Gly  
 Ala Leu Tyr Lys Val Phe Cys Asp Ser Pro Asp Leu Ala Met Lys Glu  
 Met Arg Gln Ala Cys Phe Asp Tyr Leu Ser Ile Gly Gly Val Phe Ser  
 Ser Gly Pro Val Ala Leu Leu Ser Gly Leu Asn Pro Arg Pro Leu Ser  
 Leu Val Val His Phe Phe Ala Val Ala Val Tyr Gly Val Gly Arg Leu  
 Leu Val Pro Phe Pro Ser Pro Ser Arg Val Trp Ile Gly Ala Arg Leu  
 Leu Arg Gly Ala Ala Asn Ile Ile Phe Pro Ile Ile Lys Ala Glu Gly  
 Val Arg Gln Met Phe Phe Pro Asn Met Val Pro Ala Tyr Tyr Lys Ala  
 Pro Pro Ala Glu Glu

## 02\_mm14\_a07rev

Gln Asn Pro Asp Gly Gly Trp Gly Glu Ser Cys Ala Ser Tyr Val Asp  
 Leu Gln Gln Arg Gly Val Gly Pro Ser Thr Ala Ser Gln Thr Ala Trp  
 Ala Leu Met Ala Leu Val Ser Val Arg His Ser Ser Glu Tyr Tyr Asp  
 Ala Ile Arg Asn Gly Val Glu Tyr Leu Val Arg Thr Arg Thr Ala Ala  
 Gly Ser Trp Ser Asp Gly Gly Leu Phe Thr Gly Thr Gly Phe Pro Gly  
 Asn Val Val Gly Thr Arg Ile Asp Leu Gly Thr Asp Ser Ser Lys Pro  
 Gly His Gly Asn Glu Leu Ser Arg Gly Tyr Met Leu Arg Tyr His Met  
 Tyr Pro His Tyr Phe Pro Leu Met Ala Leu Gly Arg Ala Arg Lys Tyr  
 Phe Gln His Val Lys Ser Leu Pro Arg Ser Leu

## 51\_ppprot1\_081\_a05rev

Phe Pro Asp Ala His Val Thr Gly Leu Asp Leu Ser Pro Tyr Phe Leu  
 Ala Val Ala Gln Tyr Met Glu Lys Gln Arg Ile Ser Ser Gly Leu Gly  
 Arg Arg Arg Pro Ile Ser Trp Val His Ala Asn Gly Glu Cys Thr Gly  
 Leu Pro Ser Ser Ser Phe Asp Val Val Ser Leu Ala Phe Val Ile His  
 Glu Cys Pro Gln His Ala Ile Arg Gly Leu Leu Lys Glu Ala Leu Arg  
 Leu Leu Lys Pro Gly Gly Thr Val Ser Leu Thr Asp Asn Ser Pro Lys  
 Ser Lys Val Leu Gln Asn Leu Pro Pro Ala Ile Phe Thr Leu Met Lys  
 Ser Thr Glu Pro Trp Met Asp Glu Tyr Phe Thr Phe Asp Leu Glu Gly  
 Glu Met Glu Lys Ile Gly Phe Met Asn Val Asn Ser Ile Met Thr Asn  
 Pro Arg His Arg Thr Val Thr Gly Thr Ala Pro

## 93\_ck24\_h05fwd

Asp Tyr Leu Asn Gln Leu Leu Ile Lys Phe Asp His Ala Cys Pro Asn  
 Val Tyr Pro Val Asp Leu Phe Glu Arg Leu Trp Met Val Asp Arg Leu  
 Gln Arg Leu Gly Ile Ser Arg Tyr Phe Glu Arg Glu Ile Arg Asp Cys  
 Leu Gln Tyr Val Tyr Arg Tyr Trp Lys Asp Cys Gly Ile Gly Trp Ala  
 Ser Asn Ser Ser Val Gln Asp Val Asp Asp Thr Ala Met Ala Phe Arg  
 Leu Leu Arg Thr His Gly Phe Asp Val Lys Glu Asp Cys Phe Arg Gln  
 Phe Phe Lys Asp Gly Glu Phe Phe Cys Phe Ala Gly Gln Ser Ser Gln  
 Ala Val Thr Gly Met Phe Asn Leu Ser Arg Ala Ser Gln Thr Leu Phe  
 Pro Gly Glu Ser Leu Leu Lys Lys Ala Xaa Thr Phe Ser Arg Asn Phe  
 Leu Arg Thr Lys His Glu Asn Asn Glu Cys Phe Asp Lys Trp

## 51\_ppprot1\_0052\_a05

Lys Arg Glu Glu Asn Glu Lys Ser Arg Ile Pro Met Ala Met Val Tyr  
Lys Tyr Pro Thr Thr Leu Leu His Ser Leu Glu Gly Leu His Arg Glu  
Val Asp Trp Asn Lys Leu Leu Gln Leu Gln Ser Glu Asn Gly Ser Phe  
Leu Tyr Ser Pro Ala Ser Thr Ala Cys Ala Leu Val His Lys Arg Cys  
Glu Val Leu Arg Leu Leu Glu Pro Ala Pro His Gln Val Arg Pro Arg  
Leu Ser Lys Arg Val Pro Arg

## Longest clones

## 78\_pppr0t1\_087\_e12-259rev

Met Ala Val Ala Leu Gly Ala Ala Gly Ser Phe Ala Gly Ala Ala Ala  
Ala Arg Ala Trp Thr Cys Ser Ser Ile Ser Ser Cys Asn Glu Ile  
Arg Thr Arg Ser Thr Ser Val Thr Ser Ala Gln Val Cys Gly Leu Ile  
Arg Ala Asp Asp Glu Val Gly Arg Arg Gly Val Lys Thr Arg Ser Leu  
Arg Ser Gly Gly Val Val Arg Arg Ala Val Gln Arg Thr Glu Pro Glu  
Leu Tyr Asp Gly Ile Ala His Phe Tyr Asp Glu Ser Ser Gly Val Trp  
Glu Gly Ile Trp Gly Glu His Met His His Gly Tyr Tyr Asp Glu Glu  
Ile Val Glu Ala Val Val Asp Gly Asp Pro Asp His Arg Arg Ala Gln  
Ile Lys Met Ile Glu Lys Ser Leu Ala Tyr Ala Gly Val Pro Asp Ser  
Lys Asp Leu Lys Pro Lys Thr Ile Val Asp Val Gly Cys Gly Ile Gly  
Gly Ser Ser Arg Tyr Leu Ala Arg Lys Phe Gln Ala Lys Val Asn Ala  
Ile Thr Leu Ser Pro Val Gln Val Gln Arg Ala Val Asp Leu Thr Ala  
Lys Gln Gly Leu Ser Asp Leu Val Asn Phe Gln Val Ala Asn Ala Leu  
Asn Gln Pro Phe Gln Asp Gly Ser Phe Asp Leu Val Trp Ser Met Glu  
Ser Gly Glu His Met Pro Asp Lys Lys Lys Phe Val Gly Glu Leu Ala  
Arg Val Ala Ala Pro Gly Gly Arg Ile Ile Leu Val Thr Trp Cys His  
Arg Asp Leu Lys Pro Gly Glu Thr Ser Leu Lys Pro Asp Glu Gln Asp  
Leu Leu Asp Lys Ile Cys Asp Ala Phe Tyr Leu Pro Ala Trp Cys Ser  
Pro Ser Asp Tyr Val Ser Ile Ala Lys Asp Leu Gly Leu Gln Asp Ile  
Lys Ser Glu Gly Trp Ser Glu Tyr Val Thr Pro Phe Trp Pro Ala Val  
Met Lys Thr Ala Leu Ser Met Glu Gly Leu Val Gly Leu Val Lys Ser  
Gly Trp Thr Thr Met Lys Gly Ala Phe Ala Met Thr Leu Met Ile Gln  
Gly Tyr Gln Arg Gly Leu Ile Lys Phe Ala Ala Ile Thr Cys Arg Lys  
Arg Asp

## 78\_ppprot1\_092\_e12-260rev

Met Ala Val Asn Thr Glu Arg Ser Leu Gln Ser Thr Tyr Trp Lys Glu  
His Ser Val Glu Pro Ser Val Glu Ala Met Met Leu Asp Ser Gln Ala  
Ser Lys Leu Asp Lys Glu Glu Arg Pro Glu Ile Leu Ser Leu Leu Pro  
Pro Tyr Glu Asn Lys Asp Val Met Glu Leu Gly Ala Gly Ile Gly Arg  
Phe Thr Gly Glu Leu Ala Lys His Ala Gly His Val Leu Ala Met Asp  
Phe Met Glu Asn Leu Ile Lys Lys Asn Glu Asp Val Asn Gly His Tyr  
Asn Asn Ile Asp Phe Lys Cys Ala Asp Val Thr Ser Pro Asp Leu Asn  
Ile Ala Ala Gly Ser Ala Asp Leu Val Phe Ser Asn Trp Leu Leu Met  
Tyr Leu Ser Asp Glu Glu Val Lys Gly Leu Ala Ser Arg Val Met Glu  
Trp Leu Arg Pro Gly Gly Tyr Ile Phe Phe Arg Glu Ser Cys Phe His  
Gln Ser Gly Asp His Lys Arg Lys Asn Asn Pro Thr His Tyr Arg Gln  
Pro Asn Glu Tyr Thr Asn Ile Phe Gln Gln Ala Tyr Ile Glu Glu Asp  
Gly Ser Tyr Phe Arg Phe Glu Met Val Gly Cys Lys Cys Val Gly Thr  
Tyr Val Arg Asn Lys Arg Asn Gln Asn Gln Val Cys Trp Leu Trp Arg  
Lys Val Gln Ser Asp Gly Pro Glu Ser Glu Cys Phe Gln Lys Phe Leu  
Asp Thr Gln Gln Tyr Thr Ser Thr Gly Ile Leu Arg Tyr Glu Arg Ile  
Phe Gly Glu Gly Phe Val Ser Thr Gly Gly Ile Glu Thr Thr Lys Ala  
Phe Val Ser Met Leu Asp Leu Lys Pro Gly Gln Arg Val Leu Asp Val

Gly Cys Gly Ile Gly Gly Gly Asp Phe Tyr Met Ala Glu Glu Tyr Asp  
Ala Glu Val Val Gly Ile Asp Leu Ser Leu Asn Met Ile Ser Phe Ala  
Leu Glu Arg Ser Ile Gly Arg Lys Cys Ala Val Glu Phe Glu Val Gly  
Asp Cys Thr Lys Ile Asn Tyr Pro His Ala Ser Phe Asp Val Ile Tyr  
Ser Arg Asp Thr Ile Leu His Ile Gln Asp Lys Pro Ala Leu Phe Gln  
Arg Phe Tyr Lys Trp Leu Lys Pro Gly Gly Arg Val Leu Ile Ser Asp  
Tyr Cys Arg Ala Pro Gln Thr Pro Ser Ala Glu Phe Ala Ala Tyr Ile  
Gln Gln Arg Gly Tyr Asp Leu His Ser Val Gln Lys Tyr Gly Glu Met  
Leu Glu Asp Ala Gly Phe Val Glu Val Val Ala Glu Asp Arg Thr Asp  
Gln Phe Ile Glu Val Leu Gln Arg Glu Leu Ala Thr Thr Glu Ala Gly  
Arg Asp Gln Phe Ile Asn Asp Phe Ser Glu Glu Asp Tyr Asn Tyr Ile  
Val Ser Gly Trp Lys Ser Lys Leu Lys Arg Cys Ser Asn Asp Glu Gln  
Lys Trp Gly Leu Phe Ile Ala Tyr Lys Ala Leu

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number  
**WO 01/44276 A3**

(51) International Patent Classification<sup>7</sup>: C07K 14/415,  
C12N 9/88, 15/82, C07K 16/16

(21) International Application Number: PCT/EP00/12698

(22) International Filing Date:  
14 December 2000 (14.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/171,121 16 December 1999 (16.12.1999) US

(71) Applicant (for all designated States except US): BASF  
PLANT SCIENCE GMBH [DE/DE]; 67056 Ludwigshafen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LERCHL, Jens [DE/DE]; Im Steg 36, 68256 Ladenburg (DE). RENZ, Andreas [DE/DE]; Heinrich-von-Kleist-Strasse 6, 67117 Limburgerhof (DE). EHRHARDT, Thomas [DE/DE]; Maulbronner Hof 49, 67346 Speyer (DE). REINDL, Andreas [DE/DE]; Albertine-Scherer-Strasse 21, 67134 Birkenheide (DE). CIRPUS, Petra [DE/DE]; Landteilstrasse 12, 68163 Mannheim (DE). BISCHOFF, Friedrich [DE/DE]; Eichelsheimer Strasse 6, 68163 Mannheim (DE). FRANK, Markus [DE/DE]; Georg-Herwegh-Strasse 14, 67061 Ludwigshafen (DE). FREUND, Annette [DE/DE]; Römerweg 17c, 67117 Limburgerhof (DE). DUWENIG, Elke [DE/DE]; Sternwaldstrasse 7, 79102 Freiburg (DE).

SCHMIDT, Ralf-Michael [DE/DE]; Am Schlossgarten 9 d, 67489 Kirrweiler (DE). RESKI, Ralf [DE/DE]; Am Osterbach 26, 79254 Oberried (DE). BADUR, Ralf [DE/DE]; Von Eckenbrecher-Strasse 2, 38642 Goslar (DE).

(74) Agent: FITZNER, Uwe; Lintorfer Strasse 10, 40878 Ratingen (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
8 November 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MOSS GENES FROM PHYSCOMITRELLA PATENS ENCODING PROTEINS INVOLVED IN THE SYNTHESIS OF TOCOPHEROLS CAROTENOIDS AND AROMATIC AMINO ACIDS

(57) Abstract: Isolated nucleic acid molecules, designated TCMRP nucleic acid molecules, which encode novel TCMRPs from e.g. *Physcomitrella patens* are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TCMRP nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated TCMRPs, mutated TCMRPs, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from transformed cells, organisms or plants based on genetic engineering of TCMRP genes in these organisms.



WO 01/44276 A3

# INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/EP 00/12698

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/415 C12N9/88 C12N15/82 C07K16/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Biosis, SCISEARCH, EPO-Internal, WPI Data, PAJ, EMBL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EBERHARD JENNY ET AL: "Cloning and expression in yeast of a higher plant chorismate mutase: Molecular cloning, sequencing of the cDNA and characterization of the Arabidopsis thaliana enzyme expressed in yeast." FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS, vol. 334, no. 2, 1993, pages 233-236, XP000985166 ISSN: 0014-5793 figures 2,3	9-22, 24-27, 31,33-46
X	-& DATABASE EMBL [Online] AC Z26519, EBERHARD ET AL.: "A. thaliana mRNA for chorismate mutase" XP002163766 abstract	9-22, 24-27, 31,33-46
	---	-/--



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 May 2001

Date of mailing of the international search report

28.05.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Burkhardt, P

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/12698

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EBERHARD JENNY ET AL: "Isolation of a cDNA from tomato coding for an unregulated, cytosolic chorismate mutase." PLANT MOLECULAR BIOLOGY, vol. 31, no. 4, 1996, pages 917-922, XP000985279 ISSN: 0167-4412 figures 1,2	9-22, 24-27, 31,33-46
X	-& DATABASE EMBL [Online] AC L47356, 24 November 1993 (1993-11-24) EBERHARD ET AL.: "Lycopersicon esculentum chorismate mutase mRNA" XP002163767 abstract	9-22, 24-27, 31,33-46
A	--- RESKI, R. (1) ET AL: "Moss (Physcomitrella patens) expressed sequence tags include several sequences which are novel for plants." BOTANICA ACTA, (APRIL, 1998) VOL. 111, NO. 2, PP. 143-149. , XP000985074 the whole document	1-48
A	--- RESKI, R. (1): "Development, genetics and molecular biology of mosses." BOTANICA ACTA, (FEB., 1998) VOL. 111, NO. 1, PP. 1-15. , XP000985073 the whole document	1-48
A	--- PUCHTA H: "Towards targeted transformation in plants" TRENDS IN PLANT SCIENCE, (MAR 1998) VOL. 3, NO. 3, PP. 77-78. ISSN: 1360-1385., XP002162373 page 78, last paragraph	1-48
A	--- RESKI R: "PHYSCOMITRELLA AND ARABIDOPSIS: THE DAVID AND GOLIATH OF REVERSE GENETICS" TRENDS IN PLANT SCIENCE, ELSEVIER SCIENCE, OXFORD, GB, vol. 3, no. 6, June 1998 (1998-06), pages 209-210-1385, XP000881435 ISSN: 1360-1385 page 210, last paragraph	1-48
A	--- RESKI R: "MOLECULAR GENETICS OF PHYSCOMITRELLA" PLANTA, SPRINGER VERLAG, DE, vol. 208, no. 3, May 1999 (1999-05), pages 301-309, XP000881434 ISSN: 0032-0935 page 307, last paragraph	1-48
	---	
	-/--	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/12698

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HIRSCHBERG JOSEPH: "Production of high-value compounds: Carotenoids and vitamin E."</p> <p>CURRENT OPINION IN BIOTECHNOLOGY, vol. 10, no. 2, April 1999 (1999-04), pages 186-191, XP002162837</p> <p>ISSN: 0958-1669</p> <p>the whole document</p> <p>-----</p>	1-48

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 00/12698

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 47, 48  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-48 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 47, 48

Present claims 1-46 relate to an extremely large number of possible products. In fact the artificial term Tocopheol and Carotenoid Metabolism Related Protein (TCMRP) even comprises cellular housekeeping proteins. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the products claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to SEQ ID NOs:1 and 2

Present claim 47 relates to an product that is only defined by a process of manufacture. It is impossible to carry out a meaningful search as an uncounted number of fine chemicals is falling within the scope of such a claim. The same holds true for present claim 48 directed to the use of said fine chemical.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:1 and 2, a Chorismate Mutase from *Physcomitrella patens*, vectors and host cells comprising said Mutase and methods employing said Mutase.

2. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:3 and 4, a 4-Hydroxyphenylpyruvate Dioxygenase from *Physcomitrella patens*, vectors and host cells comprising said Dioxygenase and methods employing said Dioxygenase.

3. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:5-14, a Deoxyxylulose-P-Synthase from *Physcomitrella patens*, vectors and host cells comprising said Synthase and methods employing said Synthase.

4. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:15 and 16, a Mevalonate Diphosphate Decarboxylase from *Physcomitrella patens*, vectors and host cells comprising said Decarboxylase and methods employing said Decarboxylase.

5. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:17 and 18, a HMG-CoA Reductase from *Physcomitrella patens*, vectors and host cells comprising said Reductase and methods employing said Reductase.

6. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:19 and 20, a Mevalonate Kinase from *Physcomitrella patens*, vectors and host cells comprising said Kinase and methods employing said Kinase.

7. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:21 and 22, a Farnesyl Diphosphate Synthase from *Physcomitrella patens*, vectors and host cells comprising said Synthase and methods employing said Synthase.

8. Claims: 1 - 48 (all partially)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

relating to SEQ ID NOs:23 and 24, a Geranylgeranyl Diphosphate Synthase from *Physcomitrella patens*, vectors and host cells comprising said Synthase and methods employing said Synthase.

## 9. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:25-44, a Geranylgeranyl Oxidoreductase from *Physcomitrella patens*, vectors and host cells comprising said Oxidoreductase and methods employing said Oxidoreductase.

## 10. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:45 and 46, a Geranylgeranyl Transferase Type I from *Physcomitrella patens*, vectors and host cells comprising said Transferase and methods employing said Transferase.

## 11. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:47-50, a Gamma-Tocopherol Methyltransferase from *Physcomitrella patens*, vectors and host cells comprising said Methyltransferase and methods employing said Methyltransferase.

## 12. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:51 and 52, a Lycopene Epsilon Cyclase from *Physcomitrella patens*, vectors and host cells comprising said Cyclase and methods employing said Cyclase.

## 13. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:53 and 54, a Phytoene Synthase from *Physcomitrella patens*, vectors and host cells comprising said Synthase and methods employing said Synthase.

## 14. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:55 and 56, a Phytoene Desaturase from *Physcomitrella patens*, vectors and host cells comprising said Desaturase and methods employing said Desaturase.

## 15. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:57 and 58, a Zeta-Carotene Desaturase

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

from *Physcomitrella patens*, vectors and host cells comprising said Desaturase and methods employing said Desaturase.

## 16. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:59-62, a Zeaxanthin Epoxidase from *Physcomitrella patens*, vectors and host cells comprising said Epoxidase and methods employing said Epoxidase.

## 17. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:63 and 64, a Isopentenylpyrophosphate Transferase from *Physcomitrella patens*, vectors and host cells comprising said Transferase and methods employing said Transferase.

## 18. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:65 and 66, a Nine-Cis-Epoxycarotenoid Dioxygenase from *Physcomitrella patens*, vectors and host cells comprising said Dioxygenase and methods employing said Dioxygenase.

## 19. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:67 and 68, a Fucoxanthin Chlorophyll a/c Binding Protein from *Physcomitrella patens*, vectors and host cells comprising said Binding Protein and methods employing said Binding Protein.

## 20. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:69 and 70, a Squalene Epoxidase from *Physcomitrella patens*, vectors and host cells comprising said Epoxidase and methods employing said Epoxidase.

## 21. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:71 and 72, a Squalene-Hopene Cyclase from *Physcomitrella patens*, vectors and host cells comprising said Cyclase and methods employing said Cyclase.

## 22. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:73 and 74, a 2-Heptaprenyl-1,4-Naphthoquinone Methyltransferase from *Physcomitrella patens*, vectors and host cells comprising

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

said Methyltransferase and methods employing said Methyltransferase.

23. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:75 and 76, a Copalylpyrophosphate Synthase from *Physcomitrella patens*, vectors and host cells comprising said Synthase and methods employing said Synthase.

24. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:77 and 78, a Ent-Kaurene Synthase from *Physcomitrella patens*, vectors and host cells comprising said Synthase and methods employing said Synthase.

25. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:79 and 80, a Gamma-Tocopherol Methyltransferase Type I from *Physcomitrella patens*, vectors and host cells comprising said Methyltransferase and methods employing said Methyltransferase.

26. Claims: 1 - 48 (all partially)

relating to SEQ ID NOs:81 and 82, a 2-Methyl-6-Phytylplasto-Quinol Methyltransferase from *Physcomitrella patens*, vectors and host cells comprising said Methyltransferase and methods employing said Methyltransferase.